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Almost a century ago, in 1921, Ernst Kretschmer concluded in his publication ‘Körperbau 
und Charakter’ (Physique and Character),1 based on systematic observations, that 
depressive symptoms are more common among persons with a pyknic body build. He 
described the pyknic type as  
 
”… characterized by the pronounced peripheral development of the body cavities (head, 
breast, and stomach), and a tendency to a distribution of fat around the trunk, with a 
more graceful construction of the motor apparatus (shoulders and extremities)”. 
 
Although the term pyknic build did not survive, the description he gave of this specific body 
build does closely resemble that of later observations. In 1956, Jean Vague wrote:2  
 
“Android obesity, with upper body predominance and pronounced muscle-blood 
development, leads to metabolic disturbances. It not only is associated with premature 
atherosclerosis and diabetes, but it is also the usual cause of diabetes in the adult in 80 
to 90 per cent of cases. … Overactivity of the pituitary-adrenal axis appears to be the 
most probable cause both of android obesity and it complications.”  
 
With this description Vague paved the way for what we now call the ‘metabolic syndrome’, a 
clustering of cardiovascular risk factors including abdominal obesity, unfavorable lipid 
profile, hypertension and hyperglycemia. Recent studies have abundantly confirmed that 
abdominal obesity and the metabolic syndrome are associated with increased risks of 
diabetes, atherosclerosis, and cardiovascular disease.3-9  
These early perceptions are not only in agreement with the concept of the metabolic 
syndrome, but Kretschmer’s observations also indicate that the metabolic syndrome might 
be associated with depressive disorders and symptoms. Indeed, some recent studies have 
linked depressive symptoms to individual components of the metabolic syndrome, e.g. 
hypertension, obesity, or high blood glucose levels.10-12 Considering that both depression 
and cardiovascular disease might be linked to metabolic disturbances, it has been 
hypothesized that the metabolic syndrome could play an important mediating role in the 
frequently described association between depression and cardiovascular disease.13-15 
Gaining more explicit knowledge on the association between depression and the metabolic 
syndrome could enhance insight into depression and cardiovascular disease comorbidity. 
However, until recently, only very few studies have investigated whether depressive 
disorders or symptoms are associated with the total metabolic syndrome package or have 
compared the relative influence of individual components. Besides, the temporal direction of 
the associations between depression and metabolic abnormalities remains unclear. Also, 
what exactly then causes these metabolic disturbances and their consequences? A hint for 
this was already given by Vague: hyperactivity of the hypothalamic-pituitary-adrenal (HPA)-
axis, which indeed in the past decades has recurrently been linked with depressive 
disorders16,17 and some cardiovascular risk factors.18,19 Integrating the above presented, this 
thesis will focus on the reciprocal associations between depression and the metabolic 
syndrome in older persons, taking herein into account a possible role for the HPA-axis. 
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Focus is given to older populations as both depressive symptoms and cardiovascular 
conditions are highly prevalent among the aged.20,21 In the current chapter, background 
information on issues relevant for this thesis will be given, finishing with a thesis outline. 
 
Aging 
In the Western world, the old and especially the oldest of the old comprise the fastest 
growing segment of our population. This is due to a decreasing trend in the number of 
children born as well as to dramatic changes in mortality leading to increased life 
expectancy. In the Netherlands, 14% of the population in 2007 was 65 years or older, of 
whom 25% was 80 years or older. It is expected that in 2050 even 24% of the Dutch 
population will be 65 years or older.21 Of this 65-plus population, 57% are women and, as 
life expectancy has consistently been higher for women than for men, this percentage is 
increasingly higher in older age groups.21 Consequently, in absolute terms aging is affecting 
women more than men.  
Aging has a profound impact on the individual. For the most part, individual aging is 
associated with many adverse changes in human anatomy and physiology. For a large part 
of adult life, people are normally provided with ‘biological’ reserves. In later life, these 
reserves are reduced, which can cause weakening of one or another biological function 
essential to life. As a result, conditions such as heart disease, cancer, respiratory infection, 
or osteoarthritis may arise. The biological age-related changes and the consequent 
development of degenerative and chronic conditions, have a large impact on the physical 
functioning and behaviors of older persons. The most important cause of morbidity and 
mortality at older age is cardiovascular disease.21 
 
Depression, depressive symptoms and other psychosocial factors 
In the Netherlands, yearly about 6% of the adult population suffers from a depressive 
disorder,21 which is comparable to other countries across the world.22 Although the 
prevalence of depressive disorders is rather stable over years, the relative impact of 
depressive disorders on public health is enormous and increasing. According to the World 
Health Organization depression ranks high in the top ten of diseases causing great 
worldwide burden of disease and it is projected that in 2030 depression will be leading the 
disease burden list.23 High disease burden of depression is particularly caused by a marked 
decline of quality of life. A diagnosis of major depressive disorder includes a depressed 
mood and/or a noticeable decreased interest or pleasure of almost all activities most of the 
day, nearly every day, for a minimum of two weeks.24 These key symptoms are 
accompanied by fatigue or loss of energy, marked changes in appetite or weight, sleep 
disturbances, psychomotor agitation or retardation, feelings of worthlessness or excessive 
guilt, diminished ability to concentrate or indecisiveness, and/or recurrent thoughts of death 
or suicidal ideation. In total, a person experiences at least five of the above described 
symptoms and is clearly impaired in every day functioning. 
Also in old age, the most common psychological problems experienced are depressive 
symptoms. Prevalence rates of depressive problems in later life vary considerably depending 
on the sample studied and methods used. Studies in clinical settings generally find much 
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higher prevalences than studies in community settings, and studies applying psychiatric 
diagnostic criteria for depressive disorders find much lower prevalences than studies using 
symptom checklists. It is possible to score relatively high on a symptom checklist without 
meeting diagnostic criteria for depressive disorders. Specifically in older populations, 
symptom checklists identify for a large part persons who do not fulfill the diagnostic severity 
threshold of psychiatric depressive disorders. This condition is often referred to as 
‘subthreshold depression’. As confirmed in several aging studies, major depressive disorder 
affects about 2-4% of the community-dwelling population.25 Contrary to what some people 
might expect, psychiatrically defined depression appears to be less prevalent among older 
adults than among young and middle-aged adults, although the presence of depressive 
symptoms is much more common.  
Table 1 shows the 1-year prevalence rates of depressive disorders among participants 
of the community-based Longitudinal Aging Study Amsterdam (LASA) (see also26). These 
results confirm a prevalence of 1-4% for major depressive disorder in old age, and much 
higher prevalence rates of subthreshold depressive symptoms (8-21%). Also, whereas the 
prevalence of depression does not clearly increase over time, the rates of subthreshold 
symptoms do. It is important to realize that a large proportion of older persons with a 
depressive disorder have had prior episodes during earlier phases of their lives. As in 
younger age groups, older women generally show higher rates of depressive disorders and 
symptoms than older men.  
 
 
Table 1. Presence of depressive and anxiety symptoms and disorders in older men and 
women in different age groups in LASA 
 
 Men  Women 
Age group (in years) 55-65 65-75 75-85  55-65 65-75 75-85 
N 490 456 560  526 517 558 
Depression        
Major depressive disorder a 1.2% 1.1% 0.5%  3.4% 3.5% 2.0% 
Subthreshold depression b 8.2% 8.1% 13.2%  9.7% 14.1% 21.0% 
Anxiety        
Panic disorder a 0.4% 0.2% 0.2%  1.5% 1.5% 0.4% 
Social phobia a 1.2% 0.4% 1.1%  2.1% 1.5% 1.8% 
Generalized anxiety disorder a 1.8% 2.0% 2.1%  4.6% 5.2% 4.1% 
Subthreshold anxiety c 5.3% 4.2% 4.5%  6.7% 7.7% 7.2% 
a 1-Year prevalence rates based on diagnostic DSM III-criteria using the Diagnostic Interview 
Schedule. b Indicated by Center for Epidemiologic Studies Depression Scale ≥ 16, but no major 
depression diagnosis. c Indicated by Hospital Anxiety and Depression Scale - Anxiety subscale ≥ 8, 
but no anxiety disorder diagnosis. 
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Next to depression, anxiety symptoms are also relatively common in old age. Table 1 
additionally shows 1-year prevalence rates of the main anxiety disorders (panic disorder, 
social phobia and generalized anxiety disorder) and subthreshold anxiety symptoms in LASA 
(see also27). Other psychosocial factors are important in aged persons as well, for instance 
life events such as the loss by death of age-peers such as siblings and friends, but also of 
one’s own partner. Widowhood has systematically been shown to increase the risk of 
developing consequent depression and anxiety disorders,28 which might be especially true 
for men.29 Increasing age also brings changes in relationship needs, for example as the 
result of increasing impairment. In general, when adjustment to the burdening 
circumstances related to aging is inadequate, an older person might experience substantial 
psychological stress and consequent symptoms of depression or anxiety (e.g.30). In the 
present thesis the main focus will be on depression, but some additional attention will be 
given to other psychosocial factors (anxiety, recent life events, emotional support).  
 
Depression and cardiovascular disease 
Heart disease, just like depression, is on the top list of diseases with the greatest loss of 
‘disability adjusted life years’. The World Health Organization projected that in 2030 
depression and heart disease will take in the first and second place, respectively, in high-
income countries and second and third worldwide.23 The public health impact of depression 
and heart disease is especially high, considering that an abundant amount of literature has 
associated depression with cardiovascular disease, linking depression with poorer 
cardiovascular outcome, relating depression with increased risks of cardiovascular events or 
mortality, and showing an increased onset of depression after cardiovascular events. Meta-
analyses on studies in heart patients and in the general population suggest that depression 
is associated with a twofold increased risk of cardiovascular events and mortality.31-36 
Although these systematic reviews do not explicitly distinguish between studies using 
middle-aged and older populations, it is good to realize that in fact the majority of these 
studies have been conducted among older persons, simply because morbidity and mortality 
most commonly occur in the oldest age groups. Several hypotheses exist to explain the high 
comorbidity between depression and cardiovascular disease, one of which suggests the 
metabolic syndrome as a linking mechanism.13-15  
 
Metabolic syndrome 
The metabolic syndrome is a constellation of interrelated risk factors of metabolic origin - 
metabolic risk factors - that places persons at risk for developing (atherosclerotic) 
cardiovascular disease and type 2 diabetes mellitus and was first described by Reaven in 
1988 as Syndrome X.38 The metabolic risk factors that come together in the metabolic 
syndrome include (abdominal) obesity, dyslipidemia, hypertension and hyperglycemia. 
Although these factors often cluster and therefore can be seen as a syndrome, there is still 
debate on whether there is one underlying cause of the metabolic syndrome.39 Insulin 
resistance and abdominal obesity are regarded as the key candidates for explaining the 
grouping of metabolic risk factors. Regardless of the cause, the metabolic syndrome 
identifies individuals at an elevated risk for cardiovascular disease and diabetes.3-9  
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Different definitions of the metabolic syndrome exist, but most widely used are the US 
National Cholesterol Education Program - Adult Treatment Panel III (ATP III) criteria.40 The 
ATP III guidelines define metabolic syndrome as the presence of three or more of the 
following criteria: 
 
1. Abdominal obesity: waist circumference > 102 cm (men) or > 88 cm (women); 
2. Hypertriglyceridemia: triglyceride levels ≥ 150 mg/dl (1.7 mmol/l); 
3. Low high-density lipoprotein (HDL) cholesterol:  HDL levels < 40 mg/dl  
    (1.03 mmol/l; men) or < 50 mg/dl (1.30 mmol/l; women); 
4. Hypertension: blood pressure ≥ 130/85 mmHg or use of antihypertensives; 
5. Hyperglycemia: fasting blood glucose ≥ 110 mg/dl (6.1 mmol/l) or use of   
    anti-diabetic medication. 
 
The metabolic syndrome is very common; the prevalence among US adults is estimated 
to increase from 6.7% among persons aged 20-29 years to 43.5% for persons aged 60 
years and over.41 In the Netherlands the prevalence of the metabolic syndrome is similar or 
perhaps somewhat lower: results from LASA show a prevalence of the metabolic syndrome 
of 36.5% among persons aged 65 years and older.42 Several studies have associated 
individual metabolic disturbances with depressive symptoms.10-12 
 
Hypothalamic-pituitary-adrenal axis 
During acute physical or psychological stress the hypothalamic-pituitary-adrenal (HPA)-axis 
becomes activated. Under control of the hypothalamus, corticotrophin releasing hormone 
(CRH) is released and stimulates the pituitary to circulate adrenocorticotrophic hormone 
(ACTH), which in turn signals to the adrenal cortex to release cortisol. Direct effects of 
cortisol are amongst others mobilization of glucose and free fatty acids, a decrease of 
growth and sex hormones levels, an increase in cardiac output and blood pressure, and 
tempering of the activated immune system.14,43-45 The purpose of this acute stress reaction 
is to help the body regain homeostasis. Although usually very functional, chronically 
elevated cortisol, for instance due to chronic stress, can cause tissue damage and 
neuroendocrine dysregulation. Chronic hyperactivity of the HPA-axis has recurrently been 
noted in at least a subgroup of depressed persons.16,17 Furthermore, high levels of cortisol 
have been associated with specific cardiovascular risk factors and accelerated 
atherosclerosis.18,19 These unwanted effects of hypercortisolemia are most pronouncedly 
seen in persons with Cushing’s syndrome, in which prolonged excessive cortisol secretion 
causes amongst others abdominal obesity and depressive symptoms. Considering the 
above, it was Björntorp who first explicitly hypothesized that chronic stress and/or 
depression results in abdominal obesity and associated comorbidities such as cardiovascular 
disease, through long-term activation of the HPA-axis.14 Considering a possible role of the 
HPA-axis in the association between depression and metabolic syndrome is therefore very 
desirable.  
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Epidemiological research 
Literally ‘epidemiology’ means the study of epidemics. Contrary to what many people might 
think, epidemiology is not restricted to the study of infectious diseases. An epidemic in this 
context has to be interpreted as a disease or other health-related condition which is more 
prevalent in one population defined by either time, place or a multitude of other possible 
characteristics (e.g. demographics, social factors, other diseases, environmental factors, 
treatment) than in another population which importantly differs on these characterizations. 
The task of the epidemiologist is not only to describe prevalences and incidences of disease 
in specific populations, but also to examine which factors influence the presence or 
occurrence of disease or health-related conditions. By systematically comparing persons that 
vary on well-described characteristics, it is possible to gain important knowledge about 
indicators, causes, and consequences of disease, which might ultimately help in prevention 
and treatment of the conditions studied. One important tool of the epidemiologist, which will 
be applied in this thesis, is the prospective observational cohort study. In this type of study 
a random sample of a specified population undergoes a baseline assessment in which a 
large number of features of the individuals of this sample are inventoried. This can be done 
by means of questionnaires, interviews, taking blood samples, medical assessments, and so 
on. During subsequent years, for as long as is practically and ethically possible, these same 
persons are followed-up and re-assessments of important characteristics and outcomes will 
take place at pre-specified moments (e.g. every one or two year). Major advantages of this 
type of study are the prospective nature and the ability it brings to study the natural course 
of disease. 
 
Studies used in this thesis 
Several large prospective cohort studies form the basis of the present thesis. The Health, 
Aging and Body Composition (Health ABC) study is a prospective population-based cohort 
study among 3075 well-functioning white and black older persons, aged 70-79 years, from 
Memphis, Tennessee and Pittsburgh, Pennsylvania (US). The primary goal of this study is to 
identify determinants and consequences of body composition changes during the aging 
process. Both baseline and 5-year follow-up data were used in this thesis. Another study 
that provided data was the Invecchiare nel CHIANTI (aging in the Chianti area; InCHIANTI) 
study. This study was conducted among 1155 community-dwelling older persons, aged 65 
years and older, living in the Chianti area, Italy, originally initiated to examine the influence 
of multiple physiological subsystems on the ability to walk. Data from the baseline 
measurement and 3 and 6 years follow-up were available. Also, the Longitudinal Aging 
Study Amsterdam (LASA) included an population-based sample of older persons. LASA 
focuses on the interrelationships between and changes in physical, emotional, cognitive and 
social functioning during aging. From three regions in the Netherlands (Amsterdam, Zwolle, 
Oss) 3107 participants, aged 55-85 years, underwent the baseline assessment in 
1992/1993. In the present thesis data from the first follow-up measurement in 1995/1996 
were used. Lastly, the Netherlands Study of Depression and Anxiety (NESDA) is a 
prospective cohort study among 2981 persons, aged 18-65 years, with a current or remitted 
depressive or anxiety disorder diagnosis and diagnosis-free controls. Main objective of 
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NESDA is to describe and examine predictors of the long-term cause and consequences of 
depressive and anxiety disorders, while integrating biological and psychosocial research 
paradigms. Baseline data of the NESDA study were available for the present thesis. 
 
General aim 
Bringing together the observations presented in this General Introduction, a schematic 
presentation of the research model for the present thesis is shown in Figure 1. This model 
suggests that depression might increase the risk of cardiovascular disease by first advancing 
the occurrence of metabolic syndrome. Hyperactivity of the HPA-axis in depressed persons 
might be an important underlying mechanism through which the risks of metabolic 
syndrome and subsequent cardiovascular disease are increased. Concurrently, the metabolic 
syndrome, as precursor of cardiovascular disease, is theorized to raise the occurrence of 
depression. Possibly, HPA-axis disturbances play a role in this pathway as well. Both 
pathways might provide an explanation of the frequently reported co-occurrence of 
depression and cardiovascular disease.  
Therefore, the general aim of this thesis is to examine whether depressive disorders or 
symptoms are associated with, predict, or follow metabolic disturbances, such as present in 
the metabolic syndrome and obesity. In addition, this thesis investigates whether the HPA-
axis, as indicated by serum and urinary cortisol levels, plays a mediating role between 
depression on the one hand and metabolic syndrome and cardiovascular disease on the 
other hand. Knowledge to be gained by this thesis could increase our understanding of 
pathophysiological processes linking mental and physical health, which might be very useful 
for prevention and treatment of both depression and cardiovascular disease. To study these 
research questions an epidemiological approach is taken. 
 
Outline of this thesis 
This thesis will first examine whether depression and metabolic syndrome are cross-
sectionally associated, followed by the exploration of a mediating role in this association for 
the HPA-axis. Subsequently, longitudinal examinations will investigate the temporal direction 
between depression and metabolic syndrome, with a special focus on (abdominal) obesity. 
Lastly, the presumed role of cardiovascular disease in the thesis model is tested by 
examining its association with depression and cortisol. Throughout the thesis the relative 
importance of individual metabolic disturbances in their association with depression will be 
compared.  
The numbers in Figure 1 refer to the thesis chapters which focus on the corresponding 
research questions. Chapter 2 uses data from the Health ABC study to examine the cross-
sectional association between several psychosocial risk factors (depressive and anxiety 
symptoms, recent life events, and inadequate emotional support) and metabolic syndrome 
in older persons. Using data from the InCHIANTI study, Chapter 3 investigates the 
associations between late-life depressive symptoms and urinary cortisol with metabolic 
syndrome and it components. Specifically, the role of urinary cortisol in the association 
between depressive symptoms and metabolic syndrome is explored. In  Chapter 4 the 
relationships between late-life depressive symptoms and serum cortisol with metabolic  
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Figure 1. Research model of this thesis. 
Numbers indicate thesis chapters. 
 
 
 
syndrome (components) are extended in LASA to include major depressive disorder 
diagnoses. Leaving the cross-sectional examinations, the next two chapters focus on 
(abdominal) obesity, as possibly the most important component of metabolic syndrome, and 
longitudinally examine whether depressive symptoms might bring about changes in 
(abdominal) obesity (Chapter 5) or whether (abdominal) obesity could predict the onset of 
depressive symptoms in depression-free older persons (Chapter 6). These two chapters 
make use of the Health ABC study dataset. Chapter 7 describes both the onset and 
persistence of depressive symptoms over 6 years of follow-up in older persons with and 
without metabolic syndrome at baseline by means of the InCHIANTI data. In Chapter 8, 
also based on the InCHIANTI study, the question is asked whether the often assumed 
association between high cortisol levels and increased risk of cardiovascular disease indeed 
exists. The last scientific chapter (Chapter 9) leaves the older population and examines 
whether the frequently described association between depression and cardiovascular 
disease, a basic fundament of this thesis, also exists within a younger psychopathology-
based sample (NESDA), taking into account and additionally examining the role of 
(comorbid) anxiety disorders. Finally, the results of Chapter 2 through 9 are summarized, 
discussed and integrated with current knowledge in Chapter 10. 
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Abstract 
 
Background 
Psychosocial factors have been associated with metabolic abnormalities that increase the 
risk of cardiovascular disease and diabetes. This study investigated the cross-sectional 
relationship between psychosocial risk factors and the metabolic syndrome in a community-
based sample of older persons. 
 
Methods 
Participants were 2917 persons aged 70-79 years enrolled in the Health, Aging and Body 
Composition study. Depressive and anxiety symptoms, negative life events, and inadequate 
emotional support were assessed, and a summary psychosocial risk index was calculated. 
Metabolic syndrome was defined as three or more of the following criteria: abdominal 
obesity, high triglycerides, low high-density lipoprotein cholesterol, high fasting glucose, and 
high blood pressure. 
 
Results 
Negative life events and inadequate emotional support increased the odds of having 
metabolic syndrome after adjustment for demographic and lifestyle variables (OR per life 
event = 1.13, 95% CI = 1.05-1.22; OR = 1.35, 95% CI = 1.10-1.66, respectively). The 
relationship between depressive symptoms and metabolic syndrome was only found in white 
(OR per SD = 1.11, 95% CI = 1.01-1.23), but not in black (OR per SD = 0.97, 95% CI = 
0.86-1.11) persons. Anxiety symptoms were significantly associated with metabolic 
syndrome in men (OR per SD = 1.13, 95% CI = 1.00-1.28), but not in women (OR per SD 
= 0.98, 95% CI = 0.89-1.08). Moreover, a higher score on the psychosocial risk index was 
associated with an increased probability of having the metabolic syndrome (OR = 1.30, 95% 
CI = 1.12-1.52). 
 
Conclusions 
In the elderly population, different psychosocial risk factors are associated with a higher 
prevalence of the metabolic syndrome. Whether reduction or better management of 
psychosocial risk factors can improve the metabolic profile remains to be demonstrated. 
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Introduction 
Cardiovascular disease (CVD), diabetes, and affective disorders rank high among the leading 
disorders causing distress, disability, and mortality.1 There is increasing evidence that these 
disorders are linked and that clustering of these disorders presents one of the most 
challenging problems for public health, especially in later life. For instance, depression and 
anxiety have been shown to increase the risk of new CVD events, new coronary heart 
disease (CHD) events, and cardiac mortality.2-4 Also, patients with newly diagnosed type 2 
diabetes are more likely to have a history of depression than are people free of diabetes.5 In 
addition to affective disorders, other stressors known to contribute to psychological distress 
have been associated with CVD and diabetes. Both lack of emotional support and 
experience of major stressful life events have been shown to subsequently increase the risk 
of CVD, CHD, and type 2 diabetes.6-8 These findings suggest that, although depression, 
anxiety, emotional support, and stressful life events are distinct entities, they can all be seen 
as psychosocial risk factors for developing CVD or diabetes. 
Emerging evidence suggests that part of the link between these psychosocial risk 
factors and CVD and diabetes may operate through the metabolic syndrome,9 a clustering of 
several CVD risk factors including (i) abdominal obesity, (ii) hypertriglyceridemia, (iii) low 
high-density lipoprotein (HDL) cholesterol, (iv) hypertension, and (v) hyperglycemia. 
According to the National Cholesterol Education Program Adult Treatment Panel III, a 
person has the metabolic syndrome if three or more of these conditions are present.10 Using 
these criteria, the Third National Health and Nutrition Examination Survey estimated a 
prevalence of 23.7% of the metabolic syndrome among all US adults, and a prevalence of 
42.0% among adults aged 70 years and older.11 A number of studies has shown that 
individuals with the metabolic syndrome have an increased risk of cardiovascular morbidity 
and mortality.12-15 Furthermore, persons with metabolic abnormalities have shown an 
enlarged risk of incident diabetes, with increasing risks in those exhibiting more 
abnormalities.15 
Psychosocial risk factors, which might include both exposure to stressors, e.g. life 
events, and experienced psychological distress, such as depression and anxiety, have been 
linked to individual components of the metabolic syndrome, including insulin resistance, high 
blood pressure, abdominal obesity, and lipid abnormalities.8,16,17 Such a link could be due to 
the fact that psychological stress can result in sensitization of the hypothalamo-pituitary-
adrenal (HPA) axis,18,19 elevated inflammation,20 and inhibition of sex steroid secretion,21,22 
all of which may induce metabolic abnormalities.23-25 A combination of psychosocial risk 
factors might dysregulate these biological systems even more. 
A first step in unraveling the relationship between psychosocial risk factors and the 
metabolic syndrome is to explore their cross-sectional association. In addition, it is 
important to know whether psychosocial risk factors co-occur with the metabolic syndrome. 
Treatment of both metabolic syndrome and psychosocial stress may be less effective if 
accompanying problems are ignored. Until now, few studies have examined the link 
between psychosocial risk factors and the metabolic syndrome directly, especially in old age. 
The present study investigates the association between psychosocial risk factors, as 
indicated by depression, anxiety, recent life events, and experienced inadequate emotional 
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support, and the metabolic syndrome in a large cohort of well-functioning older men and 
women. 
 
Methods 
Study population 
Participants were from the Health, Aging and Body Composition (ABC) study, a prospective 
cohort study of 3075 well-functioning white and black elders, aged 70-79 years. Participants 
were recruited in 1997 and 1998, drawn from a sample of Medicare-eligible beneficiaries 
residing in the areas surrounding Pittsburgh, Pennsylvania, and Memphis, Tennessee. 
Individuals were excluded if they (i) were incapable of communicating, (ii) reported difficulty 
with walking for one-quarter mile, walking up 10 steps, or performing activities of daily 
living, (iii) had active cancer treatment in the past 3 years, or (iv) had plans to move out of 
the area. Baseline measurements were used for the present study. Baseline data on 
metabolic syndrome were missing for 40 participants, and 118 participants had missing data 
on psychosocial risk indicators, leaving 2917 participants for the present analysis. Persons 
with missing data were more often black than those in the present study (p = .007), but 
they did not differ in terms of age, sex, and education. All participants signed an informed 
written consent, approved by the institutional review boards of the clinical sites. 
 
Measurements 
Baseline characteristics 
Demographic characteristics included age, sex, and race (white or black). Educational level 
was measured continuously on a scale from 1 (grade 1) to 18 (doctoral degree), indicating 
the highest level of education completed. Income was measured by dividing persons into 
yearly income groups: < $10,000, $10,000-$25,000, $25,000-$50,000, and ≥ $50,000. 
Because there were many missing values on this variable, missing value was included as a 
separate group. Furthermore, some lifestyle characteristics were assessed: smoking status 
(non-, former, or current), current alcohol intake (drinks > 1 drink per day or not), and 
physical activity (sum of weight training, high and medium intensity exercise, and aerobic 
dance [in kcal/kg/wk]). Baseline presence of CVD (including stroke or transient ischemic 
attack, myocardial infarction, angina pectoris, percutaneous transluminal coronary 
angioplasty, or coronary artery bypass grafting) and diabetes was adjudicated using 
standardized algorithms considering various sources of information: self-report, medication 
use, clinical examination findings, and medical claims data from the former Health Care 
Financing Administration.  
 
Metabolic syndrome 
Metabolic syndrome was defined, following the National Cholesterol Education Program 
Adult Treatment Panel III guidelines,10 as meeting at least three of the following five 
criteria: (i) abdominal obesity (waist circumference > 102 cm in men and > 88 cm in 
women), (ii) hypertriglyceridemia (triglyceride level of ≥ 150 mg/dl), (iii) low HDL 
cholesterol (< 40 mg/dl in men and < 50 mg/dl in women), (iv) high blood pressure 
(systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg, or 
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currently using antihypertensive medication), (v) high fasting glucose (≥ 110 mg/dl or 
currently using antidiabetic medication). Waist circumference and blood pressure were both 
averaged over two measurements. All medication regularly taken in the past 2 weeks were 
brought in, recorded, and coded according to the Iowa Drug Information System.26 Use of 
antidiabetic and antihypertensive drugs was ascertained from this inventory. Lipid and 
fasting glucose levels were measured after an overnight fast. In addition to presence of 
metabolic syndrome, in line with others,27 the number of metabolic syndrome components 
was used as an index of severity of metabolic abnormalities. 
 
Psychosocial risk factors 
Depressive symptoms - Depressive symptoms were measured with the 20-item Center for 
Epidemiologic Studies Depression (CES-D) scale assessing depressive symptoms in the 
previous week.28 This scale, ranging from 0 to 60, has been widely used in older populations 
and has been shown to be a valid instrument29 (internal consistency was high: Cronbach 
alpha = 0.81). 
 
Anxiety symptoms - Anxiety symptoms were measured using three items from the anxiety 
subscale of the validated Hopkins Symptom Checklist.30 The items were: “During the past 
week, have you felt nervous or shaky inside?, … tense or keyed up? … fearful?” Possible 
responses were “no”, “a little”, “quite a bit”, and “extremely”. An anxiety symptoms score 
was calculated, ranging from 0 to 9, as used before.31 The Cronbach alpha of these three 
items was 0.61. 
 
Negative life events – The occurrence of seven common and important life events during 
the past year was assessed and summed. Life events included (i) close friend or family had 
a serious accident or illness, (ii) spouse or partner died, (iii) (grand)child, close friend, or 
relative died, (iv) pet died, (v) relationship with close friend or family changed for the worse, 
(vi) participant or family has been assaulted or robbed, and (vii) close friend or family has 
been arrested or in trouble with the law. 
 
Inadequate emotional support - Participants who reported they could have used “some” or 
“a lot” more emotional support than they received in the past year were considered to have 
inadequate emotional support. This measure gives an indication of the subjective need for 
emotional support, which has been associated with the development and progression of 
CHD.7 
 
Psychosocial risk index - The above four measures have all individually been shown to be 
psychosocial risk factors for developing CVD and diabetes.2-8 Although little is known about 
the underlying biological mechanisms, it might be hypothesized that these psychosocial 
variables have a similar or, at least to some extent, an additive biological impact. In 
consequence, it might be that persons who have high scores on more than one psychosocial 
risk factor have an even greater biological dysregulation and therefore are even more at risk 
for developing the metabolic syndrome, CVD or diabetes. Therefore, the above psychosocial 
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factors were combined to calculate a summary psychosocial risk index. Depressive 
symptoms were standardized into a continuous variable ranging from 0 to 1 by dividing each 
individual score by the maximum possible CES-D score (i.e. 60). Similar standardization was 
done for anxiety symptoms (divided by 9) and life events (divided by 7). Inadequate 
emotional support was kept as a dichotomous 0-1 measure. Then, the four 0-1 measures 
were summed to attain an overall continuous psychosocial risk index, ranging from 0 to 4. 
The four psychosocial risk factors were associated with each other (all p < .001): the 
highest correlation was found between depression and anxiety (Spearman correlation = 
0.40), and the lowest correlations were found with negative life events (between 0.09 and 
0.14). 
 
Statistical analysis 
Chi-square and t test statistics were used to assess differences in psychosocial risk factors 
between participants with or without metabolic syndrome and with or without a metabolic 
abnormality. For all following analyses, age, sex, race, education, income, smoking status, 
alcohol intake, and physical activity were used as covariates. Logistic regression analyses 
were conducted to assess the association between metabolic syndrome and each of the 
psychosocial risk factors. Because a few studies reported sex differences in the link between 
psychosocial risk factors and cardiovascular outcomes,2,32 sex interactions were explored 
and also race interactions were tested. To examine if there was a linear relationship 
between psychosocial risk factors and number of metabolic syndrome components, linear 
regression was used. To test whether psychosocial risk factors were independently 
associated with the metabolic syndrome, a logistic regression analysis was conducted 
including all four psychosocial risk factors at the same time. Furthermore, we checked 
whether the link between psychosocial risk factors and metabolic syndrome was dependent 
on the presence of CVD or diabetes by testing for interactions with CVD or diabetes, 
respectively. In addition, we ran stratified analyses for persons with and without CVD. 
 
Results 
Baseline characteristics of the study population are shown in Table 1. The mean age of the 
2917 participants included in this study was 73.6 years (SD = 2.9); 51.5% were women, 
41.1% were black, and 38.6% of the participants had the metabolic syndrome. Overall, 
levels of psychosocial risk were low. 
As shown in Table 2, metabolic syndrome was associated with depressive symptoms, 
negative life events, inadequate emotional support, and the psychosocial risk index. 
Furthermore, although levels of psychosocial risk were rather low for the total sample, in 
general they appeared to be somewhat higher in participants with metabolic abnormalities, 
although differences were small and only some were statistically significant.  
We then conducted logistic regression analyses to calculate the odds ratio (OR) of 
metabolic syndrome for the different psychosocial risk factors before and after adjustment 
(Table 3). Also, sex and race interactions were explored by examining sex and race by 
psychosocial risk factor interaction terms. Before adjustment, depressive symptoms 
modestly increased the odds of the metabolic syndrome, but this was no longer significant  
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Table 1.  Baseline characteristics 
 
Characteristic N = 2917 
Age (years), mean (SD) 73.6 (2.9) 
Female, % 51.5 
Black, % 41.1 
Education, mean (SD) 13.0 (3.2) 
Family income, %  
< $ 10,000 11.7 
$ 10,000 - $ 25,000 34.0 
$ 25,000 - $ 50,000 28.1 
≥ $ 50,000 14.2 
Missing 12.1 
Smoking status, %  
Nonsmoker 43.7 
Former smoker 46.1 
Current smoker 10.1 
> 1 Alcoholic drink per day, % 7.4 
Physical activity (kcal/kg/week), mean (SD) 6.2 (15.9) 
Baseline cardiovascular disease, % 24.0 
Baseline diabetes, % 15.2 
Psychosocial risk factors  
Depressive symptoms score (0-60), mean (SD) 4.7 (5.3) 
Anxiety symptoms score (0-9), mean (SD) 0.66 (1.2) 
Negative life events in the past year (0-7), mean (SD) 1.1 (1.0) 
Inadequate emotional support, % 15.4 
Psychosocial risk index (0-4), mean (SD) 0.47 (0.5) 
Metabolic syndrome  
Abdominal obesity, % 60.9 
High triglycerides, % 30.7 
Low high-density lipoprotein cholesterol, % 29.4 
High fasting glucose, % 24.0 
High blood pressure, % 79.1 
Metabolic syndrome, % 38.6 
Number of metabolic components (0-5), mean (SD) 2.2 (1.2) 
0, % 5.9 
1, % 23.6 
2, % 32.0 
3, % 21.9 
4, % 12.5 
5, % 4.1 
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Table 2.  Association between psychosocial risk factors and metabolic syndrome in older 
men and women  
 
Abdominal 
obesity 
High 
triglycerides 
Low HDL 
cholesterol 
N = 2917 
Psychosocial risk factor No Yes No Yes No Yes 
Depressive symptoms score, mean (SD) 4.5 4.8 b 4.6 4.9 4.7 4.8 
(5.1) (5.4) (5.2) (5.5) (5.3) (5.3) 
Anxiety symptoms score, mean (SD) 0.63 
(1.2) 
0.68 
(1.2) 
0.63 
(1.2) 
0.73 a 0.66 0.67 
(1.3) (1.2) (1.2) 
Negative life events, mean (SD) 1.1 
(1.0) 
1.2 
(1.0) 
1.1 
(1.0) 
1.2 a 1.1 1.2 
(1.0) (1.0) (1.0) 
Inadequate emotional support, % 13.6 16.6 a 14.7 16.9 15.2 15.9 
Psychosocial risk index, mean (SD) 0.44 
(0.5) 
0.48 a
(0.5) 
0.45 0.50 a 0.46 0.48 
(0.5) (0.5) (0.5) (0.5) 
High blood 
pressure 
High fasting 
glucose 
Metabolic 
syndrome 
 c
Psychosocial risk factor No Yes No Yes No Yes 
Depressive symptoms score, mean (SD) 4.3 
(4.8) 
4.8 a
(5.4) 
4.7 
(5.2) 
4.7 
(5.7) 
4.5 4.9 a
(5.0) (5.7) 
Anxiety symptoms score, mean (SD) 0.66 0.66 0.65 0.70 0.64 0.70 
(1.2) (1.2) (1.2) (1.2) (1.2) (1.2) 
Negative life events, mean (SD) 1.1 
(1.0) 
1.1 
(1.0) 
1.1 
(1.0) 
1.2 
(1.0) 
1.1 1.2 a
(1.0) (1.0) 
Inadequate emotional support, % 13.6 15.9 14.3 18.7 a 13.8 18.0 a
Psychosocial risk index, mean (SD) 0.44 
(0.5) 
0.48 b
(0.5) 
0.45 
(0.5) 
0.51 a
(0.5) 
0.44 0.51 a
(0.5) (0.5) 
HDL = high-density lipoprotein. a p ≤ .05 (yes versus no) b p ≤.10 (yes versus no), based on Χ2 tests for 
dichotomous variables and independent t tests for continuous variables; c metabolic syndrome: ≥ 3 of 
the following criteria: abdominal obesity, high triglycerides, low HDL cholesterol, high fasting glucose, 
high blood pressure. 
 
 
after adjustment (OR per SD increase = 1.06, 95% CI = 0.98-1.14, p = .16). However, a 
trend was found for a race by depressive symptoms interaction (p = .10): the odds of 
metabolic syndrome increased with increases in depressive symptoms in white (OR per 
SD increase = 1.11, 95% CI = 1.01-1.23, p = .03), but not in black (OR per SD increase 
= 0.97, 95% CI = 0.86-1.11, p = .67) persons. Although there was no overall increase in 
odds of metabolic syndrome with increases of anxiety symptoms (OR per SD increase = 
1.03, 95% CI = 0.96-1.11, p = .44), a trend for a sex by anxiety symptoms interaction 
was identified (p = .08). Men had a 13% increased odds of metabolic syndrome per SD  
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Table 3. Association between psychosocial risk factors and metabolic syndrome and number of 
metabolic abnormalities 
 
Metabolic Syndrome a
N = 2917 
Unadjusted  Adjusted c  Adjusted d
Psychosocial risk factor OR 95% CI p  OR 95% CI p  OR 95% CI p 
Depressive symptoms score e f 1.08 1.00-1.16 .04  1.05 0.98-1.13 .20  1.01 0.93-1.11 .78 
Whites (N = 1718) 1.15 1.05-1.26   .003  1.11 1.01-1.23 .03  1.10 0.98-1.23 .11 
 0.97 0.86-1.11 .67  0.91 0.79-1.05 .21 Blacks (N = 1199) 0.97 0.86-1.10 .67 
Anxiety symptoms score e g 1.06 0.98-1.14 .15  1.03 0.96-1.11 .44  0.99 0.91-1.08 .78 
Men (N = 1416) 1.13 1.00-1.27 .05  1.13 1.00-1.28 .05  1.08 0.94-1.24 .26 
Women (N = 1501) 0.98 0.89-1.08 .73  0.98 0.89-1.08 .73  0.94 0.84-1.05 .25 
Negative life events  1.12 1.04-1.21    .003  1.13 1.05-1.22    .001  1.12 1.04-1.21   .004 
Inadequate emotional support 1.37 1.12-1.68    .002  1.35 1.10-1.66   .005  1.31 1.05-1.62 .02 
Psychosocial risk index 1.34 1.15-1.55 <.001  1.30 1.12-1.52   .001     
Number of Abnormalities b 
 Unadjusted  Adjusted c  Adjusted d
Psychosocial risk factor β p  β p  β p 
Depressive symptoms score e f .043 .02  .021 .25  .004 .84 
Whites (N = 1718)     .069       .004      .043      .08      .026     .37 
    -.005     .86     -.020     .54 Blacks (N = 1199)    -.001     .98 
Anxiety symptoms score e g .031 .10  .014 .44  -.002 .92 
Men (N = 1416)     .060     .02      .058     .03      .051     .09 
Women (N = 1501)    -.019     .46     -.016     .52     -.045     .13 
Negative life events  .039 .03  .043 .02  .039 .04 
Inadequate emotional support .056   .003  .047 .01  .043 .03 
Psychosocial risk index .068 <.001  .052 .005    
a Based on logistic regression analyses; b based on linear regression analyses; c adjusted for age, sex, race, 
education, income, smoking status, alcohol intake and physical activity; d additionally adjusted for other 
psychosocial risk factors; e OR per SD increase: for depressive symptoms SD = 5.3, for anxiety symptoms SD = 
1.2; f a trend for race interaction was observed with depressive symptoms: for metabolic syndrome p = .10, for 
number of abnormalities p = .19;  g a (trend for) sex interaction was observed with anxiety symptoms: for 
metabolic syndrome p = .08, for number of abnormalities p = .03. 
 
 
increase in anxiety symptoms score (OR = 1.13, 95% CI = 1.00-1.28, p = .05). For women, 
anxiety symptoms did not elevate the odds of metabolic syndrome (OR per SD increase = 
0.98, 95% CI = 0.89-1.08, p = .73). Experiencing a negative life event did increase the 
odds of metabolic syndrome by 13% (OR = 1.13, 95% CI = 1.05-1.22), p = .001). Also, 
people who experienced inadequate emotional support had a 35% increased odds of having 
the metabolic syndrome (OR = 1.35, 95% CI = 1.10-1.66, p = .005) compared to people 
with adequate emotional support. Furthermore, when the four psychosocial risk factors were 
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Table 4. Association between psychosocial risk factors and metabolic syndrome 
 
No CVD  Prevalent CVD 
  
N = 2216 N = 701 
aPsychosocial risk factor OR 95% CI p  OR a 95% CI p 
Depressive symptoms score b 1.07 0.98-1.17 .14  0.98 0.84-1.13 .75 
Whites    1.13     1.02-1.27     .03    1.04   0.85-1.26   .74 
Blacks    0.98     0.84-1.14     .78    0.93   0.74-1.17   .54 
Anxiety symptoms score b 1.02 0.93-1.11 .75  1.04 0.89-1.21 .66 
Men    1.13     0.97-1.32     .11    1.04   0.83-1.29   .74 
Women    0.97     0.87-1.08     .52    1.03   0.83-1.28   .79 
Negative life events  1.13 1.04-1.24   .006  1.10 0.94-1.29 .22 
Inadequate emotional support 1.33 1.04-1.69 .02  1.39 0.93-2.10 .11 
Psychosocial risk index 1.29 1.08-1.54   .005  1.28 0.94-1.74 .11 
CVD = cardiovascular disease. a Based on logistic regression adjusted for age, sex, race, education, 
income, smoking status, alcohol intake and physical activity; b OR per SD increase: for depressive 
symptoms SD = 5.3, for anxiety symptoms SD = 1.2. 
 
 
combined into one overall psychosocial risk index, the odds of metabolic syndrome was 1.30 
times higher per point increase on the psychosocial risk index (95% CI = 1.12-1.52, p = 
.001). For the index, no statistically significant sex or race interactions were found (all p > 
.15). The results of the linear regression analyses of the relationship between psychosocial 
risk factors and number of metabolic abnormalities are also shown in Table 3 and are in line 
with the results for the dichotomous measure of metabolic syndrome.  
When all psychosocial risk factors were included in the same model, it appeared that 
negative life events and inadequate emotional support were still independently associated 
with the metabolic syndrome (OR = 1.12, 95% CI = 1.04-1.21, p = .004 and OR = 1.31, 
95% CI = 1.05-1.62, p = .02, respectively). In contrast, associations for depressive and 
anxiety symptoms were weakened and no longer statistically significant, although there was 
a trend for association between depressive symptoms and the metabolic syndrome in whites 
(OR = 1.10, 95% CI = 0.98-1.23, p = .11) and between anxiety symptoms and number of 
metabolic abnormalities in men (β = .051, p = .09). 
Table 4 shows the results of logistic regression analyses testing the association 
between psychosocial risk factors and the metabolic syndrome, stratified by prevalent CVD 
status. The prevalence of the metabolic syndrome was 36.4% among persons without CVD 
(N = 2216) and 45.5% among those with CVD (N = 701). Among persons without CVD, the 
link between psychosocial risk factors and the metabolic syndrome was very similar as 
compared to the overall sample, and was significant for depressive symptoms in whites (p = 
.03), negative life events (p = .006), inadequate emotional support (p = .02), and the 
psychosocial risk index (p = .005). There was no evidence for a CVD by psychosocial risk 
factor interaction (all p interaction > .15). No diabetes by psychosocial risk factor interaction 
was found either (all p  > .15). interaction
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Discussion 
This study showed that distinct psychosocial risk factors were associated with the metabolic 
syndrome in a large cohort of well-functioning older persons. We found that older people 
who experienced negative life events and inadequate emotional support had an increased 
prevalence of the metabolic syndrome. For depression, an association with the metabolic 
syndrome was found only in whites and not in blacks. Anxiety symptoms appeared to be 
associated with the metabolic syndrome in men, but not in women. Furthermore, when 
these psychosocial factors were combined into a psychosocial risk index, persons with a 
higher risk index had a higher probability of having the metabolic syndrome. 
Our study is one of the first to test the relationship between different psychosocial risk 
factors and the metabolic syndrome in a population-based cohort of older people. Most 
studies so far have examined the association between psychosocial factors and the 
metabolic syndrome indirectly, by studying individual metabolic components. Only few 
studies were able to test this relationship directly. Räikkönen and colleagues33 reported an 
association between depressive symptoms, tension, and anger and the metabolic syndrome 
in a population-based cohort of 425 middle-aged women. Kinder and colleagues34 found 
that young women, but not men, with a history of depression were twice as likely to have 
the metabolic syndrome. In our study, a psychosocial risk index including depressive and 
anxiety symptoms, negative life events, and inadequate emotional support showed a linear 
relationship with the odds of having the metabolic syndrome. This finding suggests that 
persons with high values on these measures have a higher risk for the metabolic syndrome. 
However, strongest associations with the metabolic syndrome were found for negative life 
events and inadequate emotional support, and these associations appeared to be 
independent of the associations of other psychosocial risk factors. Associations between 
depressive and anxiety symptoms and the metabolic syndrome were modest and not 
consistent across race and sex. 
In addition, the results of our study show that associations between psychosocial risk 
factors and the metabolic syndrome seemed more consistent than the associations with 
individual components of the metabolic syndrome. These results may suggest that 
psychosocial risk factors may lead to not just one metabolic abnormality, but have a more 
widespread effect on metabolism and lead to a cluster of metabolic abnormalities, such as 
present in the metabolic syndrome. Furthermore, our results show that the relationship 
between psychosocial risk factors and the metabolic syndrome is not due to presence of 
CVD. When CVD patients were excluded, the found associations remained, which indicates 
that the link between psychosocial risk factors and the metabolic syndrome in our study 
does not just reflect a consequence of underlying clinical CVD. 
In our study, a trend for a race interaction for depressive symptoms was found. This 
finding is in contradiction to those in the study of Kinder and colleagues34 where no 
interaction for race was found. Furthermore, we found a trend for sex interaction for 
anxiety, which has not been described before. The prevalence of most psychosocial risk 
factors was rather similar for whites versus blacks and only slightly higher for women than 
for men, indicating that differences in prevalence cannot explain the interaction effects 
observed. Because we had a large study sample and only found trends for interaction, these 
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may be chance findings and further research should confirm and explain the interaction 
effects observed in this research. 
There may be different pathways through which psychosocial risk factors are related to 
the metabolic syndrome and, although the psychosocial risk factors used in this study are 
rather distinct concepts, these pathways may be similar. Psychosocial factors have shown to 
activate the HPA axis resulting in higher cortisol concentrations18,19 which, in turn, are 
associated with metabolic abnormalities such as obesity, insulin resistance, and high blood 
pressure.35 Another pathway may be through inflammatory processes. Psychosocial risk 
factors, especially depression, have shown to be associated with increased levels of 
inflammatory markers, such as interleukin-6 and C-reactive protein.20 Inflammatory markers 
have been linked to obesity, lower HDL cholesterol levels, and higher triglycerides and 
fasting glucose concentrations.24 A third pathway could be through sex steroid hormones, as 
low levels of testosterone and dehydroepiandrosterone sulfate (DHEA-S) have been 
associated with major depression.21,22 Alternatively, low levels of sex steroid hormones have 
been linked to various metabolic abnormalities.25 However, evidence for these pathways 
remains indirect, and additional longitudinal research is needed to investigate these 
processes further. In addition to these biological pathways, it may be that people with a 
high psychosocial risk have poorer health habits, e.g. they exercise less or have more fat 
intake, thereby increasing their metabolic risk.9 However, we did adjust for some lifestyle 
variables; this adjustment did not affect the results much. 
Our study has some limitations. First, causal inferences are limited due to the cross-
sectional design. A longitudinal design would be more appropriate to explore the direction of 
the relationship between psychological distress and the metabolic syndrome. However, in 
our study, metabolic syndrome was only remeasured after 5 years. Due to dropout (15%), 
missing values (19%), and exclusion of persons with baseline metabolic syndrome (27%), 
there was only a limited and likely very selective subsample left for longitudinal analyses. In 
addition, due to aging and frailty processes among the oldest old, several counteractive 
body composition changes exist (e.g. loss of fat mass), which could contaminate a possibly 
existing link between psychosocial risk factors and incidence of metabolic syndrome. 
Consequently, a longitudinal approach that examines the incidence of metabolic syndrome 
may be better studied in a younger cohort where frailty and selective survival play no major 
role yet. What can be said about causality is that, in our study, one of the strongest 
associations with metabolic syndrome was found for negative life events in the past year, 
which generally have a rather random and independent occurrence (e.g. death or illness of 
family member, violence, relative in trouble with the law). Consequently, for this 
association, the most likely pathway is that exposure to negative life events is associated 
with unfavorable metabolic changes. A second limitation is that our population was relatively 
healthy, with a low prevalence of depressive symptoms. The mean CES-D score was 4.7, 
and only 4.6% met the CES-D cutoff of 16 for clinically relevant depression. This percentage 
is low compared to other elder population-based studies (between 10 and 15%).3,36 
Restriction of range in the markers for psychosocial risk may have weakened the 
associations found. However, despite this limitation an association with the metabolic 
syndrome was found. Our study also had some important strengths, including the access to 
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a large cohort of elderly persons from the community, allowing sufficient statistical power to 
examine the association between psychosocial risk factors and the metabolic syndrome and 
allowing exploration of sex and race differences. Furthermore, both psychosocial risk and 
the metabolic syndrome were examined in detail, allowing assessment of associations of 
components of both. Moreover, a well-accepted definition of the metabolic syndrome was 
used, enhancing the comprehensibility and interpretability of our results. 
We believe that our findings support the idea that there is an important relationship 
between a variety of psychosocial risk factors and the metabolic syndrome, which are both 
common in later life. These results contribute significantly to the recent discussion 
implicating pathways from psychosocial factors through the metabolic syndrome to CVD and 
diabetes. A next step would be to test the hypothesis as to the mechanisms underlying the 
link between psychosocial risk factors and the metabolic syndrome. Knowing these 
mechanisms may lead to more effective and integrated efforts to prevent and treat 
cardiovascular disorders, diabetes, depression, and anxiety, which co-occur in later life. 
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Abstract 
 
Introduction 
Depression has been hypothesized to be associated with metabolic abnormalities which 
increase the risk of cardiovascular disease and diabetes. Such a link could be due to 
increased HPA-axis activity. This study investigates the cross-sectional relationship between 
depression, urinary cortisol and metabolic syndrome in an older population. 
 
Methods 
Data are from 867 participants of the InCHIANTI study, aged ≥ 65 years. Depressive 
symptoms were assessed using the Center for Epidemiologic Studies-Depression (CES-D) 
scale; cortisol levels were determined in 24-h urine samples. Metabolic syndrome was 
defined as three or more of the following: abdominal obesity, high triglycerides, low high-
density lipoprotein cholesterol, high blood pressure, and high fasting glucose. 
 
Results 
Clinically relevant depressed mood (CES-D ≥ 20) was present in 20.6% of the sample, and 
24.5% had the metabolic syndrome. After adjustment for sociodemographics and health 
indicators, depression score (per SD increase: OR = 1.20, 95% CI = 1.02-1.41) and urinary 
cortisol level (per SD increase: OR = 1.23, 95% CI = 1.01-1.51) were significantly 
associated with presence of metabolic syndrome. There was, however, a significant 
interaction (p = .003) between depressed mood and urinary cortisol in the probability of 
having metabolic syndrome. The odds of metabolic syndrome in persons with both 
depressed mood and urinary cortisol excretion in the highest tertile were 1.84 (95% CI = 
1.02-3.34) times increased compared to persons with neither condition. 
 
Discussion 
This study suggests a synergistic relationship between depression, cortisol and metabolic 
syndrome. Hypercortisolemic depression may constitute a specific risk group for the 
metabolic syndrome. 
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Introduction 
There is growing evidence that depression may cause major life-threatening and disabling 
diseases, such as cardiovascular disease (CVD) and diabetes mellitus.1-4 Recent studies 
suggest that the link between depression and CVD and diabetes may operate through the 
metabolic syndrome.5 The metabolic syndrome is a clustering of risk factors associated with 
a particularly high risk of cardiovascular events and diabetes, and includes at least three of 
the following conditions: abdominal obesity, high triglyceride levels, low high-density 
lipoprotein (HDL) cholesterol, high blood pressure, and high levels of fasting glucose.6 The 
estimated prevalence of the metabolic syndrome is as high as 42% in adults aged 60 years 
and over.7 
Depression has been linked to metabolic abnormalities, such as abdominal obesity, high 
blood pressure and insulin resistance.8-10 Several pathways for these links have been 
suggested. Vitaliano et al.5 proposed that chronic stress causes depression and successive 
poor health habits that can lead to the metabolic syndrome and subsequent coronary heart 
disease. On the other hand more biological mechanisms have been proposed.11 Probably 
one of the most important biological mechanisms is the dysregulation of the hypothalamic-
pituitary-adrenal (HPA)-axis, of which cortisol is an essential component. Dysregulation of 
the HPA-axis is typically associated with chronic stress and a number of studies have 
described an association between depression and high cortisol levels12,13 and, in turn, 
elevated levels of cortisol have been related to metabolic syndrome components such as 
abdominal obesity and glucose intolerance.14 Although a few studies have examined the link 
between depression and individual components of the metabolic syndrome, there is little 
research on the extent to which depressive symptoms correlate with the metabolic 
syndrome as a whole, and the role of cortisol in this link. A study by Weber-Hamann et al.10 
among 45 older women found that hypercortisolemic depression, compared to 
normocortisolemic depression, was associated with increased visceral fat, indicating the 
importance of considering cortisol levels when examining the link between depression and 
metabolic abnormalities and suggesting that associations with metabolic abnormalities may 
be especially powerful for hypercortisolemic depression. 
The present study uses data from a large sample of community-dwelling older persons 
to investigate the associations between depressive symptoms and urinary cortisol levels with 
metabolic syndrome and its components. We hypothesize that higher depressive symptoms 
and higher levels of cortisol are associated with metabolic syndrome and its components. In 
addition, the existence of an interaction between depressive symptoms and cortisol levels 
on the presence of metabolic syndrome will be explored, since we hypothesize that 
hypercortisolemic depression in particular will be linked to metabolic syndrome. 
 
Methods 
Study population 
Participants were part of the InCHIANTI study, a prospective population-based study of 
older persons. In 1998 and 1999, the study sample was randomly selected from the 
population registry of two sites in Italy: Greve in Chianti, and Bagno a Ripoli, using a 
multistage stratified sampling method. Data collection consisted of a home interview, a 24-h 
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urine collection and a medical evaluation at the study clinic, which took place within 21 days 
after the home interview. The Italian National Institute of Research and Care on Aging 
ethical committee approved the study protocol and all respondents signed informed 
consent. A more detailed description of the study design is given elsewhere.15 
The InCHIANTI study included 1155 participants aged 65 and over, but because of 
missing data on depressive symptoms (N = 76), metabolic syndrome (N = 101), urinary 
cortisol (N = 51), or incomplete (< 20 h) urine collection (N = 60), the present analysis 
included data from 867 participants. Excluded persons were significantly older (79.4 versus 
74.1, p < .001), more often women (61.8% versus 55.0%, p = .04), and had less years of 
education (4.7 versus 5.5, p = .002). 
 
Metabolic Syndrome 
Metabolic syndrome was defined as the presence of three or more of the following criteria: 
(i) abdominal obesity (waist circumference > 102 cm in men or > 88 cm in women); (ii) 
hypertriglyceridemia (triglyceride level ≥ 150 mg/dl); (iii) low HDL cholesterol (< 40 mg/dl 
in men or < 50 mg/dl in women); (iv) high blood pressure (systolic/diastolic blood pressure 
≥160/90 mmHg, and/or currently using anti-hypertensive medication); (v) high fasting 
glucose (≥ 110 mg/dl and/or currently using anti-diabetic medication). These criteria are 
similar to those outlined by the National Cholesterol Education Program (NCEP) Adult 
Treatment Panel III,6 with a minor modification for hypertension. Ninety-two percent of the 
InCHIANTI respondents met the original blood pressure criterion (130/85 mmHg). In order 
to take into account the characteristics of the older study population and to only classify 
those participants who were definitively hypertensive the diagnostic cutoff was raised to 
160/90 mmHg as done in other aging studies.16 
During the medical evaluation, after a fasting period of at least 8 h, a 60-ml blood 
sample was drawn, stored in cold glass tubes, and delivered within 2 h to a central 
laboratory. Serum glucose, HDL cholesterol, and triglycerides were measured by standard 
laboratory methods. Waist circumference was measured by trained examiners at the largest 
mid-body point. Three blood pressure measurements were taken using a standard mercury 
sphygmomanometer with the respondent in a supine position; the average of the last two 
readings was used in this analysis. Drugs taken in the previous two weeks were identified 
and coded using the Anatomical Therapeutic Chemical (ATC) system to ascertain anti-
diabetic and anti-hypertensive medication use. In addition to a dichotomous indicator of the 
metabolic syndrome, analyses were also conducted with continuous measures of metabolic 
syndrome components in order to investigate the consistency over and the importance of 
individual components. To incorporate medication use into the continuous metabolic 
syndrome component measures, 10 and 5 mmHg was added to systolic and diastolic blood 
pressure, respectively, for persons using antihypertensive medication since these values 
represent the average decline in blood pressure in antihypertensive medication trials.17,18 
Similarly, persons who used anti-diabetic medication and had a glucose level below 126 
mg/dl, were given a value of 126 for fasting glucose. 
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Urinary Cortisol 
The assessment of urinary cortisol over a 24-h period provides a rather stable indicator of 
the total cortisol excretion by the adrenals and measures the biologically active (unbound) 
cortisol. Before the in-clinic assessment, study participants were asked to collect all urine 
produced during a 24-h period starting after the first voided urine following awakening and 
including the first voided urine on the following day. At assessment, 10 ml aliquots of urine 
were prepared and stored at -80°C for later assaying at the Clinical Chemistry Laboratory of 
the Careggi Hospital, Italy. Urinary cortisol was measured by an immunochemiluminescence 
method and an ADVIA-Centaur immunoassay system (Bayer Diagnostics). The intra-assay 
coefficient of variation was less then 2.0% and the inter-assay coefficient of variation was 
less then 3.0%. Urinary cortisol level was defined as micrograms of cortisol excreted over  
24 h. Both a continuous measure and a tertile categorization of urinary cortisol were used in 
the present study.
 
Depressive Symptoms 
Depressive symptoms were assessed using the original 20-item version of the Center for 
Epidemiologic Studies-Depression Scale (CES-D) administered during the home interview.19 
The CES-D is a self-report scale, ranging from 0 to 60, which has been shown to be a valid 
instrument for identifying depressive symptoms in older community-dwelling adults20 also in 
an Italian sample.21 In our study, the internal consistency was high: Cronbach alpha = 0.82. 
Analyses were performed with both the continuous CES-D score (referred to as depressive 
symptoms) as well as a dichotomous indicator for clinically relevant depressed mood (CES-D 
≥ 20; referred to as depressed mood). Normally, a cutoff score of 16 on the CES-D is 
considered to represent clinically relevant depression; however, previous studies have 
demonstrated that a cutoff of 20 on the CES-D avoids overestimation in older adult 
populations.1,22,23 
 
Covariates 
Covariates included sociodemographic variables (age, sex, and years of education), smoking 
status (non-, former, or current smoker) and current alcohol intake (yes or no 3 or more 
drinks a day). Number of chronic diseases (including cancer, liver disease, gastrointestinal 
disease, congestive heart failure, Parkinson’s disease, peripheral arterial disease, lung 
disease, hip fracture, herniated disc, arthritis, osteoporosis and dementia) was calculated as 
a global indicator of poor physical health. Serum creatinine, measured through a modified 
Jaffe method, was used to calculate creatinine clearance with the Cockcroft-Gault formula. 
Following K/DOQI guidelines,24 a creatinine clearance rate of 30 ml/min or lower was 
considered to indicate severe renal function impairment, which may profoundly disturb 
urinary cortisol levels. Identification of CVD (including angina pectoris, myocardial infarction, 
stroke or transient ischemic attack) and diabetes was based on a standardized algorithm 
using information on self-reported history, pharmacological treatments, medical exam data, 
and hospital discharge records. Use of corticosteroids, antidepressants, and benzodiazepines 
was assessed and coded according to ATC-codes. 
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Statistical Analyses 
Baseline characteristics were compared across depression status using Χ  and t-test 
statistics. Logistic regression analyses, adjusted for age, sex, education, smoking status, 
alcohol intake, number of chronic diseases, severe renal function impairment, and urine 
volume (analyses with cortisol only), were conducted to independently assess the 
association between depression and urinary cortisol variables with metabolic syndrome. To 
examine whether the relationship between depression and metabolic syndrome is (partially) 
mediated by urinary cortisol, analyses including both cortisol and depression variables were 
conducted as well. For the latter, both a linear variable and the squared term for urinary 
cortisol were used, because earlier findings in this study sample  found a U-shaped 
association between depression and urinary cortisol, which was best described by a linear 
and squared term for urinary cortisol. In addition, since we hypothesized that especially 
hypercortisolemic depression could be associated with the metabolic syndrome, we tested 
for interaction between depressed mood and urinary cortisol by entering a depressed mood 
by cortisol interaction term. 
2
25
Since sex differences in the relationship between depression and CVD have been 
observed before,  sex interactions were explored by entering sex by depression/cortisol 
interaction terms in adjusted models.
1,26
 In addition, it was explored whether associations were 
different for persons with and without already existing CVD or diabetes by exploring 
CVD/diabetes by depression/cortisol interaction terms. Finally, in order to examine whether 
associations with depression and cortisol variables were consistent for individual metabolic 
syndrome components, adjusted linear regression analyses were conducted with continuous 
variables for all five components as the outcomes. For these analyses, triglycerides, HDL 
cholesterol, and fasting glucose were log-transformed in order to normalize distributions. 
 
Results 
The mean age of the participants included in these analyses was 74.1 years (SD = 6.6) and 
55.0% of the participants were women. 20.6% were depressed (CES-D ≥ 20) and 24.5% 
had the metabolic syndrome. The mean urinary cortisol level was 98.8 μg per 24 h (SD = 
48.1). As shown in Table 1, depressed persons were older, more often women, less likely to 
be a (former) smoker or heavy alcohol drinker, and had more chronic diseases than the 
non-depressed. Although cortisol levels appeared to be somewhat higher in the depressed 
group, this was not statistically significant. The prevalence of metabolic syndrome and some 
of its components (abdominal obesity, low HDL cholesterol, antihypertensive medication) 
was higher among depressed participants. Use of corticosteroids (p = .59), antidepressants 
(p = .50), and benzodiazepines (p = .33) was not associated with metabolic syndrome (data 
not shown). 
Table 2 shows that after adjustment for covariates there was a significant association 
between the severity of depressive symptoms (continuous CES-D score) and metabolic 
syndrome (OR per SD increase = 1.20, 95% CI = 1.02-1.41). However, the association 
between depressed mood (CES-D ≥ 20) and the metabolic syndrome was not statistically 
significant (OR = 1.30, 95% CI = 0.88-1.90). Level of urinary cortisol showed a significant 
linear association with metabolic syndrome (OR per SD increase = 1.18, 95% CI = 1.01- 
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Table 1. Baseline characteristics according to depressed mood 
 
Characteristic 
Non-depressed 
N = 688 
Depressed 
N = 179 p a
Age (years), mean (SD) 73.7 (6.6) 75.8 (6.3) <.001 
Women, % 50.1 73.7 <.001 
Years of education, mean (SD) 5.6 (3.1) 5.1 (3.5) .12 
Smoking status    
Nonsmoker, % 53.8 72.6 <.001 
Former smoker, % 31.1 16.2  
Current smoker, % 15.1 11.2  
Alcohol intake (≥ 3 drinks a day), %  11.9 5.0   .007 
Number of chronic diseases, mean (SD) 1.0 (0.9) 1.3 (1.0) <.001 
Severe renal function impairment, % 1.6 1.7 .94 
Corticosteroid use, % 1.6 2.8 .29 
Antidepressant use, % 1.7 10.6 <.001 
Benzodiazepine use, % 15.0 36.3 <.001 
Urine volume (ml), mean (SD) 1522 (551) 1521 (619) .99 
Baseline cardiovascular disease, % 13.1 11.2 .49 
Baseline diabetes, % 12.4 10.6 .52 
Cortisol    
Urinary cortisol (µg), mean (SD) 97.3 (43.2) 104.6 (63.5) .15 
Metabolic Syndrome    
Waist circumference (cm), mean (SD) 92.9 (10.0) 92.0 (11.6) .36 
Abdominal obesity, % 38.1 48.3 .01 
Triglycerides (mg/dl), mean (SD) 128.7 (73.3) 128.8 (66.3) .99 
High triglycerides, % 24.9 25.1 .94 
HDL cholesterol (mg/dl), mean (SD) 56.0 (15.3) 56.2 (14.7) .92 
Low HDL cholesterol, % 20.1 27.9 .02 
Systolic blood pressure (mmHg), mean (SD) 150 (19.5) 150 (19.2) .81 
Diastolic blood pressure (mmHg), mean (SD) 84 (8.5) 84 (8.6) .66 
Antihypertensive medication, % 40.0 50.3 .01 
High blood pressure, % 65.5 67.8 .56 
Fasting glucose (mg/dl), mean (SD) 96.7 (25.8) 92.9 (23.4) .08 
Anti-diabetic medication, % 6.7 6.7 .99 
High fasting glucose, % 16.9 12.8 .19 
Metabolic syndrome, % 22.8 30.7 .03 
Number of metabolic components, mean (SD) 1.7 (1.2) 1.8 (1.2) .12 
HDL = high-density lipoprotein. a Based on Χ2 tests for dichotomous variables and independent t tests 
for continuous variables. 
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Table 2.  Associations between depressed mood, urinary cortisol and metabolic syndrome 
 
 Unadjusted a Adjusted b
Adjusted for  
cortisol c
 OR 95% CI p OR 95% CI p OR 95% CI p 
Total sample (N = 867)          
Depressive symptoms d 1.29 1.11-1.50 .001 1.20 1.02-1.41 .03 1.11 0.94-1.32 .23 
Depressed mood (CESD ≥ 20) 1.50 1.04-2.16 .03 1.30 0.88-1.90 .19 1.13 0.76-1.68 .55 
Urinary cortisol e 1.12 0.96-1.30 .14 1.18 1.01-1.38 .04    
Depressed mood * urinary cortisol  .001   .003    
Non-depressed (N = 688)          
Urinary cortisol d 0.87 0.72-1.09 .25 0.95 0.67-1.18 .61    
Depressed (N = 179)          
Urinary cortisol e 1.52 1.18-1.94 .001 1.56 1.20-2.04 .001    
a Based on unadjusted logistic regression analyses; b adjusted for age, sex, education, smoking status, alcohol 
intake, number of chronic diseases, severe renal function impairment, and urine volume (analyses with cortisol 
only); c additionally adjusted for cortisol and cortisol2; d per SD (= 8.7) increase in CES-D score; e per SD (= 48) 
increase in urinary cortisol (µg). 
 
 
1.38). Additional adjustment for urinary cortisol and the squared term of urinary cortisol 
weakened the associations between depression and metabolic syndrome considerably: OR 
per SD increase in CES-D score became 1.11 (95% CI = 0.94-1.32) and the OR for 
depressed mood became 1.13 (95% CI = 0.76-1.68). 
Figure 1 shows that the unadjusted prevalence of metabolic syndrome differed 
significantly (p = .008) across depressed mood and urinary cortisol tertile groups. Metabolic 
syndrome was more prevalent among the depressed in the highest cortisol tertile than in all 
other groups defined by tertile of cortisol and depression status. After adjustment, when 
persons had both depressed mood and urinary cortisol excretion in the highest tertile, the 
odds of metabolic syndrome was 1.84 (95% CI = 1.02-3.34, p = .04) times increased 
compared to persons without depression in the lowest tertile of urinary cortisol (reference 
group). Other depression/cortisol groups did not differ from the reference group (all p > 
.15). The interaction between depressed mood and urinary cortisol levels in predicting the 
odds of metabolic syndrome was significant (p interaction = .003). Consequently, additional 
analyses stratified for depressed mood were conducted. For those without depressed mood 
(N = 688), urinary cortisol was not associated with the metabolic syndrome (OR per SD 
increase = 0.95, 95% CI = 0.67-1.18). In the depressed group (N = 179), however, the 
odds of having the metabolic syndrome increased significantly with increasing levels of 
urinary cortisol (OR per SD increase = 1.56, 95% CI = 1.20-2.04).  
Next, logistic regression analyses were repeated including sex by depressed mood, sex 
by urinary cortisol, and sex by depressed mood by urinary cortisol interaction terms, 
respectively. No significant sex interactions were found (all p > .15; data not shown). Also, 
when testing for CVD/diabetes interactions with depressed mood, urinary cortisol and their  
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Figure 1. Prevalence of metabolic syndrome across depression status and tertiles of urinary 
cortisol 
 
 
interacting effect, no significant interactions in the odds of having the metabolic syndrome 
were found (all p > .15; data not shown), which suggests that the link between depression, 
cortisol and metabolic syndrome is consistent for persons with and without CVD or diabetes. 
Finally, Table 3 shows that depressive symptoms tended to be associated with waist 
circumference (β = .064, p = .07) and were negatively associated with HDL cholesterol 
levels (β = -.070, p = .05). However, no associations between depressed mood (CES-D ≥ 
20) and any of the individual metabolic syndrome components were observed. Further, 
urinary cortisol levels showed a significant association with waist circumference (β = .081, p 
= .02) and fasting glucose levels (β = .082, p = .02). Moreover, there was a significant 
interaction between depressed mood and urinary cortisol levels in predicting levels of 
triglycerides (p < .001), HDL cholesterol (p = .02), and fasting glucose (p = .003), and a 
trend for an interaction for waist circumference (p = .08). Large waist circumference, high 
triglycerides levels and low HDL levels were significantly associated with higher cortisol 
levels in the depressed group only (β = .178, p = .02; β = .247, p = .001; β = -.156, p = 
.04, respectively). In the non-depressed group, higher levels of urinary cortisol were 
associated with lower triglycerides levels (β = -.103, p = .01) and with higher levels of 
fasting glucose (β = .156, p < .001). 
 
Discussion 
This community-based study among a large sample of older adults examined the 
relationship between depression, urinary cortisol and the metabolic syndrome. Higher levels 
of depressive symptoms were significantly associated with an increased prevalence of the  
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Table 3. Adjusted a associations between depressed mood, urinary cortisol, 
and continuous metabolic syndrome measures 
 
 
Waist 
circumference
 
Triglycerides b
 HDL   
cholesterol b
 β p  β p  β p 
Total Sample (N = 867)         
Depressive symptoms .064 .07  .006 .88  -.070 .05 
Depressed mood (CESD ≥ 20) .025 .46  .009 .79  -.048 .15 
Urinary cortisol .081 .02  -.003 .92  -.017 .61 
Depressed mood * urinary cortisol  .08   <.001   .02 
Non-depressed (N = 688)         
Urinary cortisol .028 .46  -.103 .01  .051 .17 
Depressed (N = 179)         
Urinary cortisol .178 .02  .247 .001  -.156 .04 
 
Systolic blood 
pressure 
 Diastolic blood 
pressure 
 Fasting   
glucose b
 β p  β p  β p 
Total Sample (N = 867)         
Depressive symptoms -.049 .17  .024 .52  -.038 .30 
Depressed mood (CESD ≥ 20) -.033 .35  .024 .51  -.053 .13 
Urinary cortisol   .014 .70  .025 .47    .082 .02 
Depressed mood * urinary cortisol  .72   .58     .003 
Non-depressed (N = 688)         
Urinary cortisol   .006 .87  .011 .78    .156 <.001 
Depressed (N = 179)         
Urinary cortisol   .048 .53  .059 .46  -.065 .39 
HDL = high-density lipoprotein. a Based on linear regression analyses adjusted for age, sex, education, 
smoking status, alcohol intake, number of chronic diseases, severe renal function impairment, and urine 
volume (analyses with cortisol only); b log-transformed values of triglycerides, HDL cholesterol and 
fasting glucose were used.   
 
 
metabolic syndrome. This relationship might be partially mediated by urinary cortisol levels, 
since entering cortisol levels in the analyses reduced the association between depressive 
symptoms and metabolic syndrome. Moreover, we found an interaction between depressed 
mood and urinary cortisol in predicting metabolic syndrome. Among non-depressed 
participants, no association between urinary cortisol and metabolic syndrome was found. 
However, among depressed persons, urinary cortisol level did strongly predict the likelihood 
of having the metabolic syndrome. Persons with depressed mood and urinary cortisol levels 
in the highest tertile in particular had an increased prevalence of metabolic syndrome, which 
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suggests that hypercortisolemic depression constitutes a specific risk factor for the 
metabolic syndrome.  
Our results are consistent with a few other studies that investigated the relationship 
between depressive symptoms and the metabolic syndrome. McCaffery et al.27 found an 
association between depressive symptoms and metabolic risk in adult male twins, and 
Räikkönen et al.28 confirmed this association in middle-aged women. Furthermore, a study 
by Kinder et al.29 suggests that a history of depression increases the risk of metabolic 
syndrome in young women, but not men. Our results show that the relationship between 
depression and the metabolic syndrome extends to an older population. In addition, the 
involvement of the HPA-axis in the link between depression and the metabolic syndrome has 
been hypothesized by others11, but no study has tested this directly. Our study provides 
evidence for the proposition that elevated cortisol levels increase the risk of the metabolic 
syndrome. An association between urinary cortisol and metabolic parameters was not 
observed in a study by Otte et al.30; however this study did not investigate the metabolic 
syndrome as a whole and did not examine depression by cortisol interactions. Most 
importantly, our study confirmed the hypothesis that when both depression and high cortisol 
levels are present, the odds of the metabolic syndrome is increased. This is consistent with 
a study by Weber-Hamann et al.10, who found among 45 older women that 
hypercortisolemic depression was associated with increased visceral fat and a larger 
accumulation of visceral fat over time.31 
How can it be explained that hypercortisolemic depression in particular is associated 
with a higher prevalence of metabolic syndrome? Previous findings from this and other 
aging studies have suggested that late-life depression may be associated with high as well 
as low levels of cortisol.25,32,33 A number of studies provided some evidence that 
hypocortisolemic depression is associated with physical frailty and conditions characterized 
by fatigue and pain,25,34,35 whereas hypercortisolemic depression is linked with more severe 
symptoms of depression.25,36 In addition, it has been suggested that melancholic depression 
is associated with a hyperactive HPA-axis, whereas a hypoactive HPA-axis may be linked 
with atypical depression.37 Therefore, it is possible that hyperactivity of the HPA-axis 
identifies a specific subtype of depression and it may be that only this subtype of depression 
is associated with the metabolic syndrome. What mechanisms, then, could underlie this 
association between hypercortisolemic depression and the metabolic syndrome? As 
described in a review by Björntorp,38 cortisol binds to glucocorticoid receptors which have a 
high density in visceral fat depots; there it activates lipoprotein lipase and inhibits lipid 
mobilization, which leads to an accumulation of triglycerides in this area. This review also 
suggests that these effects are even more pronounced when combined with inhibition of sex 
steroids. Since low sex steroid hormones levels have also been associated with depression39 
this could explain why especially the combination of depression and high levels of cortisol 
increase the prevalence of the metabolic syndrome. Additionally, both depression and 
hyperactivity of the HPA-axis have been associated with increased inflammation,40,41 which 
in turn have been linked to metabolic abnormalities.42 Therefore, a combination of 
depression and hypercortisolemia could increase the risk for metabolic syndrome even 
more. Future studies should test these hypothesized explanations. 
HYPERCORTISOLEMIC DEPRESSION & METABOLIC SYNDROME |  53 
We evaluated whether depression and cortisol associations were consistent across the 
various metabolic syndrome components. Higher depressive symptoms were associated with 
larger waist circumference and lower HDL cholesterol levels, but for the other metabolic 
syndrome components no significant associations with depression were observed. 
Furthermore, in the depressed, we observed expected relationships between urinary cortisol 
and waist circumference, triglycerides and HDL cholesterol. This may indicate that 
hypercortisolemic depression is especially associated with the obesity-related components of 
the metabolic syndrome. However, Kopf et al.43 found that in depressed persons higher 
cortisol levels were associated with a better lipid profile, although only in overweight 
subjects. In contradiction to some studies,10,31,43 we did not find an association between 
hypercortisolemic depression and fasting glucose. In contrast, we found an association 
between cortisol levels and high fasting glucose in the non-depressed only. We do not have 
a clear explanation for this finding and it may be a chance finding, since it is contrary to 
findings for the other metabolic syndrome components. Lastly, no associations were found 
between depression/cortisol and high blood pressure, which may be in line with other 
research showing that the blood pressure component contributes less strongly and 
consistently to the concept of ‘metabolic syndrome’ compared to other components.44 
Our definition of the metabolic syndrome did not exclude persons who already had CVD 
or diabetes. In fact, in our sample 19.7% and 31.2% of those with metabolic syndrome had 
CVD and diabetes. Since previous studies reported a relationship between depression and 
CVD or diabetes,1-3 it is possible that an observed link between depression and metabolic 
syndrome merely reflects the association between depression and existing CVD/diabetes. 
However, we observed no CVD/diabetes interactions, suggesting that the relationship 
between depression and the metabolic syndrome is independent of the presence of 
CVD/diabetes and also exists among persons without CVD or diabetes.  
Some limitations of our study should be acknowledged. Because of the cross-sectional 
nature of our study, we cannot make inferences about causality. Longitudinal analyses are 
needed to address this issue. Further, we did not have access to psychiatric diagnoses of 
depression. However, the CES-D is a commonly-used scale to measure depressive 
symptoms and has been linked to CVD outcomes. When persons have psychiatric diagnoses 
of depression, the association with the metabolic syndrome could even be stronger. Lastly, 
the InCHIANTI sample is comprised only of Italian older adults, who generally score rather 
high on depressive symptoms questionnaires compared to northern European countries and 
the US, which may be due to cultural but not per se clinical differences. Nevertheless, the 
Italian version of the CES-D has shown to be similarly predictive of major depression than 
other language versions, which suggests that its validity is comparable to that used in other 
international studies.21 Strengths of our study were the large, randomly selected sample, 
and the 24-h urine measures of cortisol. This measure of cortisol is rather stable and 
insensitive to transient fluctuations in cortisol that lead to over- and underestimates in 
moment-by-moment sampling. On top, this assessment of the HPA-axis reflects biologically 
active, or unbound cortisol. 
In conclusion, our results suggest a synergistic relationship between depression, 
cortisol, and the metabolic syndrome in an elderly population. Persons with 
| CHAPTER 3 54 
hypercortisolemic depression in particular may be at risk for having the metabolic syndrome, 
and therefore have an increased risk for developing cardiovascular disease or diabetes. 
Further research should confirm our findings and investigate the causality of the 
relationships between depression, cortisol and the metabolic syndrome using prospective 
studies. 
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In their letter to the Editor, Castillo-Quan et al. suggest that hyperinsulinemia might be an 
underlying factor explaining the relationship between depression, hypercortisolemia, 
metabolic syndrome and diabetes. Although this is indeed a potentially interesting 
mechanism, our data do not provide much evidence for a large effect of hyperinsulinemia. 
In our study among 867 older persons,1 we showed that hypercortisolemic depression was 
associated with the metabolic syndrome in an older population. Although we found a weak 
association between 24-h urinary cortisol and serum glucose in the total sample (adjusted β 
= 0.08, p = .02), among depressed persons (N = 179) cortisol appeared to be associated 
more strongly with the obesity-related components of the metabolic syndrome such as waist 
circumference, triglycerides, and high density lipoprotein cholesterol than with serum 
glucose. Actually, for the latter, the correlation with urinary cortisol was not found to be 
significant (β = −0.07, p = .39, see Table 3 in our paper).  
In our study, we also had assessments of serum insulin available. When exploring the 
association between urinary cortisol levels and serum insulin, we found a significant but not 
very large association (β = 0.07, p = .04). However, as with glucose, the association 
between cortisol and insulin was not significant among the depressed (β = 0.05, p = .48). It 
seems therefore rather unlikely that in our conducted study insulin was the driving force 
behind the association between hypercortisolemic depression and the metabolic syndrome.  
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Abstract 
 
Objectives 
High cortisol levels in depressed persons could possibly give rise to the metabolic syndrome. 
This study investigated cross-sectionally whether depression and high cortisol levels 
increased the odds of metabolic syndrome in an older community-based sample.  
 
Methods 
In 1212 participants, aged ≥ 65 years, enrolled in the Longitudinal Aging Study Amsterdam, 
depression (major [1-month diagnosis] or subthreshold [no 1-month diagnosis, but 
symptoms]), metabolic syndrome (modified Adult Treatment Panel III criteria) and free 
cortisol index (total serum cortisol / cortisol binding globulin) were assessed.  
 
Results 
Major depression was not associated with the metabolic syndrome (OR = 1.16, 95% CI = 
0.54-2.49), but subthreshold depression was associated with a decreased odds (OR = 0.55, 
95% CI = 0.37-0.82). Persons with higher levels of free cortisol index showed a higher odds 
of metabolic syndrome (OR per SD increase = 1.21, 95% CI = 1.06-1.39).  
 
Conclusions 
As persons with high cortisol levels more often had metabolic syndrome, hypercortisolemia 
within depressed persons may increase the risk of metabolic syndrome.  
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Introduction 
Recently, several studies have linked metabolic syndrome, a clustering of cardiovascular risk 
factors including abdominal obesity, unfavorable lipid profile, high blood pressure and insulin 
resistance, with depression,1-4 but results have been inconsistent.5 Cortisol, an important 
product of the hypothalamic-pituitary-adrenal (HPA)-axis, has been associated with 
metabolic abnormalities, such as abdominal obesity and insulin resistance and is suggested 
to play a role in the association between depression and metabolic syndrome.6 As 
depression has been associated with both hypo- and hypercortisolemia, at least in later 
life,7,8 this may partly account for inconsistent findings in the association between 
depression and metabolic syndrome. Little research has addressed the joint effect of 
depression and cortisol on the metabolic syndrome in older persons. One recent study in 
older persons showed an increased likelihood of metabolic syndrome in hypercortisolemic 
depressed persons only, supportive of a mediating role of cortisol.9 Identifying depression 
subgroups at increased risk of metabolic syndrome is important for treatment and 
prevention of (consequences of) depression. Furthermore, most studies assessed depression 
using symptoms scales, but distinguishing symptoms from a major depression diagnosis 
might be relevant. Therefore, we investigated the relationship of depression (symptoms or 
diagnosis) and cortisol with metabolic syndrome in community-dwelling older persons.  
 
Methods 
Study population 
Data are from the Longitudinal Aging Study Amsterdam (LASA), a population-based older 
cohort (for details see10). In short, a random sample of men and women aged 55-85 years, 
stratified by age, sex, urbanization and expected five year mortality, was drawn from the 
population registries of eleven municipalities in three regions in the Netherlands. 
Respondents gave informed written consent and the study was approved by the Ethical 
Review Board of the VU University Medical Center. 3107 Respondents aged 55 years and 
over participated in the baseline examination (1992/1993) conducted at the respondents’ 
homes. Data on metabolic syndrome were available at the first follow-up assessment 
(1995/1996; N = 2545, mainly lost to mortality) for persons aged 65 or above (N = 1720). 
Persons with complete data on metabolic syndrome, depression and cortisol (N = 1212) 
were younger (p <. 001), more often men (p = .03), higher educated (p < .001), and had 
less depressive symptoms (p = .004) than persons not included in the analytic sample (N = 
508). 
 
Depression 
The Center for Epidemiologic Studies-Depression Scale (CES-D), a 20-item self-report scale 
on depressive symptoms in the past week, was administered (in our study: Cronbach alpha 
= 0.87). Participants scoring ≥ 16, a commonly used cut-off score indicating clinically 
relevant depressive symptoms,11 were administered the Diagnostic Interview Schedule to 
assess major depression disorder in the past month according to DSM-III criteria. 
Subthreshold depression was defined as a CES-D score ≥ 16, but no major depression in the 
past month.  
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Cortisol 
Blood samples were collected in the morning. Total serum levels of cortisol were determined 
using a commercially available competitive immunoassay (ACS:Centauer, Bayer Diagnostics, 
The Netherlands). Cortisol binding globulin (CBG) levels were determined using a radio 
immunoassay (Medgenix Diagnostics, Belgium). Bound to CBG, cortisol is biologically 
inactive. Therefore, a free cortisol index was computed as total serum cortisol / CBG.  
 
Metabolic syndrome 
Blood pressure was measured in sitting position using a standard mercury 
sphygmomanometer. Waist circumference was averaged over two readings measured 
midway between the lower rib margin and the iliac crest. Fructosamine was determined by a 
colorimetric test, and high-density lipoprotein (HDL) cholesterol and triglycerides by an 
enzymatic colorimetric test (Roche diagnostics, Mannheim, Germany). Prescription drugs 
taken in the previous two weeks were identified by container inspection.  
Metabolic syndrome was defined by slightly modified National Cholesterol Education 
Program Adult Treatment Panel III12 criteria as presence of three or more of the following: 
(i) waist circumference > 102 cm in men or > 88 cm in women; (ii) triglyceride level ≥ 1.7 
mmol/l; (iii) HDL cholesterol < 1.0 mmol/l in men or < 1.3 mmol/l in women; (iv) blood 
pressure ≥ 160/90 mmHg or anti-hypertensive medication; (v) fructosamine ≥ 247 umol/l 
or anti-diabetic medication. Considering the older age of the study population, the cut-off 
for blood pressure was increased (original criterion: ≥ 130/85 mmHg). Because the 
instructions before blood sampling allowed respondents to take tea and dry toast but no 
diary products, fasting blood samples could not be fully guaranteed. Therfore, fructosamine, 
which is less affected by eating, was used as a proxy for glucose. The cutoff of 247 umol/l 
for fructosamine corresponds to the cut-off of 6.1 mmol/l for fasting plasma glucose in 
terms of sensitivity and specificity for insulin resistance.13  
Metabolic syndrome components were analyzed continuously. For persons using 
antihypertensive medication 10 and 5 mmHg were added to systolic and diastolic blood 
pressure, respectively, and persons on anti-diabetics were at least given a value of 247 
umol/l for fructosamine, as in a previous study.9 To normalize distributions, triglycerides, 
HDL cholesterol and fructosamine were log-transformed.  
 
Covariates 
Covariates were selected a priori and included sociodemographic (age, sex, and educational 
level [low, medium, high]), and lifestyle variables (smoking status [non, former, current], 
current alcohol intake [yes/no excessive drinking], and physical activity [total day activities 
in min/day]). Cardiovascular disease (myocardial infarction, angina pectoris, stroke) was 
assessed combining self-reports, medication use, and general practitioner records in a 
standardized algorithm. Diabetes and other chronic diseases (including lung disease, 
arthritis, and cancer) were self-reported.  
 
 
 
| CHAPTER 4  64 
 
Statistical analyses 
Adjusted logistic and linear regression analyses assessed associations between depression 
or cortisol with (number of) metabolic syndrome (components) as outcome. To assess 
whether hypercortisolemia contributed to metabolic syndrome in both depressed and non-
depressed, a cortisol by depression status interaction was tested. 
 
Results 
Mean age of the 1212 participants was 75.3 years (SD = 6.5), 51.5% were women, and 
40.9% had low education. Of the participants, 12.5% had a subthreshold depression, 2.6% 
had a major depression in the past month, and 36.4% had metabolic syndrome. Mean free 
cortisol index level was 12.4 (SD = 4.6). Sample characteristics according to depression 
status are reported elsewhere.7 Table 1 shows adjusted regression analyses with metabolic 
syndrome (components) as outcome. Compared to no depression, subthreshold depression 
decreased odds of metabolic syndrome (OR = 0.55, 95% CI = 0.37-0.82), while major 
depression did not change probability of metabolic syndrome (OR = 1.16, 95% CI = 0.54-
2.49). High free cortisol index increased likelihood of metabolic syndrome (OR per SD 
increase = 1.21, 95% CI = 1.06-1.39). There was no significant free cortisol index by 
depression status interaction (subthreshold depression: p = .85; major depression p = .18), 
indicating that cortisol is associated with metabolic syndrome in both non-depressed and 
depressed subjects. Similar associations for depression and cortisol were found using 
number of metabolic syndrome components as outcome (not shown). Overall, associations 
between depression and individual metabolic syndrome components were in the same 
direction as with metabolic syndrome (see Table 1). Significant associations of free cortisol 
index were found with higher triglyceride levels (β = .080), lower HDL cholesterol levels (β 
= -.153), and higher systolic blood pressure (β = .067). 
 
Conclusions 
This population-based study among older persons showed that persons with high levels of 
cortisol have an increased probability of metabolic syndrome. No associations between 
major depression and metabolic syndrome were found. Unexpectedly, subthreshold 
depression decreased the odds of metabolic syndrome. Up until now some studies did show 
a positive association between depression or depressive symptoms and metabolic 
syndrome,1-4 but absence of associations have been reported too.5 One recent study by 
Skilton et al.,3 reporting an increased depression rate in metabolic syndrome, was 
conducted among a population at risk for cardiovascular disease. Other studies that related 
depression to the metabolic syndrome were conducted among young adults1 or in middle-
aged populations.2,4,14 One study in the older general population reported only a weak 
association between depressive symptoms and metabolic syndrome in White persons only.15 
Also, Giltay et al.16 showed in an older general population, that persons who scored high on 
‘classic’ cardiovascular risk factors related to the metabolic syndrome, such as obesity, 
hypertension, hypercholesterolemia and diabetes did not report more depressive symptoms 
than persons who scored low on these risk factors. Possibly, in a more diffuse general older 
population, associations are not as clear. As was recently also pointed out by Lyness,17  
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Table 1.  Depression, free cortisol index and association with metabolic syndrome a (components b) 
 
N = 1212  Metabolic syndrome 
Waist 
circumference 
Triglycerides  d
N OR 95%CI p β p β p 
Depression         
Depressive symptoms c 1212 0.85 0.74-0.97 .02 -.063 .03 -.039 .20 
Depression status         
No depression  1029 Ref     Ref    Ref  
Subthreshold depression  152 0.55 0.37-0.82 .004 -.085 .002 -.032 .27 
Major depression  31 1.16 0.54-2.49 .71 .024 .38 -.007 .81 
Cortisol         
Free cortisol index c 1212 1.21 1.06-1.39 .004 -.040 .18 .080 .01 
Free cortisol tertiles         
Low free cortisol index (< 9.9) 404 Ref     Ref    Ref  
Middle free cortisol index (9.9-14.1) 404 1.09 0.79-1.49 .61 -.009 .78 .048 .16 
High free cortisol index (> 14.1) 404 1.44 1.04-1.99 .03 -.030 .37 .056 .11 
  
HDL 
cholesterol  d
Systolic  
bl. Pressure 
Diastolic  
bl. pressure 
Fructo-  
samine d
 N β p β P β p β p 
Depression          
Depressive symptoms c 1212 .089  .003 -.044 .16 .053 .09 -.026 .33 
Depression status          
No depression  1029   Ref    Ref    Ref    Ref  
Subthreshold depression  152 .074  .009 -.037 .22 .042 .16 -.033 .19 
Major depression  31 -.011  .68 -.018 .53 .009 .77 -.021 .41 
Cortisol          
Free cortisol index c 1212 -.153 <.001 .067 .03 .046 .14 .043 .10 
Free cortisol tertiles          
Low free cortisol index (< 9.9) 404   Ref    Ref    Ref    Ref  
Middle free cortisol index (9.9-14.1) 404 -.073  .03 .056 .11 .036 .30 .002 .95 
High free cortisol index (> 14.1) 404 -.155 <.001 .047 .19 .018 .62 .045 .14 
HDL: high-density-lipoprotein. a Based on logistic and b linear regression analyses adjusted for age, sex, 
educational level, smoking status, alcohol intake, physical activity, diabetes, cardiovascular disease, and 
number of other chronic diseases; c OR per SD increase: depressive symptoms SD = 7.6; free cortisol index SD 
= 4.6; d to normalize distributions, triglycerides, HDL cholesterol and fructosamine were log-transformed.   
 
 
 
 
| CHAPTER 4  66 
 
associations between depression and disease might be more specific in less heterogeneous 
subpopulations. 
A previous LASA paper7 showed that older depressed persons either had low or high 
levels of cortisol, with the majority of depressed persons in this study having low cortisol. It 
is possible that the nonlinear association between depression and cortisol precluded us from 
finding a positive association between depression and metabolic syndrome, which we 
hypothesized to be partly mediated by cortisol. Contrary to our expectations, persons with 
subthreshold depression were less likely to have metabolic syndrome. As cortisol levels did 
correlate with metabolic syndrome, it is possible that the large proportion of depressed 
persons with low cortisol levels in fact decreased their odds of metabolic syndrome. Low 
cortisol levels in older persons may reflect biological exhaustion or frailty and has been 
associated with reversed metabolic abnormalities.18 In contrast, increased HPA-axis activity 
stimulates accumulation of triglycerides in visceral regions6 and therefore increases the risk 
of metabolic syndrome. Another recent study, in which hypo- and hypercortisolemia was 
more evenly spread over depressed persons,8 did show that hypercortisolemic depression 
was associated with metabolic syndrome in older persons.9 Together, these results suggest 
that hypercortisolemia within depressed persons may increase the risk of metabolic 
syndrome. Longitudinal studies should address the relative timing of disturbed HPA-axis 
activity, depression and metabolic syndrome. 
Associations for cortisol were relatively consistent across metabolic syndrome 
components, with strongest associations for HDL cholesterol, triglycerides and systolic blood 
pressure. In the general population and among depressed persons, associations of cortisol 
with HDL cholesterol and triglycerides have been reported before. In contrast with our 
findings, these studies also found an association of cortisol with abdominal obesity.9,19 
Some limitations of our study need to be addressed. As fasting blood levels could not 
be fully guaranteed, this might have affected our findings for triglycerides, and to a lesser 
extent HDL cholesterol. However, a recent study found that lipid profiles at most change 
minimally in response to normal food and non-fasting levels still predict cardiovascular 
events.20 Yet, would truly fasting lipid levels have been used in our study, associations of 
cortisol with triglycerides and HDL cholesterol might have been even stronger. Furthermore, 
fructosamine was used as a proxy of glucose, because it is less affected by eating. The 
cutoff for fructosamine we used was shown to have maximal effectiveness in discriminating 
subjects with impaired glucose tolerance from subjects with normal glucose tolerance.13 
However, it is possible that, unlike fructosamine, glucose levels would have shown 
associations with depression or cortisol.  
Our study was one of the very few using psychiatric diagnoses of major depression,1 in 
stead of a depression symptoms scale only2-5,14,15 and suggests that associations between 
depression and metabolic syndrome might be different for persons with depressive 
symptoms compared to persons with a depression diagnosis. This might indicate partly 
different constructs, although the number of major depression cases in our study was 
relatively small. Therefore, no definite conclusions can be drawn from our study on the 
association between major depression and the metabolic syndrome.  
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In this study, depression, either defined by diagnosis or symptom scale, was not 
associated with an increased odds of metabolic syndrome. However, high cortisol levels did 
increase the likelihood of metabolic syndrome. This suggests that when depression presents 
with hypercortisolemia it might be important to be watchful of metabolic syndrome to be 
able to prevent metabolic and cardiovascular health consequences.  
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Abstract 
 
Context  
Depression has been hypothesized to result in abdominal obesity through the accumulation 
of visceral fat. No large study has tested this hypothesis longitudinally. 
 
Objective 
To examine whether depressive symptoms predict an increase in abdominal obesity in a 
large population-based sample of well-functioning older persons. 
 
Design 
The Health, Aging, and Body Composition Study, an ongoing prospective cohort study with 
5 years of follow-up. 
 
Setting 
Community-dwelling older persons residing in the areas surrounding Pittsburgh, 
Pennsylvania, and Memphis, Tennessee. 
 
Participants  
A total of 2088 well-functioning white and black persons aged 70 to 79 years. 
 
Main Outcome Measures 
Baseline depression was defined as a Center for Epidemiologic Studies Depression score of 
16 or higher. At baseline and after 5 years, overall obesity measures included body mass 
index (calculated as weight in kilograms divided by height in meters squared) and percent 
body fat (measured by dual-energy x-ray absorptiometry). Abdominal obesity measures 
included waist circumference, sagittal diameter, and visceral fat (measured by computed 
tomography). 
 
Results 
After adjustment for sociodemographics, lifestyle, diseases and overall obesity, baseline 
depression was associated with a 5-year increase in sagittal diameter (β = .054, p = .01) 
and visceral fat (β = .080, p = .001). 
 
Conclusions 
This study shows that depressive symptoms result in an increase in abdominal obesity 
independent of overall obesity, suggesting that there may be specific pathophysiological 
mechanisms that link depression with visceral fat accumulation. These results might also 
help explain why depression increases the risk of diabetes and cardiovascular disease.  
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Introduction 
Depression is common in later life. Clinically relevant depressive symptoms are present in 
10% to 15% of the older population.1 According to the World Health Organization, 
depression is among the leading disorders causing disability and will be the second most 
important cause of disability worldwide in 2020.2 Depression has been associated with the 
onset of diabetes, cardiovascular disease (CVD) and cardiac mortality.3-6 To better prevent 
occurrence of these major disabling and life-threatening diseases, more insight into 
underlying mechanisms relating depression to these disorders, is needed. 
Neuroendocrine disturbances found in depressed persons include dysregulation of the 
hypothalamic-pituitary-adrenal (HPA)-axis and hypothalamic-pituitary-gonadal axis, 
indicated by high levels of cortisol7,8 and low levels of sex steroid hormones,9 respectively. 
In addition, high levels of inflammatory markers have been observed in persons who report 
clinically relevant depressive symptoms.10 Similar abnormalities have been identified in 
persons with abdominal obesity.11,12 Consequently, Björntorp hypothesized that chronic 
stress and/or depression results in abdominal obesity through long-term activation of the 
HPA-axis.13 Björntorp argued that elevated cortisol, particularly when combined with low sex 
steroid hormones, causes fat to accumulate in visceral adipose tissue. This might be due to 
specific properties of visceral fat, such as a high density of glucocorticoid receptors.14 Excess 
visceral fat, as indicated by abdominal obesity, subsequently has been found to predict 
diabetes, CVD, and mortality to a greater degree than overall obesity.15-18 
Until now, no large study has longitudinally tested the hypothesis that depressive 
symptoms lead to an increase in visceral fat. Some cross-sectional studies report an 
association between abdominal obesity and depression19-24 independent of overall obesity. 
One prospective study found that 29 patients with major depression had a larger increase in 
visceral fat than 17 persons without depression.25 
The present study investigates the longitudinal association between depressive 
symptoms at baseline and 5-year changes in abdominal obesity in a large community 
sample of older persons. We hypothesize that depressive symptoms at baseline will predict 
an increase in abdominal obesity over time and that this association is specific to abdominal 
obesity compared with overall obesity. 
 
Methods 
Study population 
Data are from 3075 well-functioning white and black men and women aged 70 to 79 years 
enrolled in the Health, Aging, and Body Composition (Health ABC) study, an ongoing 
prospective cohort study. Participants were recruited in 1997 and 1998 from a sample of 
white and black Medicare-eligible beneficiaries residing in the areas surrounding Pittsburgh, 
Pennsylvania, and Memphis, Tennessee. Race was self-identified and black persons were 
over-sampled to be able to examine race differences. Subjects were eligible if they reported 
no difficulty with walking for a quarter of a mile, walking up 10 steps, or performing 
activities of daily living. Subjects were ineligible if they had severe difficulty communicating, 
had active cancer treatment in the past three years, had plans to move out of the area, or 
were participating in a randomized trial of a lifestyle intervention. All participants signed an 
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informed written consent form approved by the institutional review boards of the clinical 
sites. In the present study, persons with missing baseline data on depressive symptoms 
and/or obesity were excluded (N = 26). In addition, persons without obesity data at the 5-
year assessment in 2002-2003 were excluded (N = 961; 375 persons had died, 13 were lost 
to follow-up, 63 did not participate that year, and 510 were assessed by phone interview 
only), leaving 2088 persons for the present analyses. Included persons (N = 2088) were 
younger (73.4 versus 74.1 years at baseline; p < .001), more often women (52.7% versus 
48.9%; p = .05), white (63.6% versus 47.2%; p < .001), and college educated (46.7% 
versus 32.8%; p < .001) and had lower rates of depression at baseline (4.0% versus 6.2%; 
p = .007) than excluded persons (N = 987). 
 
Depressive symptoms 
During the baseline interview, depressive symptoms were measured with the 20-item Center 
for Epidemiologic Studies Depression (CES-D) scale assessing depressive symptoms in the 
previous week.26 This scale, ranging from 0 to 60, has been widely used in older populations 
and has been shown to be a valid and reliable instrument among the elderly.27 In our study 
the internal consistency was high: Cronbach alpha = 0.81. A score of 16 or higher, the usual 
cut-off, identified persons with clinically relevant depressive symptoms. Although this 
definition does not reflect a psychiatric diagnosis of depression, for convenience in this 
paper we will refer to this cut-off measure as depression. In addition, the CES-D 10 item 
version, which has shown good predictive accuracy when compared with the 20-item CES-D 
scale,28 was administered at follow-up after 2, 3, 4, and 5 years. For sensitivity analyses, 
depressed persons were subdivided into persons who were only depressed at baseline 
(single depression) and those who also had depression at at least one follow-up assessment 
(CES-D-10 ≥ 10) (persistent or recurrent depression).   
 
Obesity 
All obesity measures were assessed at the clinic visit at baseline and after 5 years. 
 
Overall obesity 
Body weight was measured on a standard balance beam scale to the nearest 0.1 kg. Height 
was measured barefoot using a wall-mounted stadiometer to the nearest 0.1 cm. Body mass 
index (BMI) was calculated as weight in kilograms divided by the height in meters squared. 
Total mass (grams) and total fat mass (grams) were determined via a whole body dual 
energy x-ray absorptiometry (DXA) scan using fan beam technology (QDR4500A; Hologic, 
Waltham, Massachusetts, US). The percent body fat was defined as (total fat mass / total 
mass) * 100; when total mass was missing, weight (grams) was used instead. 
 
Abdominal obesity 
Computed tomography (CT) scanning was performed at the level between the fourth and 
fifth lumbar vertebrae to measure visceral fat (cm2) using a Somatom Plus 4 (Siemens, 
Erlangen, Germany) or a Picker PQ 2000S (Marconi Medical Systems, Cleveland, Ohio, US) 
scanner in Memphis and a 9800 Advantage scanner (General Electric, Milwaukee, Wisconsin, 
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US) in Pittsburgh. The scans were conducted at 120 kilovolt (peak) and 200 to 250 mA/s at 
a slice thickness of 10 mm. Areas were calculated by multiplying the number of pixels of a 
given tissue type by the pixel area using IDL development software (Research Systems Inc, 
Boulder, Colorado, US). Visceral fat was manually distinguished from abdominal 
subcutaneous fat by tracing along the fascial plane defining the internal abdominal wall. 
Quality of repositioning on CT scans between baseline and the 5-year assessment was 
rated, incorporating abdominal level and anatomical landmarks. In addition to the 
continuous measure of 5-year change in visceral fat, a categorical measure was constructed, 
defining loss, no change, or gain of visceral fat. A cut-off of 30% change in visceral fat was 
selected, because this approximated 1 SD in the visceral fat change score. Besides the direct 
CT measure of visceral fat, some anthropometric measures were assessed. Maximum 
sagittal diameter (cm), the distance between the abdomen and back, was derived from the 
CT scans. Waist circumference (cm) was measured at the largest abdominal circumference 
to the nearest 0.1 cm using a flexible plastic tape measure. 
 
Baseline characteristics 
Sociodemographic characteristics included age, sex, race (white, black), site (Pittsburgh, 
Memphis), and education (less than high school, high school, post-secondary education). 
We also assessed lifestyle characteristics known to be related to both abdominal obesity and 
depression: smoking status (nonsmoker, former, or current), current alcohol intake (0-1 
versus ≥ 2 drinks per day) and physical activity (sum of weight training, high and medium 
intensity exercise, aerobic dance, [exercise] walking, and stair climbing [in 
kilocalories/week]). Presence of baseline diabetes and CVD (including stroke or transient 
ischemic attack, myocardial infarction, angina pectoris, percutaneous transluminal coronary 
angioplasty, or coronary artery bypass grafting) were adjudicated using standardized 
algorithms considering various sources of information: self-report, medication use, oral 
glucose tolerance testing, and medical claims data from the former Health Care Financing 
Administration. Number of other chronic diseases was mainly based on self-report and 
included congestive heart failure, peripheral arterial disease, cancer, lung disease, 
osteoarthritis, osteoporosis, gastrointestinal disease, prostate disease, thyroid disease, 
Parkinson’s disease, and kidney disease. In addition, all medications regularly taken in the 2 
weeks before baseline were recorded and coded according to the Iowa Drug Information 
System (IDIS).29 From this inventory, the total number of prescription medications taken 
was calculated. In addition, use of antidepressant medication was ascertained, which 
included monoamine oxidase inhibitors (IDIS code 281605), tri/tetracyclic antidepressants 
(IDIS code 281606), selective serotonin reuptake inhibitors (IDIS code 281607), and other 
antidepressants (IDIS code 281604), regardless of reason. Other psychoactive medication 
included antipsychotic (phenothiazines, IDIS code 281609; butyrophenones, IDIS code 
282610; other, IDIS code 281608) and anxiolytic (benzodiazepines, barbiturates, other, IDIS 
code 2824) medication.  
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Statistical analysis 
Sample characteristics were compared between depressed and non-depressed persons 
using Χ2 tests for dichotomous and categorical variables and independent t tests for 
continuous variables. Because some of the obesity measures differ greatly between men 
and women, sex-adjusted means were presented based on analyses of covariance. Paired-
sample t-tests were performed to assess whether 5-year changes in obesity were 
statistically significant. To evaluate the association between depressive symptoms at 
baseline (both continuous as well as dichotomous) and 5-year change in abdominal obesity, 
linear regression analyses were conducted with abdominal obesity change scores as the 
outcome. For comparison, associations between depressive symptoms and overall obesity 
were also presented. Covariates were a priori selected and initial analyses were adjusted for 
the corresponding baseline obesity measure and sociodemographic variables (sex, age, 
race, site, and education). Next, to assess whether results were independent of baseline 
overall obesity, abdominal obesity analyses were additionally adjusted for BMI. Finally, 
because lifestyle, abdominal obesity-related diseases, and general health status might partly 
explain the association between abdominal obesity and depression, we examined their role 
by additionally adjusting analyses for smoking status, alcohol intake, physical activity, 
prevalent diabetes, prevalent CVD, number of other chronic diseases, and number of 
prescription medications taken.  
Because depression has also been associated with weight loss,30,31 it is possible that a 
U-shaped association exists between depression and change in visceral fat, with depression 
being associated with both gain and loss of visceral fat. Therefore, it was checked whether 
baseline depression was also associated with a decrease in visceral fat, distinct from a 
potential increase in visceral fat. For this purpose, an adjusted multinomial logistic 
regression analysis was performed using categories of visceral fat change (loss, no change, 
gain) as the outcome. By choosing the no change group as the reference category, this 
analysis gives 2 odds ratios, one assessing the risk of losing visceral fat when depressed at 
baseline, and one assessing the risk of gaining visceral fat when depressed at baseline. 
Furthermore, to verify that the association between depression and visceral fat was 
independent of change in BMI a linear regression analysis was performed with change in 
visceral fat as the outcome, adjusted for change in BMI. In addition, it was tested whether 
an interaction existed with change in BMI, to assess whether the relationship between 
depression and change in visceral fat was consistent across the whole range from weight 
loss and weight stability to weight gain. 
Because sex differences in the relationships between depression, abdominal obesity, 
and CVD have been observed3,18 and because fat distribution differs across sex and race, all 
analyses were repeated including sex by depression and sex-specific race by depression 
interaction terms, to test whether findings were consistent across sex and race. For 
graphing purposes, adjusted mean 5-year changes in abdominal obesity were calculated 
using analyses of covariance. Finally, because a significant proportion of persons enrolled at 
baseline did not have a clinic visit after 5 years, leaving the most healthy persons for 
analysis, missing values at follow-up were multiply imputed. Multiple imputation was 
established by Multivariate Imputation by Chained Equations32 using R statistical software. 
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Obesity follow-up measures were only imputed if depression and the corresponding obesity 
measure at baseline were not missing. Missing follow-up obesity values were 5 times 
imputed by predictive mean matching using information from all available covariates (sex, 
age, race, site, education, smoking status, alcohol intake, physical activity, prevalent 
diabetes, prevalent CVD, number of other chronic diseases, number of prescription 
medications taken, antidepressant medication, other psychoactive medication), predictors 
(CES-D score, yes or no depression, yes or no persistent depression), the corresponding 
baseline obesity measure, BMI and change in BMI for abdominal obesity measures, and 
visceral fat and change in visceral fat for overall obesity measures. Fully adjusted (including 
adjustment for yes/no imputed value) linear regression analyses that associated depression 
with change in obesity were conducted on each of the 5 newly created datasets and the 
results were pooled.  
 
Results 
Sample characteristics 
At baseline, the mean (SD) age of the participants was 73.4 (2.8) years, 52.7% were 
women, and 36.4% were black. Depression was present in 4.0% of participants and the 
mean (SD) BMI was 27.3 (4.7). Women had a greater percent body fat than men (40.5% 
versus 29.5%), but had less visceral fat (130.7 cm2 versus 157.4 cm2). Overall, 5-year 
changes in obesity were small, although some increases in obesity were seen in men while 
decreases in abdominal obesity were observed in women, especially in visceral fat (-11.4 
cm2), consistent with earlier reported findings in this older sample.33 Visceral fat correlated 
more strongly with waist circumference (Pearson’s r = 0.63) and sagittal diameter 
(Pearson’s r = 0.75) than with BMI (Pearson’s r = 0.54). Table 1 shows the sample 
characteristics for persons with and without depression. Persons with baseline depression 
were less educated, had more chronic diseases and were taking more prescription 
medication. Depressed persons had slightly higher sex-adjusted percent body fat at baseline 
(35.2% versus 36.6%, p = .02) and showed a (larger) sex-adjusted 5-year increase in 
sagittal diameter (0.2 cm versus 0.9 cm, p = .007) and visceral fat (-7.1 cm2 versus 9.0 
cm2, p = .001) than non-depressed persons. 
 
Baseline depressive symptoms and 5-year change in abdominal obesity 
Table 2 describes the results of adjusted linear regression analyses assessing the association 
between baseline CES-D score (continuous) and depression (CES-D ≥ 16) with 5-year 
changes in obesity measures. No significant associations were found for the continuous 
CES-D score or the depression variable with 5-year changes in overall obesity (BMI or 
percent body fat). In contrast, after full adjustment for covariates, baseline depression was 
associated with increases in sagittal diameter (β = .054, p = .01), and visceral fat (β = 
.080, p = .001), with a trend for an increase in waist circumference (β = .031, p = .08). For 
the continuous CES-D score these associations were still consistent but somewhat 
attenuated (waist circumference: β = .026, p = .15; sagittal diameter: β = .037, p = .10; 
visceral fat: β = .042, p = .07).  
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Table 1. Sample characteristics 
 
Characteristic 
CES-D < 16 
N = 2004 
CES-D ≥ 16 
N = 84 
p a
Sociodemographic variables    
Age (years), mean (SD) 73.4 (2.8) 73.6 (2.9) .50 
Black, % 36.3 38.1 .74 
Memphis site, % 50.0 42.9 .20 
Education, %    
Less than high school 21.6 27.4 .05 
High school 31.2 36.9  
Postsecondary 47.2 35.7  
Lifestyle variables    
Current smoker, % 7.7 11.9 .16 
> 1 Alcoholic drink / day, % 7.3 7.1 .96 
Physical activity (kcal/week), mean (SD) 1177 (2023) 1118 (2615) .80 
Somatic comorbidities    
Prevalent diabetes, % 20.9 17.9  .50 
Prevalent cardiovascular disease, % 21.1 25.0 .39 
Number of other chronic diseases, mean (SD) 1.2 (1.0) 1.5 (1.1) .02 
Number of prescription medications, mean (SD) 3.0 (2.4) 4.2 (3.4) .002 
Depression variables    
Baseline CES-D score (0-60), mean (SD) 3.8 (3.7) 20.9 (5.3) <.001 
Baseline antidepressant use, % 5.0 13.1 .001 
Baseline other psychoactive medication use, % 6.3 22.6 <.001 
Obesity variables    
Overall obesity    
Body mass index (kg/m2), mean (SD) 27.3 (4.7) 27.9 (4.7)  .28 
Percent body fat, mean (SD) 35.2 (5.2) 36.6 (5.2)  .02 
5-y Change in body mass index, (kg/m2), mean (SD) -0.0 (1.8) 0.2 (2.2)  .18 
5-y Change in percent body fat, mean (SD)  0.4 (2.7) b 0.3 (2.7)  .78 
Abdominal obesity    
Waist circumference (cm), mean (SD) 99.3 (12.2) 100.7 (12.2)  .29 
Sagittal diameter (cm), mean (SD) 23.5 (3.3) 23.5 (3.3)  .87 
Visceral fat (cm2), mean (SD) 142.8 (64.7) 155.7 (64.7)  .08 
5-y Change in waist circumference (cm), mean (SD) -0.8 (9.3) b 0.9 (9.3)  .09 
5-y Change in sagittal diameter (cm), mean (SD)  0.2 (2.1) b 0.9 (2.1) b  .007 
5-y Change in visceral fat (cm2), mean (SD) -7.1 (40.4) b 9.0 (40.4)   .001 
CES-D = Center for Epidemiologic Studies Depression scale. a Based on Χ2 tests for dichotomous and 
categorical variables and on independent t tests for continuous variables; for obesity variables sex-
adjusted means and SD’s are presented based on analyses of covariance; b paired-sample t tests 
indicated statistically significant 5-y increase or decrease in (abdominal) obesity: p ≤ .001. 
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Table 2: Baseline depressive symptoms and 5-year change in obesity 
 
  Overall obesity  Abdominal obesity 
 
  
BMI 
N = 2088 
Percent 
 body fat 
N = 1944 
waist 
circumference
N = 2067 
sagittal 
diameter 
N = 1885 
visceral 
fat 
N = 1752 
Depressive symptoms  β P β p  β p β p β p 
Continuous CES-D score             
Sociodemographics a  .037 .09 .012 .59  .028 .16 .048 .04 .045 .06 
+ Overall obesity b  -  - -  -  .032 .07 .044 .05 .045 .05 
+ Life style and diseases c  .035 .11 .007 .76  .026 .15 .037 .10 .042 .08 
Depression: CES-D ≥ 16             
Sociodemographics a  .033 .13 .003 .88  .034 .08 .061 .006 .079 .001 
+ Overall obesity b  -  - -  -  .034 .05 .057 .008 .079 .001 
+ Life style and diseases c  .030 .18 -.002 .94  .031 .08 .054 .01 .080 .001 
CES-D = Center for Epidemiologic Studies Depression scale. a Linear regression analyses adjusted for 
corresponding baseline obesity measure, sex, age, race, site and education; b previous model plus baseline BMI 
for abdominal obesity measures; c previous model plus smoking status, alcohol intake, physical activity, prevalent 
diabetes, prevalent cardiovascular disease, number of other chronic diseases and number of prescription 
medications taken. 
 
 
Role of weight change 
To check whether depressive symptoms were also associated with a loss in abdominal 
obesity, an adjusted multinomial logistic regression analysis was performed using visceral 
fat change categories (≥ 30% loss, no change, ≥ 30% gain) as the outcome. Persons with 
baseline depression had odds of 0.43 (95% CI = 0.18-1.04, p = .06; i.e. a decreased risk) 
to lose visceral fat and odds of 2.06 (95% CI = 1.04-4.05, p = .04; i.e. an increased risk) to 
gain visceral fat compared with having no change in visceral fat, indicating a linear 
association between baseline depression and change in visceral fat. To verify that the 
association between depression and visceral fat was independent of change in BMI, the 
association between depression and visceral fat, as reported in Table 2, was additionally 
adjusted for change in BMI. The relationship between depression and change in visceral fat 
remained statistically significant (β = .050,  p= .009). Furthermore, no interaction between 
depression and change in BMI in the association with visceral fat was found (p = .95). 
 
Sex and race differences 
To examine whether associations between depression and abdominal obesity were 
consistent across sex and race, sex by depression and sex-specific race by depression 
interaction terms were included in the fully adjusted models assessing the association 
between depression and change in abdominal obesity as described in Table 2. A significant 
sex by depression interaction (p = .03) was found for change in visceral fat only. No race 
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interactions were found for men (all p > .20), but in women, trends for race by depression 
interactions in predicting 5-year change in abdominal obesity were found for waist 
circumference (p = .06), sagittal diameter (p = .09), and visceral fat (p = .08). Because 
race interactions were found in women only, subsequent analyses were stratified by sex and 
race. Depression rates across sex by race groups were as follows: white men (N = 683): 
3.5%, white women (N = 645): 4.3%, black men (N = 304): 3.3%, and black women (N = 
456): 4.8%. Stratification showed that the association between depression and 5-year 
change in visceral fat was generally consistent across sex and race with the exception of 
black women (white men: β = .154, p < .001; white women: β = .078, p = .05; black men: 
β = .121, p = .06; black women: β = -.029, p = .54). To graph these findings for all 
abdominal obesity measures, adjusted mean 5-year changes in abdominal obesity were 
calculated for persons with and without baseline depression using analyses of covariance 
stratified by sex and race (Figure 1). The figure shows that baseline depression was 
associated with an increase in abdominal obesity while persons without depression showed 
a much smaller increase or even a decrease in abdominal obesity over 5 years. This finding 
was consistent across all abdominal obesity measures and across sex and race, with the 
exception of black women. 
 
Additional analyses 
To assess the robustness of our findings, a set of sensitivity analyses was conducted. First, 
the association between depression and change in abdominal obesity was assessed in 
persons with a single depression at baseline (N = 17) and in those with persistent/recurrent 
depression (N = 67). These analyses showed rather consistent associations for both 
depression groups (waist circumference: β = .016, p = .36 and β = .027, p = .13, sagittal 
diameter: β = .028, p = .21 and β = .047, p = .03, visceral fat: β = .070, p = .002 and β = 
.055, p = .02, respectively). To ensure that associations between depression and increases 
in abdominal fat were not due to antidepressant use, the analyses described in Table 2 were 
additionally adjusted for antidepressant use, which did not change the results in any 
meaningful way. Similar results were also found when adjusting for other psychoactive 
medications. Also, when persons with a low quality of repositioning on the CT scans (N = 
84) were excluded from the analyses, associations with increases in visceral fat were 
comparable. Finally, to include all persons with baseline obesity data and to check the 
potential effect of selective drop-out, analyses were conducted after multiple imputation for 
missing values. When repeating the fully adjusted analyses described in Table 2, 
associations between depression and change in abdominal obesity largely remained (waist 
circumference: N = 3038, β = .021, p = .27; sagittal diameter: N = 2998, β = .041, p = 
.03; visceral fat: N = 2931, β = .073, p < .001).  
 
Discussion 
This study examined whether depressive symptoms could predict an increase in abdominal 
obesity over time in a large community-based sample of older persons. As hypothesized, 
depressed persons showed a significantly greater increase in abdominal obesity over 5 
years, especially in visceral fat, than non-depressed persons. Such an association was not  
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Figure 1. Adjusted mean 5-year changes in abdominal obesity according to baseline 
depression across sex and race groups 
Waist circumference (A; overall p = .08), sagittal diameter (B; overall p = .01), and visceral fat (C; 
overall p= .001); based on analyses of covariance adjusted for corresponding baseline abdominal 
obesity measure, age, site, education, body mass index, smoking status, alcohol intake, physical 
activity, prevalent diabetes, prevalent cardiovascular disease, number of other chronic diseases and 
number of prescription medications taken. 
 
 
found for an increase in overall obesity and also appeared to be independent of changes in 
overall obesity, suggesting that depressive symptoms are rather specifically associated with 
fat gain in the visceral region. 
To our knowledge, this is the first study to examine the association between depressive 
symptoms and increases in abdominal obesity over time in a large cohort. Our results are 
consistent with a study by Weber-Hamann et al.,25 that showed a larger accumulation of 
visceral fat mass over time in 29 depressed patients compared with 17 controls. Most 
studies so far have assessed the association between abdominal obesity and depression 
cross-sectionally, using either anthropometric measures alone, or CT measures in relatively 
small study samples.19-24 Most of these studies showed a positive relationship between 
depression and abdominal obesity, although one large epidemiological study could not 
demonstrate an association between waist circumference and depression.34 In our study, 
associations with waist circumference were also weaker than those with visceral fat, possibly 
owing to the fact that waist circumference is only an indirect measure of visceral fat and is 
determined by both abdominal subcutaneous and visceral fat mass. Also, measuring waist 
circumference might be less precise than CT scanning. Stronger associations were found for 
sagittal diameter, which is considered a better indicator of visceral fat than waist 
circumference in older persons.35 Our results indeed show a higher correlation of sagittal 
diameter (r = 0.75) than waist circumference (r = 0.63) with visceral fat. Most pronounced, 
however, were the associations with visceral fat, which is in line with our hypothesis that 
depressive symptoms contribute to an accumulation of visceral fat specifically. 
Although depression has been associated with weight loss,30,31 our results show an 
increase in visceral fat in persons with depressive symptoms, even in this aging population 
where decreases in fat mass are common.36 We found no evidence that depression would 
result in a loss of visceral fat. In fact, we found that depression was negatively associated 
with a loss of visceral fat, indicating that depression is linearly linked with the accumulation 
of visceral fat and no U-shaped association exists. Furthermore, depression appeared to be 
specifically associated with abdominal obesity stronger than and independent of overall 
obesity. Associations between depressive symptoms and overall obesity were not found, and 
adjusting abdominal obesity analyses for baseline BMI did not influence findings. We 
additionally adjusted for change in BMI which was partly an over-adjustment because 
changes in BMI also reflect changes in visceral fat. However, despite this relatively strict 
adjustment, the relationship between depression and change in visceral fat remained. 
Moreover, our results showed that across the whole range of weight change, an association 
existed between depression and visceral fat, suggesting that even in persons who lost 
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weight, visceral fat was preferentially retained in those with depression. The finding that 
associations were specific for abdominal obesity is in line with other studies showing that 
abdominal obesity, more than overall obesity, is associated with poor health outcomes such 
as diabetes, CVD, and mortality.15-18 Because depression as well as diabetes and CVD 
appear to be specifically associated with excess visceral fat, this could help explain the 
frequently found increased risk of diabetes and CVD in depressed persons.  
Our results indicate that depression predicts increases in abdominal obesity in all but 
black women. Reasons for this exception are not entirely clear. One explanation may be that 
the black women in this older sample experienced a relatively large decrease in visceral fat, 
which might have obscured the association between depressive symptoms and the 
accumulation of visceral fat. Alternatively, this could have been a chance finding due to 
small sample sizes after stratification by sex and race. However, expected associations were 
found for the other 3 sex by race groups. Future research should explore sex and race 
differences further in younger samples. 
What are the mechanisms by which depression may promote visceral fat accumulation? 
As suggested by Björntorp, stress activates the HPA-axis, which leads to an accumulation of 
visceral fat.13 Studies show that chronic stress and depression are, at least in a subset of 
patients, associated with a dysregulation of the HPA-axis and elevated concentrations of 
cortisol.7,8 Visceral fat is highly sensitive to cortisol owing to a high density of glucocorticoid 
receptors.14 Cortisol promotes the accumulation of visceral fat by activating lipoprotein 
lipase and inhibiting lipid mobilization.13 Indeed, it has been shown that hypercortisolemic 
depression is associated with abdominal obesity.20,37 Moreover, these effects might be most 
pronounced when levels of sex steroid hormones, which have been found to reduce visceral 
fat mass and have a lipid-mobilizing effect,13,38 are low, as has been observed in late-life 
depression.9 Further, depression has been linked to high levels of inflammatory markers,10 
which can activate the HPA-axis39 and therefore subsequently result in visceral obesity. 
Moreover, as described by Gold and Chrousos,40 even in persons with non-hypercortisolemic 
atypical depression, owing to overeating, a cycling of weight gain and loss occurring 
throughout recurrent episodes of depression could preferentially distribute weight to visceral 
fat areas. An alternative explanation for why depression may lead to abdominal obesity is 
that depressed persons have an unhealthier lifestyle. Although we adjusted our analyses for 
some lifestyle behaviors (smoking status, alcohol intake, and physical activity), it is possible 
that depressed persons have a poorer dietary pattern. However, a poor diet in itself would 
likely lead to an increase in both overall and abdominal obesity.41 In combination with a 
hyperactive HPA-axis, however, it is possible that excess caloric intake is preponderantly 
stored into visceral fat depots.42 In addition, somatic comorbidities of depressed persons 
could have led to the increase in visceral fat, although our results were little affected by 
adjustment for diabetes, CVD, and general health status. Furthermore, weight gain in 
depressed persons has been associated with the use of antidepressants.43 However, in our 
study antidepressant use was not associated with increases in (abdominal) obesity, and 
therefore our findings can not be the result of antidepressant use. 
The link between depressive symptoms and increased abdominal obesity was stronger 
for the dichotomous indicator of depression than for the continuous CES-D score, suggesting 
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that a certain amount of distress is needed before visceral fat starts to accumulate. On the 
other hand, we did not find evidence that the association between depression and an 
increase in abdominal obesity was specific for persons with persistent/recurrent depression 
compared with persons with a single depression episode at baseline. However, most 
persons depressed at baseline did have an additional episode of depression during follow-up 
and it is possible that persons only depressed at baseline did experience additional 
depressive episodes between annual assessments.  
Our study has some limitations. We did not have well-accepted criterion-based 
psychiatric diagnoses of depression. However, the CES-D is a commonly used scale to 
measure clinically relevant depressive symptoms. Our results might have been even 
stronger for persons with a diagnosis of major depressive disorder. Further, our sample 
showed low levels of depressive symptomatology at baseline and this aging population 
exhibited little change or even decrease in obesity, making it more difficult to detect 
associations with changes in obesity. Possibly, associations may be even stronger in a 
middle-aged population were visceral fat tends to increase over time. In addition, after 5 
years of follow-up, there was drop-out owing to mortality and non-response, likely resulting 
in a relatively healthy sample, which could have led to an underestimation of the association 
between depression and change in abdominal obesity. On the other hand, studying the 
most healthy had the advantage that associations found were less likely confounded by 
somatic comorbidities. When missing values of persons without 5-year follow-up data were 
imputed, thereby including the less healthy, associations between depression and increase 
in abdominal obesity largely remained. Our study also has some important strengths, 
including use of a large community-based cohort followed up for several years with 
repeated DXA and CT scans, which provide more direct assessments of total and visceral fat 
stores, as well as the more commonly used anthropometric measures. 
Our longitudinal results suggest that clinically relevant depressive symptoms give rise to 
an increase in abdominal obesity, in particular visceral fat, which seems to be stronger than 
and independent of overall obesity. Because of this specific accumulation of visceral fat, 
these results clearly suggest that there may be certain underlying pathophysiological 
mechanisms, plausibly involving the HPA-axis, which link depression with visceral fat. This 
could also help explain why depression is often followed by diabetes or CVD. Future 
research should further disentangle these mechanisms because this will yield important 
information for prevention or treatment of depression-related health consequences.  
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Abstract 
 
Objective 
Although several cross-sectional studies have linked obesity and depression, less is known 
about their longitudinal association and about the relative influence of obesity subtypes. We 
prospectively examined whether obesity (specifically, abdominal) increased the risk of onset 
of depression in a population-based sample of older persons. 
 
Method 
Participants were 2547 non-depressed, well-functioning white and black persons, aged 70-
79 years, enrolled in the Health, Aging and Body Composition study, an ongoing prospective 
community-based cohort study. Baseline measurements were conducted between April 1997 
and June 1998. Overall obesity was assessed by body mass index (BMI) and percent body 
fat (measured by dual energy x-ray absorptiometry), whereas abdominal obesity measures 
included waist circumference, sagittal diameter, and visceral fat (measured by computer 
tomography). Onset of significant depressive symptoms was defined as a Center for 
Epidemiologic Studies Depression 10-item score ≥ 10 at any annual follow-up over 5 years 
and/or new antidepressant medication use. Persistent depression was defined as depression 
at 2 consecutive follow-up visits. 
 
Results 
Over 5 years, significant depressive symptoms emerged in 23.7% of initially non-depressed 
persons. In men, both overall (BMI: HR per SD increase = 1.20, 95% CI = 1.03-1.40) and 
abdominal obesity (visceral fat: HR per SD increase = 1.19, 95% CI = 1.07-1.33) predicted 
onset of depressive symptoms after adjustment for sociodemographics. When BMI and 
visceral fat were adjusted for each other, only visceral fat was significantly associated with 
depression onset (HR = 1.18, 95% CI = 1.04-1.34). Stronger associations were found for 
persistent depressive symptoms. No associations were found in women. 
 
Conclusion 
This study shows that obesity, in particular visceral fat, increases the risk of onset of 
significant depressive symptoms in men. These results suggest that specific mechanisms 
might relate visceral fat to the onset of depression.  
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Introduction 
In a recent systematic review of epidemiological studies Atlantis and Baker1 concluded there 
is a weak level of evidence that obesity increases the incidence of depression, 
predominantly based on cross-sectional studies.2-4 The prevalence of overweight and obesity 
is increasing worldwide at an alarming rate.5 In the US, obesity is prevalent among almost 
one-third of the general population, and another third is overweight.6 Overweight and 
obesity are associated with a multitude of health risks, including increased risks of diabetes 
and cardiovascular disease (CVD).7,8 This combination of high prevalence and poor 
outcomes makes obesity a major public health concern with implications for depression 
outcomes, as well. At this moment, however, depression guidelines do not consider obesity 
as a major comorbidity of depression. Before obesity comorbidity can be incorporated in 
depression treatment, it is important to gain more knowledge of the direction, specifics, and 
strength of the association between obesity and depression.  
Longitudinal studies that examine the direction of the association between depression 
and obesity are relatively sparse, were mostly conducted among adolescents, and show 
mixed results. Recently, we showed that depression is associated with an increase in obesity 
over time.9 Conversely, one study showed that obesity was associated with subsequent 
depression,10 but this was not confirmed in another study.11 In addition, sex inconsistencies 
in the obesity-depression relationship have been found.1-3,11,12 Furthermore, different 
subtypes of obesity exist, and the location of excess fat storage may be an important 
determinant of subsequent health risks. Excess fat in the visceral region has been found to 
be a stronger predictor of diabetes and CVD than overall obesity.13,14 Longitudinal studies on 
the association between abdominal obesity and depression are even more sparse.  
The present study investigated prospectively whether obesity predicted the onset of 
significant depressive symptoms in an older sample of initially non-depressed persons. In 
addition, this study examined whether the association between obesity and onset of 
depressive symptoms was consistent for men and women, and whether type of obesity 
(overall versus abdominal) influenced the obesity-depression link. 
 
Methods 
Study Population 
The Health, Aging and Body Composition (ABC) study is an ongoing prospective cohort 
study among 3075 well-functioning white and black men and women, aged 70-79 years. 
The Health ABC study was designed to prospectively investigate changes in body 
composition and weight-related health outcomes in an aging population. Participants were 
recruited between April 1997 and June 1998 from a random sample of white and black 
Medicare-eligible beneficiaries residing in the areas surrounding Pittsburgh, Pennsylvania 
and Memphis, Tennessee. Eligible subjects reported no difficulty with walking for a quarter 
of a mile, walking up 10 steps, or performing activities of daily living. Subjects were 
ineligible if they had severe difficulty communicating, active cancer treatment in the past 3 
years, or plans to move. After complete description of the study, all participants signed an 
informed written consent approved by the institutional review boards of the clinical sites. 
For the present study, only persons free of depression at baseline were selected (N = 
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2802). Of these, persons without data on baseline body mass index (BMI) or visceral fat (N 
= 104) or with no follow-up data on depressive symptoms (N = 151) were excluded, leaving 
2547 persons for the present analyses. Excluded persons were more often men (57.6% 
versus 48.6%, p = .006), black (52.2% versus 40.6%, p < .001), less educated (35.7% 
versus 43.6% with postsecondary education; p < .001), had more often onset of depressive 
symptoms (33.7% versus 23.9%, p = .03), and had a lower (sex-adjusted) percent body fat 
(33.7% versus 35.1%, p = .002) than included persons, but did not differ in age or other 
obesity measures.   
 
Significant depressive symptoms 
During the baseline interview and at follow-up (after 2, 3, 4, and 5 years), depressive 
symptoms were measured with the Center for Epidemiologic Studies Depression (CES-D) 
scale 10-item version, assessing depressive symptoms in the previous week.15 The original 
20-item CES-D scale has been widely used in older populations and has been shown to be a 
valid and reliable instrument (100% sensitivity and 88% specificity for detecting a major 
depressive disorder in the older population),16 but the 10-item subset of the CES-D, ranging 
from 0 to 30, has shown good predictive accuracy when compared to the 20-item CES-D 
scale.17 In addition, at baseline and at follow-up (after 1, 2, 4 and 5 years) all medications 
regularly taken in the past 2 weeks were recorded and coded according to the Iowa Drug 
Information System (IDIS).18 Antidepressant use included monoamine oxidase inhibitors 
(IDIS code 281605), tri/tetracyclic antidepressants (IDIS code 281606), selective serotonin 
reuptake inhibitors (IDIS code 281607), and other antidepressants (IDIS code 281604) with 
depression or mood disorder as self-reported reason. Persons with antidepressant use or a 
CES-D-10 score ≥ 10 (compares to the commonly used cut-off of ≥ 16 on CES-D-2017) at 
baseline were excluded from the analyses. For the present analyses, onset of significant 
depressive symptoms was defined as having a CES-D-10 score ≥ 10 on any of the follow-up 
assessments and/or new antidepressant medication use during follow-up. To identify the 
onset of more chronic depressive symptoms, persistent depressive symptoms were defined 
as depressive symptoms at 2 consecutive follow-up visits. For sensitivity analyses 2 
alternative definitions of depressive symptoms were constructed: one based on CES-D-10 
scores only (since antidepressant medications are sometimes used in the treatment of 
obesity), and another incorporated an additional requirement of a minimum increase of 3 
points on the CES-D-10 (to assure an actual onset of depressive symptoms and not just a 
crossing of the cut-off point).  
 
Obesity 
Overall obesity 
Body weight was measured on a standard balance beam scale to the nearest 0.1 kg. Height 
was measured barefoot using a wall-mounted stadiometer to the nearest 0.1 cm. BMI was 
calculated as weight (kg) divided by the square of height (m2). BMI categories were 
constructed to indicate normal weight (BMI < 25), overweight (BMI ≥ 25 and < 30), and 
obesity (BMI ≥ 30). Percent body fat was determined via a whole body dual energy x-ray 
absorptiometry (DXA) scan (for details, see9).  
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Abdominal obesity 
Computed tomography (CT) scanning was performed at the level between the fourth and 
fifth lumbar vertebrae (L4-L5) to measure visceral fat (cm2), as described in Vogelzangs et 
al.9 Next to this continuous measure of visceral fat, sex-specific quartiles of visceral fat were 
constructed and a dichotomous visceral fat variable compared persons in the highest 
quartile to persons in quartiles 1 to 3. In addition to this direct CT measure of visceral fat, 
some anthropometric measures were assessed. Maximum sagittal diameter (cm), the 
distance between the abdomen and back, was derived from the CT scans. Waist 
circumference (cm) was measured at the largest abdominal circumference to the nearest 
0.1 cm using a flexible plastic tape measure. 
 
Covariates 
Covariates were a priori selected on the basis of previously reported associations with both 
obesity and depression. Sociodemographic characteristics included age, sex, site 
(Pittsburgh, Memphis), race (white, black), marital status (yes or no currently married) and 
education (less than high school, high school, postsecondary). Lifestyle characteristics were 
also assessed, including smoking status (non, former, or current), current alcohol intake 
(yes or no > 1 drink per day) and physical activity (sum of weight training, high and 
medium intensity exercise, aerobic dance, [exercise] walking, and stair climbing [in 
kcal/week]). As both obesity (specifically, abdominal) and depression have consistently been 
associated with CVD and diabetes, these diseases were specifically addressed. Presence of 
baseline diabetes and CVD (including stroke, myocardial infarction, angina pectoris, 
coronary angioplasty or coronary artery bypass grafting) was adjudicated using standardized 
algorithms, considering various sources of information that included self-report, medication 
use, clinical examination findings, and medical claims data from the former Health Care 
Financing Administration. Identification of incident diabetes and new CVD events during 
follow-up additionally included hospitalization records assessed according to set algorithms. 
Also, we included 2 indicators for general health status. Number of other chronic diseases 
was mainly based on self-report and included congestive heart failure, peripheral arterial 
disease, cancer, lung disease, osteoarthritis, osteoporosis, gastrointestinal disease, prostate 
disease, thyroid disease, Parkinson’s disease, and kidney disease. In addition, all 
medications regularly taken in the past 2 weeks before baseline were recorded and coded 
according to the Iowa Drug Information System.18 From this inventory, the total number of 
prescription medication taken was calculated. 
 
Statistical Analyses 
Because sex differences in the relationship between obesity and depression have been 
observed3,12 and since men and women differ in body composition, all analyses were 
presented for men and women separately, and sex-interaction effects were tested for 
statistical significance. Sample characteristics were compared between persons with and 
without onset of depressive symptoms during follow-up using Χ2 tests for dichotomous and 
categorical variables and independent t tests for continuous variables. Risk of onset of 
significant depressive symptoms (overall, non-persistent and persistent) according to 
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different measures of baseline obesity (overall and abdominal) was assessed using Cox 
regression analyses, and the proportional hazards assumption was examined. The 
assumption of linearity was assessed by checking improvement of model fit after inclusion of 
a quadratic term for each corresponding obesity measure, respectively. Presence of 
multicollinearity was assessed by means of the  variance inflation factor (VIF) when all 
covariates were included in the same model. To be able to compare hazard ratios (HRs) 
across obesity measures, HRs with 95% confidence intervals (CIs) were expressed per 
standard deviation (SD) increase. For comparability across subsamples, sex-weighted SDs 
were used. Analyses were adjusted for baseline CES-D-10 score, sex, age, race, site, marital 
status and education. Because fat distribution differs between whites and blacks, all 
analyses were repeated, including race-interaction terms, to test whether findings were 
consistent across race.  
To examine whether associations between obesity and onset of significant depressive 
symptoms could be explained by lifestyle or disease differences at baseline, the above 
described Cox regression analyses were additionally adjusted for smoking status, alcohol 
intake, physical activity, prevalent and incident diabetes and CVD, number of other chronic 
diseases, and number of prescription medication taken. In order to compare the 
independent effects of overall and abdominal obesity, the associations between overall 
obesity measures and onset of depressive symptoms were adjusted for visceral fat, and the 
associations between abdominal obesity measures and onset of depression were adjusted 
for BMI.  
Finally, the risks of onset of depressive symptoms and of persistent depressive 
symptoms were plotted for men and women across BMI categories and for men and women 
with high versus normal visceral fat mass, and onset rates of depressive symptoms were 
calculated (in percent per year). In addition, population attributable risks (PARs) of obesity 
(BMI ≥ 30) and high visceral fat (≥ 194 cm2) in men were calculated. PAR describes the 
percentage by which the onset rate of depressive symptoms or persistent depressive 
symptoms could be reduced when the risk factor would be completely eliminated. The 
following equation was used: PAR = p(HR-1) / (1+ p[HR-1]), where p is the prevalence of 
the risk factor in the population at risk.19 
 
Results 
The mean age of the participants was 73.6 (SD = 2.9) years, 51.4% were women and 
40.6% were black. During a mean follow-up of 4.3 (SD = 1.1) years, significant depressive 
symptoms emerged in 23.9% (N = 609) of the initially non-depressed sample and 
significant persistent depressive symptoms in 7.8% (N = 198). Men experienced more 
diabetes and CVD, but women had a higher rate of onset of depressive symptoms. The 
mean BMI was comparable between men and women, however women had a higher 
percent body fat (40.7% versus 29.3%) than men, but had less visceral fat (132.2 versus 
155.2 cm2). Visceral fat correlated more strongly with waist circumference (Pearson’s r = 
0.65) and sagittal diameter (Pearson’s r = 0.75) than with BMI (Pearson’s r = 0.56). Table 1 
shows sample characteristics for persons with and without onset of depressive symptoms 
during follow-up for men and women separately. 
| CHAPTER 6 96 
 
Table 1. Sample characteristics 
 
 Men  Women 
 
Depressive symptoms     
during follow-up 
 
Depressive symptoms 
during follow-up 
Characteristic 
No        
N=988 
Yes       
N=250 
p a  
No       
N=950 
Yes       
N=359 
p a
Sociodemographic variables        
Age (years), mean (SD) 73.6 (2.9) 73.9 (2.8) .22  73.5 (2.9) 73.5 (2.9) .90 
Black, % 33.7 44.0 .002  43.9 48.7 .12 
Memphis site, % 47.1 52.4 .13  49.4 53.2 .22 
Married, % 73.0 65.6 .02  39.7 39.6 .97 
Educational level, %   <.001    <.001 
Less than high school 22.9 35.6   19.8 28.1  
High school 26.5 21.6   38.2 42.6  
Postsecondary 50.6 42.8   42.0 29.2  
Lifestyle variables        
Smoking status, %   .87    .28 
Never 30.9 29.2   56.8 61.6  
Former 59.2 60.4   34.5 30.1  
Current 9.9 10.4   8.6 8.4  
> 1 Alcoholic drink / day, % 12.9 8.8 .08  3.7 2.8 .43 
Physical activity (kcal/week),         
mean (SD) 
1539 (2514) 1215 (1879) .02  743  (1240) 649 (1309) .23 
Health & disease variables        
Prevalent cardiovascular disease, % 28.1 29.2 .74  16.9 23.7 .005 
Prevalent diabetes, % 25.7 28.4 .39  17.9 24.8 .005 
New cardiovascular event during 
follow-up, % 
16.5 11.6 .06  8.4 9.5 .55 
Incident diabetes during follow-up, % 4.6 5.2 .67  4.9 2.8 .09 
Number of other chronic diseases,  
mean (SD) 
1.4 (1.0) 1.5 (1.1) .24  0.9 (0.9) 1.2 (1.0) <.001 
Number of prescription medication 
taken, mean (SD) 
2.8 (2.4) 3.2 (2.7) .02  3.0 (2.5) 3.8 (2.8) <.001 
Depression-related variables        
Baseline CES-D-10 score (0-30), 
mean (SD) 
1.9 (2.1) 3.5 (2.6) <.001  2.3 (2.3) 3.8 (2.6) <.001 
Onset of persistent depressive 
symptoms, % 
NA 30.0 NA  NA 34.3 NA 
CES-D = Center for Epidemiologic Studies Depression scale; NA = not applicable. a Based on Χ2 tests for 
dichotomous and categorical variables and independent t tests for continuous variables. 
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Table 1. Continued 
 
 Men  Women 
 No Yes p a  No Yes p a
Obesity variables        
Overall obesity        
Body mass index (kg/m2), mean (SD) 27.0 (3.7) 27.5 (4.3) .09  27.7 (5.4) 27.9 (5.4) .52 
Percent body fat, mean (SD) 29.2 (4.7) 29.7 (5.4) .14  40.7 (5.6) 40.6 (5.9) .87 
Abdominal obesity        
Waist circumference (cm), mean (SD) 100.7 (10.3) 102.3 (11.3) .04  97.9 (13.4) 99.0 (13.8) .22 
Sagittal diameter (cm), mean (SD) 23.6 (3.2) 24.2 (3.5) .01  23.4 (3.5) 23.6 (3.5) .28 
Visceral fat (cm2), mean (SD) 153.0 (68.8) 163.8 (78.7) .05  131.8 (61.1) 133.4 (59.9) .66 
a Based on Χ2 tests for dichotomous and categorical variables and independent t tests for continuous variables. 
 
 
Table 2 shows the results of Cox regression analyses assessing the risk of onset of 
significant depressive symptoms according to baseline obesity among non-depressed 
persons at baseline. In the total sample, no associations were found for overall obesity 
measures, but sagittal diameter (HR per SD [3.4 cm] increase = 1.11, 95% CI = 1.02-1.20) 
and visceral fat (HR per SD [65.5 cm2] increase = 1.10, 95% CI = 1.02-1.20) predicted 
onset of depressive symptoms after adjustment for sociodemographics. Sex-stratified 
analyses showed that both overall and abdominal obesity increased the risk of onset of 
depressive symptoms in men. For instance, risk of depressive symptoms increased by 20% 
for each SD (4.6 kg/m2) increase in BMI (HR = 1.20, 95% CI = 1.03-1.40) and by 19% for 
each SD (65.5 cm2) increase in visceral fat (HR = 1.19, 95% CI = 1.07-1.33) (Table 2). No 
associations were found in women. When tested, obesity by sex interactions were found 
(BMI: p = .04, percent body fat: p = .03, waist circumference: p = .04, sagittal diameter: p 
= .04, visceral fat: p = .06). No significant obesity by race interactions were observed 
among men and women (all p > .20). Similar results were found when the definition of the 
onset of depressive symptoms was determined without data on new antidepressant use (N 
with depression = 553) or when an additional requirement of a minimum 3 point increase 
on the CES-D-10 was incorporated (N with depression = 593). Persons with significant 
depressive symptoms at follow-up (based on CES-D-10), increased from a mean baseline 
CES-D-10 score of 3.7 (SD = 2.6) to a mean CES-D-10 score of 12.4 (SD = 2.8) during their 
depressed episodes. As can be seen in Table 2, additional adjustment for smoking status, 
alcohol intake, physical activity, prevalent and incident diabetes and CVD, number of other 
chronic diseases and number of prescription medication taken did not change the results in 
any meaningful way. 
Next, to assess the effect of abdominal obesity versus overall obesity, the associations 
between overall obesity measures and onset of significant depressive symptoms were 
adjusted for visceral fat and were found to be no longer significant in men (e.g. for BMI: HR 
= 1.10, 95% CI = 0.93-1.32; Table 2). Alternatively, when associations between abdominal  
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Table 2.  Risk (per SD increase e) of onset of significant depressive symptoms among initially non-depressed 
persons according to baseline obesity 
 
 Unadjusted risk a
Risk adjusted for 
sociodemographics b
Risk additionally 
adjusted for lifestyle 
and diseases c
Risk additionally 
adjusted for obesity d
Obesity HR (95% CI) P HR (95% CI) p HR (95% CI) p HR (95% CI) p 
Total sample (N = 2547)      
Overall obesity   
N cases = 609 
    
Body mass index 1.06 (0.99-1.15) .11 1.04 (0.96-1.12) .32 1.02 (0.94-1.1)0 .71 0.96 (0.87-1.06) .41 
Percent body fat 1.03 (0.95-1.12) .42 1.04 (0.96-1.13) .34 1.02 (0.94-1.11) .58 0.98 (0.89-1.08) .68 
Abdominal obesity         
Waist circumference 1.11 (1.03-1.20) .01 1.08 (0.99-1.17) .07 1.05 (0.97-1.14) .27 1.10 (0.95-1.27) .19 
Sagittal diameter 1.14 (1.05-1.23) .002 1.11 (1.02-1.20) .02 1.08 (0.99-1.17) .09 1.23 (1.05-1.43) .01 
Visceral fat 1.10 (1.02-1.19) .02 1.10 (1.02-1.20) .02 1.07 (0.99-1.17) .09 1.10 (0.99-1.22) .06 
Men  (N = 1238)       
Overall obesity   
N cases = 250 
    
Body mass index 1.18 (1.01-1.37) .03 1.20 (1.03-1.40) .02 1.18 (1.01-1.37) .04 1.10 (0.93-1.32) .27 
Percent body fat 1.14 (0.99-1.31) .08 1.19 (1.03-1.36) .02 1.15 (1.00-1.33) .05 1.10 (0.94-1.28) .22 
Abdominal obesity         
Waist circumference 1.20 (1.04-1.39) .01 1.23 (1.06-1.42) .006 1.20 (1.04-1.39) .01 1.26 (1.04-1.52) .02 
Sagittal diameter 1.24 (1.09-1.40) .001 1.24 (1.08-1.41) .001 1.21 (1.06-1.38) .004 1.31 (1.11-1.56) .002 
Visceral fat 1.16 (1.04-1.29) .01 1.19 (1.07-1.33) .002 1.17 (1.04-1.31) .009 1.18 (1.04-1.34) .009 
Women  (N = 1309)       
Overall obesity   
N cases = 359 
    
Body mass index 1.03 (0.94-1.12) .54 0.99 (0.91-1.08) .84 0.97 (0.88-1.06) .47 0.93 (0.83-1.03) .16 
Percent body fat 0.99 (0.90-1.09) .82 0.97 (0.88-1.07) .55 0.96 (0.87-1.06) .45 0.93 (0.84-1.04) .20 
Abdominal obesity         
Waist circumference 1.07 (0.98-1.18) .14 1.02 (0.92-1.12) .74 0.99 (0.90-1.09) .80 1.04 (0.89-1.21) .66 
Sagittal diameter 1.08 (0.98-1.20) .13 1.03 (0.93-1.15) .53 1.00 (0.90-1.11) .98 1.12 (0.93-1.34) .23 
Visceral fat 1.05 (0.94-1.18) .37 1.03 (0.92-1.15) .64 1.00 (0.89-1.12) .93 1.02 (0.88-1.17) .83 
a Based on Cox regression analyses adjusted for sex (total sample only); b additionally adjusted for baseline CES-D-10 
score, age, race, site, marital status and educational level; c additionally adjusted for smoking status, alcohol intake, 
physical activity, prevalent diabetes or cardiovascular disease, incident diabetes, new cardiovascular events, number of 
other chronic diseases and number of prescription medication taken; d additionally adjusted for visceral fat (overall 
obesity only) and body mass index (abdominal obesity only); e per SD increase: 4.6 kg/m2 for body mass index, 5.3% 
for percent body fat, 12.0 cm for waist circumference, 3.4 cm for sagittal diameter, and 65.5 cm2 for visceral fat. 
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Table 3.  Risk (per SD increase c) of onset of significant non-persistent and persistent depressive symptoms 
among initially non-depressed persons according to baseline obesity 
 
 Non-persistent depressive symptoms Persistent depressive symptoms 
 
Risk adjusted for  
lifestyle and diseases a
Risk additionally 
adjusted for obesity b
Risk adjusted for 
lifestyle and diseases a
Risk additionally adjusted 
for obesity b
Obesity HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p 
Men  (N = 1238) 
Overall obesity 
N cases = 175 N cases = 75 
Body mass index 1.07 (0.89-1.29) .49 1.03 (0.83-1.28) .76 1.50 (1.13-1.98) .005 1.29 (0.94-1.76) .12 
Percent body fat 1.05 (0.89-1.25) .54 1.03 (0.85-1.24) .76 1.50 (1.16-1.95) .002 1.37 (1.04-1.82) .03 
Abdominal obesity         
Waist circumference 1.12 (0.94-1.34) .20 1.23 (0.99-1.54) .07 1.46 (1.12-1.92) .006 1.41 (1.01-1.96) .05 
Sagittal diameter 1.14 (0.97-1.33) .11 1.27 (1.04-1.56) .02 1.43 (1.12-1.83) .004 1.47 (1.08-2.01) .01 
Visceral fat 1.08 (0.94-1.25) .27 1.10 (0.94-1.29) .22 1.40 (1.17-1.68) <.001 1.42 (1.17-1.73) <.001
Women  (N = 1309) 
Overall obesity  
      N cases = 236 N cases = 123 
Body mass index 0.96 (0.86-1.07) .47 0.94 (0.82-1.07) .35 0.96 (0.81-1.12) .58 0.86 (0.72-1.04) .12 
Percent body fat 0.95 (0.84-1.07) .40 0.93 (0.82-1.07) .31 0.98 (0.82-1.16) .80 0.91 (0.76-1.11) .35 
Abdominal obesity         
Waist circumference 1.00 (0.88-1.12) .96 1.10 (0.91-1.34) .32 0.94 (0.80-1.11) .47 0.90 (0.69-1.18) .45 
Sagittal diameter 1.00 (0.87-1.14) .95 1.17 (0.93-1.46) .18 0.99 (0.82-1.19) .88 1.03 (0.74-1.42) .87 
Visceral fat 0.97 (0.84-1.12) .64 0.99 (0.84-1.18) .94 1.02 (0.84-1.23) .86 1.05 (0.83-1.32) .71 
a Based on Cox regression analyses adjusted for baseline CES-D-10 score, age, race, site, marital status, educational 
level, smoking status, alcohol intake, physical activity, prevalent diabetes or cardiovascular disease, incident diabetes, 
new cardiovascular events, number of other chronic diseases and number of prescription medication taken; b additionally 
adjusted for visceral fat (overall obesity only) and body mass index (abdominal obesity only); c per SD increase: 4.6 for 
body mass index, 5.3% for percent body fat, 12.0 cm for waist circumference, 3.4 cm for sagittal diameter, and 65.5 cm2 
for visceral fat; persons with persistent depressive symptoms were excluded from the analyses on non-persistent 
depressive symptoms and persons with non-persistent depressive symptoms were excluded from the analyses on 
persistent depressive symptoms. 
 
 
obesity and onset of depressive symptoms in men were adjusted for BMI, the associations 
remained similar (e.g. for visceral fat: HR = 1.18, 95% CI = 1.04-1.34; Table 2). Table 3 
presents fully adjusted models (with and without adjustment for obesity) with onset of non-
persistent depressive symptoms and persistent depressive symptoms as the outcome. 
Although associations of abdominal obesity with onset of non-persistent depressive 
symptoms were found, obesity was more strongly associated with the more chronic 
indicator of depressive symptoms in men; in women associations remained absent. When 
tested, no indications of non-linearity or multicollinearity were found (all quadratic terms p 
> .05; all VIF < 2). 
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To graphically illustrate the association between obesity and onset of both significant 
depressive symptoms and persistent depressive symptoms, the cumulative onset of 
depressive symptoms over time adjusted for sociodemographics, lifestyle, and diseases was 
plotted for men and women across BMI categories (Figure 1A and 1C) and for men and 
women with normal (Q1-Q3) and high (Q4) visceral fat (Figure 1B and 1D). In addition, 
unadjusted onset rates of depressive symptoms across groups are presented in Figure 1. 
Obese men (BMI > 30) were at the highest risk for onset of depressive symptoms, which 
was statistically significant for persistent depressive symptoms (HR = 2.03, 95% CI = 1.06-
3.89). Men with high visceral fat (≥ 194 cm2) had a 1.33 increased risk (95% CI = 1.00-
1.77) of becoming depressed and a 2.04 increased risk (95% CI = 1.25-3.34) of becoming 
persistently depressed compared to men with visceral fat < 194 cm2. As can be seen from 
Figure 1, men with high visceral fat were at an equal risk of becoming depressed than 
women in general. In fact, the unadjusted hazard ratio of onset of depressive symptoms for 
women compared to men was 1.38 (95% CI =1.17-1.62) and 1.62 (95% CI = 1.22-2.16) 
for onset of persistent depressive symptoms, which is equal to or even lower than the 
hazard ratios of onset of depressive symptoms and persistent depressive symptoms due to 
high visceral fat in men. High BMI or visceral fat did not increase the risk of becoming 
depressed in women. Finally, the population attributable risks of BMI > 30 and high visceral 
fat adjusted for sociodemographics, lifestyle and diseases were calculated for men and 
found to be 7% and 8%, respectively, for onset of depressive symptoms and 17% and 19% 
for onset of persistent depressive symptoms. This suggests that in the entire older male 
population, 19% of all new cases with persistent depressive symptoms were related to 
having high visceral fat mass. 
 
Discussion 
This study examined whether obesity was associated with onset of significant depressive 
symptoms in a large community-based sample of older, initially non-depressed, persons 
during 5 years of follow-up. The results showed that in men, but not in women, obesity 
increased the risk of onset of significant depressive symptoms. Specifically, abdominal 
obesity appeared to be associated with the onset of depressive symptoms, independent of 
and more consistently than overall obesity. Men with high visceral fat had a more than 2-
fold increased risk of becoming persistently depressed compared to men with normal 
amounts of visceral fat. Moreover, results showed that in men, almost 10% of the onsets of 
depressive symptoms and 20% of the onsets of persistent depressive symptoms was related 
to having high visceral fat. 
Several studies indicated that obesity and depression are associated.2-4 However, as 
concluded by Atlantis and Baker1 in their systematic review on obesity an depression, few 
studies have investigated the temporal direction of this association. Our findings correspond 
to a study by Roberts et al.,10 which showed among persons aged ≥ 50 years that obesity at 
baseline was associated with an increased risk of depression 5 years later. Our results 
additionally showed that associations with depressive symptoms appear to be more 
consistently related to abdominal obesity than to overall obesity. The association between 
depressive symptoms and overall obesity in men was not consistently found after  
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Figure 1. Cumulative onset of depressive symptoms according to sex and A) BMI 
categories; B) visceral fat status. 
a Unadjusted rates; b based on Cox regression analyses adjusted for baseline CES-D-10 score, age, race, 
site, marital status, educational level, smoking status, alcohol intake, physical activity, prevalent 
diabetes or cardiovascular disease, incident diabetes, new cardiovascular events, number of other 
chronic diseases, number of prescription medication taken. 
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Figure 1. Cumulative onset of persistent depressive symptoms according to sex and C) BMI 
categories; D) visceral fat status. 
Persons with non-persistent depressive symptoms were excluded from the analyses. a Unadjusted rates; 
b based on Cox regression analyses adjusted for baseline CES-D-10 score, age, race, site, marital status, 
educational level, smoking status, alcohol intake, physical activity, prevalent diabetes or cardiovascular 
disease, incident diabetes, new cardiovascular events, number of other chronic diseases, number of 
prescription medication taken. 
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adjustment for visceral fat, while the association with visceral fat remained after controlling 
for BMI. At least, these results show that abdominal obesity has an additional effect on 
onset of depressive symptoms above the influence of overall obesity. These results are in 
line with other studies showing that, in particular, abdominal obesity, more than overall 
obesity, is associated with poor health outcomes, such as diabetes and CVD.13,14 
To our knowledge, the current study was the first to test and demonstrate that 
abdominal obesity increases the risk of onset of significant depressive symptoms in men. 
This evidence should be considered together with other recent longitudinal results that 
illustrate - the other way around - that depressive symptoms also lead to increases in 
abdominal obesity over 5 years.9 The fact that abdominal obesity and depressive symptoms 
are found to be reciprocally associated indicates that the two are strongly intertwined and 
suggests that a vicious cycle might exist. The bidirectional relationship between abdominal 
obesity and depressive symptoms further indicates that when trying to break this vicious 
cycle, treatment of either obesity or depression cannot be given in isolation and comorbidity 
between these two should be taken into consideration.  
How might abdominal obesity increase the risk of incident depression? First, a poor self-
image or perceived stigma of an obese person might induce depression.20 Also, binge-eating 
behavior, not uncommon in obese persons, has been associated with major depressive 
disorder.21 These mechanisms are probably true for overall obesity as well as and not 
specific for abdominal obesity. Poor lifestyle behaviors might lead to both abdominal obesity 
and depression. However, in our analyses, adjustment for lifestyle behaviors did not 
influence results much. In addition, diseases related to abdominal obesity such as diabetes 
and CVD have been associated with depression22,23 and might be responsible for the 
association between abdominal obesity and depression. In our study, adjustment for 
prevalent as well as incident diabetes and CVD did not affect the relationship between 
abdominal obesity and the onset of depressive symptoms, suggesting that such an 
association does exist rather independently of diabetes and CVD. Other pathophysiological 
explanations may exist. Studies have shown that visceral fat produces cytokines in higher 
amount than subcutaneous fat.24 High levels of cytokines such as TNF-alpha, IL-6, and C-
reactive protein have been found both in visceral obesity25 and depression.26 In addition, the 
mechanisms discussed above (poor lifestyle, more diabetes and CVD, and inflammation in 
obese persons) might all induce vascular damage and are, therefore, in line with the 
vascular depression hypothesis, which states that vascular damage in the brain might 
predispose, precipitate, or perpetuate depression in the elderly.27 Other linking mechanisms 
could be a dysregulation of the hypothalamic-pituitary-adrenal axis28,29 or diminished 
functioning of sex steroid hormones30,31 as these mechanisms have been linked to both 
abdominal obesity and depression.  
The link between abdominal obesity and significant depressive symptoms was restricted 
to men. A reason for this could be due to the fact that men have more visceral fat than 
women. If the amount of visceral fat is important for negative health effects to emerge, 
than men will be more at risk to experience such negative health effects. In addition, this is 
an aging population in which losses of fat (including visceral fat) over time are not 
uncommon, especially in women,32 which might leave women at a smaller risk of visceral fat 
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to cause poor health. Another explanation might be that, in women, the relative contribution 
of visceral fat to depression onset is small due to a larger influence of competing risk 
factors. For instance, insufficient social support and stressful life events have been found to 
pose a greater risk for depression among women compared to men.33,34 Although previous 
cross-sectional studies that examined sex differences predominantly showed stronger results 
for women in the association between overall obesity and depression,3,12 one study reported 
an association between depression and abdominal obesity only in men.2 Future research 
should explore these sex differences further in younger samples to eliminate counteracting 
effects of aging.  
Our study has some limitations. We did not have well-defined DSM-IV-based depression 
diagnoses. However, the CES-D is a commonly used scale to assess clinically significant 
depressive symptoms. In addition, since we had no information on history of depression, 
onset of depressive symptoms might represent recurrence of an earlier depression in life. 
Therefore, results do not necessarily indicate incidence of a first depression episode in life, 
which is less common in later life, but do reflect a new occurrence of depressive symptoms 
during later life. Our study also had some important strengths including a large sample with 
longitudinal assessments of depressive symptoms. In addition, DXA and CT scans were 
performed, which assess total and visceral fat stores directly, and we were able to compare 
them with more commonly used anthropometric measures. 
In all, our findings indicate that the strength of the association between abdominal 
obesity and depressive symptoms is of both clinical and public health relevance. Men with 
visceral fat levels in the highest quartile (≥194 cm2) had almost a 35% greater chance of 
becoming depressed over 5 years than men with normal amounts of visceral fat. The risk of 
becoming persistently depressed was more than 2-fold for men with high visceral fat. We 
found that the size of this effect was at least equal to the difference in the onset rate of 
depressive symptoms between men and women. A 35-40% increased risk of incident 
depression for women versus men is comparable to what has been found in other studies 
among older persons35 and is normally considered to be an important predictor for 
depression onset. In contrast to sex, however, high visceral fat is potentially modifiable, and 
it is tempting to consider the possibility that weight reduction might reduce the onset of new 
depressive symptoms. Future research should investigate whether visceral fat reduction 
indeed can prevent onset of depressive symptoms.  
In conclusion, our results suggest that, in older men, obesity relates to the onset of 
significant depressive symptoms. Abdominal obesity appears to be more consistently 
associated with onset of depressive symptoms than overall obesity or at least shows an 
additional effect above overall obesity. These findings strengthen the idea that specific 
properties of visceral fat might give rise to depression. The impact of the association 
between abdominal obesity and onset of significant depressive symptoms on public mental 
health seems to be of great enough importance to warrant additional research that confirms 
our findings and explores underlying mechanisms. When these mechanisms are known, this 
might have direct implications for depression treatment and prevention. 
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Abstract 
 
Context 
Several studies report a cross-sectional association between metabolic syndrome and 
depression. Possibly, metabolic syndrome promotes onset or chronicity of depression. 
However, such a longitudinal link has not yet been confirmed. 
 
Objective 
To examine whether metabolic syndrome and its components are associated with onset and 
chronicity of depression during 6 years of follow-up. 
 
Design 
The InCHIANTI study, an ongoing prospective cohort study with 6 years of follow-up. 
 
Setting  
Community-dwelling older persons from the Chianti area, Italy. 
 
Participants  
A total of 823 persons aged ≥ 65 years. 
 
Main Outcome Measures 
Metabolic syndrome was assessed at baseline and defined as three or more of the following: 
abdominal obesity, high triglycerides, low high-density lipoprotein cholesterol, high blood 
pressure, and high fasting glucose. Depressive symptoms were assessed using the Center 
for Epidemiologic Studies-Depression (CES-D) scale at baseline and after 3 and 6 years of 
follow-up.  
 
Results 
At baseline, 202 persons (24.5%) had metabolic syndrome, and 168 (20.4%) were 
depressed (CES-D ≥ 20). Among non-depressed persons, 26.0% developed depression. 
Higher waist circumference increased odds of depression onset (adjusted OR per SD 
increase = 1.31, 95% CI = 1.08-1.59), but there was no association between other 
metabolic syndrome components or metabolic syndrome and onset of depression. Among 
depressed persons, depression had a chronic character in 69.0% of persons without and 
88.5% of persons with metabolic syndrome. Metabolic syndrome was associated with an 
almost 3-fold increased odds of chronicity of depression after adjustment for 
sociodemographics, lifestyle and health factors (OR = 2.71, 95% CI = 1.00-7.33), with 
almost every metabolic syndrome component contributing to this association. 
 
Conclusions 
In late life, waist circumference, but not metabolic syndrome, predicted onset of depression. 
Depressed persons with metabolic syndrome were more likely to have persistent or 
recurrent depression. The latter may suggest that depression with metabolic abnormalities 
(‘metabolic depression’) identifies a chronic subtype of depression.  
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Introduction 
Depression and cardiovascular disease are leading causes of disease burden worldwide and 
their relative impact on public health will continue to increase.1 Substantial evidence 
supports an association between these harmful disorders.2,3 Gaining knowledge on the 
underlying mechanisms to comorbidity of disease could direct prevention and treatment 
strategies. Over the past few years metabolic syndrome - a combination of cardiovascular 
risk factors, including abdominal obesity, lipid abnormalities, hypertension, and 
hyperglycemia4 - has become a key topic of interest as a possible link between depression 
and cardiovascular disease.5  
Recent cross-sectional studies indicate a link between depression and metabolic 
syndrome,6-14 although some negative findings have been reported too.15-17 Insight into 
cause and consequence between these disorders is still very limited as only few studies 
have assessed the temporal direction of the association between depression and metabolic 
syndrome.18-23 Three studies in middle-aged persons demonstrated that depressive 
symptoms predicted onset of metabolic syndrome.21-23 However, to improve both prevention 
and treatment of depression it is essential to know whether metabolic syndrome could 
initiate and/or perpetuate depression. Two studies in middle-aged populations18,19 and one 
in an older population20 showed an increased risk of depressive symptoms onset for persons 
with the metabolic syndrome. To our knowledge, no previous study has examined whether 
metabolic syndrome is a prognostic factor of chronicity of depression in older persons. 
In older persons, metabolic syndrome as a precursor of depression has been suggested 
to be supportive of the vascular depression hypothesis,24 which states that vascular lesions 
in the brain - that might be caused by metabolic disturbances - give rise to depressive 
symptoms. It is however very well possible that metabolic disturbances in themselves give 
rise to depression. In line with this, we have previously shown that abdominal obesity, a 
central component in metabolic syndrome, predicted the new onset of significant depressive 
symptoms over 5 years.25 Even stronger associations were found with the onset of more 
persistent depressive symptoms. This last finding suggests that metabolic syndrome might 
continue to promote depressive symptoms after they have emerged, resulting in more 
chronic depression. 
Therefore, the aims of the present study were to examine in a community-based 
sample of older persons whether metabolic syndrome and its components were associated 
with (1) onset of depression in depression-free persons at baseline, and (2) chronicity of 
depression in persons already presenting with depression at baseline.  
 
Methods 
Study sample 
Participants were part of the InCHIANTI study, a prospective population-based study of 
older persons. From 1998 to 2000, the study sample was randomly selected from the 
population registry of two sites in Italy: Greve in Chianti and Bagno a Ripoli, using a 
multistage stratified sampling method. Baseline data collection consisted of a home 
interview and a medical evaluation at the study clinic, which took place within 21 days after 
the home interview. Follow-up assessments were performed three and six years after the 
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baseline visit. The Italian National Institute of Research and Care on Aging ethical 
committee approved the study protocol and all respondents signed informed consent. A 
more detailed description of the study design is given elsewhere.26 
The InCHIANTI study consisted of 1155 participants aged 65 and over, but because of 
missing data on metabolic syndrome (N = 54), depression status at baseline (N = 4) or 
during follow-up (N = 274), the present study included data from 823 participants. Excluded 
persons were significantly older (80.1 versus 73.3 years, p < .001), were less educated (4.4 
versus 5.6 years, p < .001) and were more likely to have depression at baseline (28.5% 
versus 20.4%, p = .007) than included persons. No significant baseline differences in sex, 
number of chronic diseases or metabolic syndrome were found between in- and excluded 
persons.  
 
Depression 
Depressive symptoms were assessed at baseline and after 3 years and 6 years of follow-up 
using the Center for Epidemiological Studies-Depression (CES-D) scale, a widely used self-
report scale to assess depressive symptoms in the past week.27 The original 20-item version, 
ranging from 0-60 points, was used and filled in during the home interview. The CES-D-20 
has been shown to be a valid instrument for identifying depression in community-dwelling 
older adults28 and in Italian persons.29 In our study, the internal consistency was high: 
Cronbach alpha = 0.82. Onset of depression was defined as having no depression at 
baseline (CES-D < 20), but having a CES-D ≥ 20 after three or six years of follow-up. 
Chronicity of depression was defined as having a CES-D ≥ 20 both on baseline and on at 
least one of the follow-up assessments (year three or year six). In line with other research, 
overestimation in this older and Italian population was avoided by using the cut-off of 20 (as 
opposed to 16) as indication of depression.13 Although scoring above a depressive 
symptoms cut-off does not necessarily imply depression, in this paper for convenience we 
will refer to CES-D ≥ 20 as depression. Also, we cannot be sure whether a depression was 
persistent or recurrent. For convenience, we refer to this as chronic depression because it 
does suggest a chronic character of the depression. 
 
Metabolic syndrome 
Metabolic syndrome was defined as the presence of three or more of the following criteria: 
(i) abdominal obesity (waist circumference > 102 cm in men or > 88 cm in women); (ii) 
hypertriglyceridemia (triglyceride level ≥ 150 mg/dl); (iii) low high-density lipoprotein (HDL) 
cholesterol (< 40 mg/dl in men or < 50 mg/dl in women); (iv) high blood pressure 
(systolic/diastolic blood pressure ≥ 160/90 mmHg, and/or currently using anti-hypertensive 
medication); (v) high fasting glucose (≥ 110 mg/dl and/or currently using anti-diabetic 
medication). These criteria are similar to those outlined by the National Cholesterol 
Education Program Adult Treatment Panel III,4 with a minor modification for hypertension 
as 92% of the InCHIANTI respondents met the original blood pressure criterion (130/85 
mmHg). In order to take into account the characteristics of the older study population and 
to only classify those participants who were definitively hypertensive the diagnostic cut-off 
was raised to 160/90 mmHg as done in other aging studies.30 
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During the medical evaluation, after a fasting period of at least 8 hours, a 60 ml blood 
sample was drawn, stored in cold glass tubes, and delivered within two hours to a central 
laboratory. Serum glucose, HDL cholesterol, and triglycerides were measured by standard 
laboratory methods. Waist circumference was measured by trained examiners at the largest 
mid-body point. Three blood pressure measurements were taken using a standard mercury 
sphygmomanometer with the respondent in a supine position; the average of the last two 
readings was used in this analysis. Drugs taken in the previous two weeks were identified 
and coded using the Anatomical Therapeutic Chemical system to ascertain anti-diabetic and 
anti-hypertensive medication use. In addition to a dichotomous indicator of metabolic 
syndrome and a count of the number of criteria met, analyses were also conducted with 
continuous measures of metabolic syndrome components in order to investigate the 
consistency over and the importance of individual components. To incorporate medication 
use into the continuous metabolic syndrome component measures, as done previously,13,31 
10 and 5 mmHg was added to systolic and diastolic blood pressure, respectively, for persons 
using antihypertensive medication since these values represent the average decline in blood 
pressure in antihypertensive medication trials.32,33 Similarly, persons who used anti-diabetic 
medication and had a glucose level below 126 mg/dl (the usual cut-off to identify diabetes), 
were given a value of 126 for fasting glucose, as done before.13 
 
Covariates 
Covariates were a priori selected based on previously reported associations with both 
metabolic syndrome and depression. Sociodemographic factors included age, sex and years 
of education. Life style and health factors included baseline smoking status (non-, former, or 
current smoker), alcohol intake (< 3 or ≥ 3 drinks a day), and number of chronic diseases 
(including diabetes, cardiovascular disease, cancer, liver disease, gastrointestinal disease, 
congestive heart failure, Parkinson’s disease, peripheral arterial disease, lung disease, hip 
fracture, herniated disc, arthritis, osteoporosis, and cognitive deterioration). Cardiovascular 
disease and diabetes were also considered separately and were adjudicated based on 
information from self-reported history, medical exam data, hospital discharge records and 
medication use. Other diseases were self-reported only. In addition, onset of new 
cardiovascular events during follow-up was assessed based on similarly adjudicated 
information. 
 
Statistical analyses 
Sample characteristics were compared between persons with and without depression at 
baseline using X2 and t test statistics. Logistic regression analyses were conducted 
separately in persons without and with depression at baseline to test whether metabolic 
syndrome at baseline could predict onset and chronicity of depression at follow up, 
respectively. Analyses were performed unadjusted, adjusted for sociodemographics (age, 
sex, years of education) and additionally adjusted for health indicators (smoking status, 
alcohol intake, number of chronic diseases). As some previous studies showed sex 
differences in the association between metabolic syndrome and depression,23,34 a sex by 
metabolic syndrome interaction term was entered into the fully-adjusted logistic regression 
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analyses to assess whether findings were consistent for men and women. To test whether 
associations with onset or chronicity of depression were consistent across all components of 
metabolic syndrome, a series of fully adjusted logistic regression analyses was conducted 
with each metabolic syndrome component entered as predictor separately. Lastly, an 
additional logistic regression analysis tested the association between number of metabolic 
syndrome components, as an indication of severity of metabolic disturbances, and onset or 
chronicity of depression. 
 
Results 
Mean age of the participants was 73.3 (SD = 6.2) years, 55.9% were women, 24.5% had 
metabolic syndrome and 20.4% were depressed at baseline. Table 1 shows baseline 
characteristics for persons without and with depression at baseline. Persons with baseline 
depression were somewhat older, more often women, less often smoker, drank less alcohol, 
and had more chronic diseases. Also, persons with depression at baseline had lower glucose 
levels, but more often metabolic syndrome. During the 6-year follow-up, 26.0% of the 
initially non-depressed persons (N = 655) experienced onset of depression and 75.0% of 
the initially depressed persons (N = 168) had a chronic depression.  
Onset of depression was assessed in persons non-depressed at baseline (N = 655). Of 
those without metabolic syndrome 24.2% had developed depression at follow-up, compared 
to 32.0% of those with metabolic syndrome. Table 2 describes the results of logistic 
regression analyses assessing the association between metabolic syndrome (components) 
and onset of depression in non-depressed persons at baseline. Although metabolic 
syndrome showed a trend for increased likelihood of depression onset in the unadjusted 
model (OR = 1.48, 95% CI = 0.99-2.20), after adjustment for sociodemographics, lifestyle 
and diseases this association completely disappeared (OR = 1.07, 95% CI =0.69-1.66). No 
indication of a sex by metabolic syndrome interaction was found (p interaction = .79). When 
examining separate metabolic syndrome components, waist circumference was associated 
with increased odds of depression onset during follow-up (OR per SD increase = 1.31, 95% 
CI = 1.08-1.59). This association was not mediated by new cardiovascular events during 
follow-up (N = 72), as adjustment for this variable did not change the OR (OR per SD 
increase = 1.32, 95% CI = 1.08-1.60, p = .006). When persons with diabetes or 
cardiovascular disease at baseline (N = 144) were excluded, the association between waist 
circumference and depression onset became somewhat stronger (OR per SD increase = 
1.50, 95% CI = 1.18-2.15, p = .001). None of the other components, nor the sum of the 
components, resulted in increased risks of depression onset. To verify that these findings 
were not distorted by persons who merely crossed the cut-off of 20 on the CES-D from 
baseline to follow-up, the above analyses were repeated among persons with a CES-D score 
below 16 (in stead of below 20) at baseline (N = 567), such that onset of depression 
represented a relevant increase in depressive symptoms. This did not change findings 
importantly (e.g. metabolic syndrome: fully adjusted OR = 1.24, 95% CI = 0.76-2.01, p = 
.40; waist circumference: fully adjusted OR = 1.25, 95% CI = 1.00-1.56, p = .05). 
Chronicity of depression was assessed within persons depressed at baseline (N = 168). 
When metabolic syndrome was not present, 69.0% of persons experienced chronic  
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Table 1.  Sample characteristics according to depression at baseline 
 
Characteristic 
No depression 
N = 655 
Depression 
N = 168 
p a
Sociodemographics    
Age (years), mean (SD) 72.7 (6.0) 75.3 (6.3) <.001 
Women, % 50.7 76.2 <.001 
Education (years), mean (SD) 5.7 (3.2) 5.3 (3.3) .08 
Health indicators    
Smoking   <.001 
Non-smoker, % 54.2 72.6  
Former smoker, % 30.4 16.7  
Current smoker, % 15.4 10.7  
Alcohol use (≥ 3 drinks a day), % 12.5 6.0 .02 
Baseline cardiovascular disease, % 12.2 10.1 .45 
Baseline diabetes, % 12.7 10.1 .37 
Number of chronic diseases, mean (SD) 1.2 (1.0) 1.5 (1.1) .02 
New cardiovascular event during follow-up, % 11.0 9.5 .58 
Metabolic syndrome    
Waist circumference (cm), mean (SD) 93.2 (9.9) 92.0 (10.7) .16 
Triglycerides (mg/dl), mean (SD) 130.2 (74.1) 125.4 (62.3) .43 
HDL cholesterol (mg/dl), mean (SD) 55.9 (14.5) 56.8 (14.6) .48 
Systolic blood pressure (mmHg), mean (SD) 153.7 (20.4) 154.7 (20.1) .57 
Diastolic blood pressure (mmHg), mean (SD) 85.8 (9.1) 86.5 (9.1) .40 
Glucose (mg/dl), mean (SD) 97.2 (24.9) 91.4 (21.4) .007 
Metabolic syndrome, % 22.9 31.0 .03 
Number of components, mean (SD) 1.7 (1.2) 1.8 (1.2) .31 
Depression    
Depressed during follow-up, % 26.0 75.0 <.001 
HDL = high-density lipoprotein. a Based on Χ2 tests for dichotomous and categorical variables and 
independent t tests for continuous variables. 
 
 
depression compared to 88.5% when metabolic syndrome was present. Results of logistic 
regression analyses examining the association between metabolic syndrome (components) 
and chronicity of depression are presented in Table 3. Metabolic syndrome strongly 
predicted chronicity of depression (unadjusted OR = 3.45, 95% CI = 1.35-8.81), even after 
adjustment for sociodemographics, lifestyle and diseases (OR = 2.71, 95% CI = 1.00-7.33). 
Further adjustment for new cardiovascular events during follow-up (N = 16) did not change 
this finding (OR = 2.73, 95% CI = 1.01-7.39, p = .05). The association between metabolic 
syndrome and chronicity of depression was similarly present in both men and women  
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Table 2. Metabolic syndrome and onset of depression  
 in persons non-depressed at baseline (N = 655) 
 
Metabolic syndrome OR 95%CI p 
Metabolic syndrome a 1.48 0.99-2.20 .06 
Metabolic syndrome b 1.24 0.82-1.88 .32 
Metabolic syndrome c 1.07 0.69-1.66 .76 
    
Waist circumference c 1.31 1.08-1.59 .006 
Triglycerides c 1.09 0.92-1.30 .33 
High-density lipoprotein cholesterol c 0.92 0.76-1.12 .39 
Systolic blood pressure c 0.93 0.77-1.12 .43 
Diastolic blood pressure c 0.90 0.75-1.09 .27 
Glucose c 1.04 0.87-1.24 .69 
    
Number of metabolic syndrome components c 1.00 0.85-1.17 .97 
Based on logistic regression analyses a unadjusted, b adjusted for age, sex, and years of 
education, and c additionally adjusted for smoking status, alcohol intake, and number of 
chronic diseases; ORs are given per SD increase; waist circumference: SD = 10.0 cm; 
triglycerides: SD = 71.9 mg/dl; HDL cholesterol: SD = 14.5 mg/dl; systolic blood pressure: SD 
= 20.4 mmHg; diastolic blood pressure: SD = 9.1 mmHg; glucose: SD = 24.3 mg/dl. 
 
 
Table 3. Metabolic syndrome and persistence of depression  
 in persons depressed at baseline (N = 168) 
 
Metabolic syndrome OR 95%CI p 
Metabolic syndrome a 3.45 1.35-8.81 .01 
Metabolic syndrome b 3.18 1.22-8.31 .02 
Metabolic syndrome c 2.71 1.00-7.33 .05 
    
Waist circumference c 1.39 0.95-2.01 .09 
Triglycerides c 1.61 0.90-2.88 .11 
High-density lipoprotein cholesterol c 0.72 0.49-1.06 .10 
Systolic blood pressure c 1.21 0.82-1.80 .34 
Diastolic blood pressure c 1.31 0.90-1.92 .16 
Glucose c 1.02 0.63-1.66 .93 
    
Number of metabolic syndrome components c 1.66 1.16-2.38 .005 
Based on logistic regression analyses a unadjusted, b adjusted for age, sex, and years of 
education, and c additionally adjusted for smoking status, alcohol intake, and number of 
chronic diseases; ORs are given per SD increase; waist circumference: SD = 10.0 cm; 
triglycerides: SD = 71.9 mg/dl; HDL cholesterol: SD = 14.5 mg/dl; systolic blood pressure: SD 
= 20.4 mmHg; diastolic blood pressure: SD = 9.1 mmHg; glucose: SD = 24.3 mg/dl. 
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(p interaction = .81). Exclusion of persons who already had diabetes or cardiovascular 
disease at baseline (N = 30) did not importantly affect findings (OR = 3.33, 95% CI = 0.99-
11.18, p = .05). Examining different metabolic syndrome components showed that not one 
component was specifically associated with chronicity of depression: all components - 
except glucose - showed an expected increased (or decreased for HDL cholesterol) odds of 
chronic depression, although these relationships were not statistically significant. A logistic 
regression analysis with number of metabolic syndrome components as predictor indicated 
that odds of chronicity of depression increased with 66% for each additional component of 
metabolic syndrome a person had (OR = 1.66, 95% CI = 1.16-2.38). 
 
Discussion 
The present study is to our knowledge the first to examine both onset and chronicity of 
depression in relation to metabolic syndrome in a community-based sample of older 
persons. The results show that abdominal obesity, but not metabolic syndrome as a whole, 
predicts onset of depression. Once depressed, metabolic syndrome increases odds of 
remaining depressed or having recurrent episodes by almost 3-fold. These results are 
indicative of the existence of a chronic depressive subtype associated with metabolic 
disturbances which could be labeled ‘metabolic depression’. 
Onset of depression was predicted by large waist circumference, but not metabolic 
syndrome and its other components. These results are not completely in line with two 
recent studies in middle-aged persons and one in older persons, as these studies reported a 
link between metabolic syndrome as a whole and new depression onset.18-20 Differences in 
study characteristics (age range, general health status, duration of follow-up) might play a 
role in the found discrepancies. However, the specific association for waist circumference is 
striking. Abdominal obesity is often regarded as a key component of the metabolic 
syndrome35 and previous reports have suggested that waist circumference might be the 
most important metabolic syndrome feature in relation with depression.6,11,13,18 Our results 
are in agreement with these and other findings from an older population-based study, which 
show that abdominal obesity, as indicated by high levels of visceral fat, are associated with 
onset of depressive symptoms.25 Moreover, results from that same study also indicated - the 
other way around - an association between depressive symptoms and an increase in visceral 
fat over time,36 emphasizing that in fact a vicious cycle might exist between abdominal 
obesity and depression.  
To our knowledge, it has not been examined before whether metabolic syndrome 
negatively affects depression prognosis. Our results clearly show that depression associated 
with metabolic syndrome is less likely to resolve. Although the rate of chronic depression in 
this older population was already high among persons without metabolic syndrome (about 
70%), it was even noticeably higher among those with metabolic syndrome (about 90%). 
This was reflected in an almost 3-fold increased adjusted odds of persistent or recurrent 
depression, which strongly indicates the chronic character of depression in the presence of 
metabolic syndrome. These findings were not restricted to a specific metabolic abnormality. 
Although most metabolic syndrome components by themselves were not significantly 
associated with chronicity of depression, possibly due to limited power in the smaller 
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depressed group, all of the metabolic syndrome components, except glucose levels, pointed 
in the direction of harmful disturbances. Moreover, a count of number of metabolic 
syndrome components was strongly associated with chronicity of depression, indicating that 
(almost) every component contributed to heightened likelihood of a chronic depression 
character. It is unclear why no effect for glucose levels was found, but previous studies 
have reported a lack of association between glucose levels and depressive symptoms.6,11-13 
Nevertheless, our findings that metabolic disturbances are associated with a more chronic 
course of depression are in line with recent findings in older men showing that abdominal 
obesity, in particular visceral fat, predicts onset of persistent depressive symptoms, even 
more strongly than onset of non-persistent depressive symptoms.25 In addition, another 
recent study showed that men with metabolic syndrome were more likely to have 
experienced long-term depressive symptoms,34 although it was not examined whether 
metabolic syndrome was more strongly associated with long-term than with short-term 
depressive symptoms.  
Considering both our and earlier results, it seems that depression and metabolic 
syndrome are intertwined and represent a chronic depressive subtype. Depression and 
abdominal obesity might stimulate each other’s occurrence, but once both present, multiple 
progressive metabolic abnormalities may arise, worsening depression as well as metabolic 
outcome more and more. These results are indicative of a distinct condition, which might be 
labeled ‘metabolic depression’. Metabolic abnormalities as a defining component in 
depressive disorders have been suggested before.37 The idea of a specific metabolic 
depressive subtype is further supported by recent findings from the Netherlands Study of 
Depression and Anxiety, which used data-driven techniques to identify depressive 
subtypes.38 This study distinguished three depressive subtypes of which only one, 
characterized by atypical symptoms, was associated with metabolic syndrome. The possible 
existence of a metabolic depression clearly opens up opportunities for prevention and 
treatment of both depression and metabolic syndrome. Recognizing that metabolic 
disturbances are hampering remission from depression raises the possibility that treating 
metabolic abnormalities could in fact stimulate remission. 
Which mechanisms may underlie this interconnection between metabolic syndrome and 
(chronic) depression? Possible mechanisms include inflammatory processes, hyperactivity of 
the hypothalamic-pituitary-adrenal (HPA)-axis, autonomic nervous system (ANS) 
dysfunction, and diminished functioning of the hypothalamic-pituitary-gonadal axis, as these 
have all been associated with both depression39-42 and metabolic syndrome.13,17,43-46 Further, 
the leptin hypothesis suggests that insufficiency or resistance of the adipose-derived 
hormone leptin forms a link between depression and obesity,47 and might therefore also be 
involved in the relationship between depression and metabolic syndrome. Another possibility 
is the vascular depression hypothesis, which states that vascular damage in the brain might 
predispose, precipitate, or perpetuate depression in the elderly.24 This vascular damage may 
be caused by continuing influence of metabolic abnormalities, HPA-axis disturbances, ANS 
dysfunction or chronic low-grade inflammation. Our results show that metabolic syndrome 
and depression are also related in the absence of overt vascular disease as adjustments for 
diabetes and (intermediate) cardiovascular events did not change our findings. Although 
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subclinical vascular damage may still be present, metabolic disturbances without having yet 
caused profound vascular damage might very well be sufficient on their own to produce 
depressive symptoms. 
Our study has some important strengths. It prospectively examined the association 
between metabolic syndrome and depression. This study made use of a large community-
based sample and was able to investigate both onset and chronicity of depression. Also, 
besides examining metabolic syndrome as one unified condition, associations with different 
metabolic syndrome components were explored as well. Some limitations have to be 
acknowledged too. First, we used a self-report scale to assess depressive symptoms, which 
do not necessarily represent psychiatric diagnoses. However, the CES-D is a well-described 
and valid instrument in older populations.28,29 In addition, this study could not differentiate 
between recurrent or persistent depression, but the results do indicate a more chronic 
character of depression in persons who additionally have metabolic syndrome. Also, we had 
no information on history of depression, thus some of the depression-free persons at 
baseline might have had experienced depressive periods in the past.  
To conclude, the results of the present study show that the central metabolic syndrome 
component, abdominal obesity, is an important risk factor for new onset of depression. 
Once persons are depressed, more widespread metabolic disturbances, such as present in 
metabolic syndrome, are highly indicative of persistent or recurrent depression. In concert 
with other research findings, these findings strongly indicate that depression with metabolic 
abnormalities (‘metabolic depression’) identifies a chronic depressive subtype. It is to be 
examined whether treatment of metabolic disturbances could improve depression prognosis.  
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Abstract 
 
Context 
The stress hormone cortisol has been linked with unfavorable cardiovascular risk factors, but 
longitudinal studies examining whether high levels of cortisol predict cardiovascular 
mortality are largely absent. 
 
Objective 
The aim of this study was to examine whether urinary cortisol levels predict all-cause and 
cardiovascular mortality over 6 years of follow-up in a general population of older persons. 
 
Design 
InCHIANTI study, a prospective cohort study with 6 years of follow-up. 
 
Setting 
General older population. 
 
Participants 
900 participants aged 65 years and older. 
 
Main outcome measure 
24-H urinary cortisol levels were assessed at baseline. In the following 6 years, all-cause 
and cardiovascular mortality was ascertained from death certificates. Cardiovascular 
mortality included deaths due to ischemic heart disease and cerebrovascular disease. 
 
Results 
During a mean follow-up of 5.7 (SD = 1.3) years, 207 persons died, of whom 47 from 
cardiovascular disease. After adjustment for sociodemographics, health indicators and 
baseline cardiovascular disease, urinary cortisol did not increase the risk of all-cause 
mortality, but did increase cardiovascular mortality risk. Persons in the highest tertile of 
urinary cortisol had an almost three times increased risk of dying of cardiovascular disease 
(HR = 2.92, 95% CI = 1.31-6.50).This effect was found to be consistent across persons 
with and without cardiovascular disease at baseline (p interaction = .66). 
 
Conclusions 
High cortisol levels predict cardiovascular death among both persons with and without pre-
existing cardiovascular disease. The specific link with cardiovascular - and not all-cause - 
mortality suggests that high cortisol levels might be particularly damaging to the 
cardiovascular system. 
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Introduction 
Cortisol is an important component of the stress system of the human body. In an acute 
physical or psychological stressful situation, the stress system becomes activated, with 
upregulation of the hypothalamic-pituitary-adrenal (HPA)-axis resulting in the secretion of 
cortisol. Direct effects of cortisol are amongst others mobilization of glucose and free fatty 
acids, a decrease of growth and sex hormones levels, an increase in cardiac output and 
blood pressure, and tempering of the activated immune system.1-4 The function of cortisol is 
to help the body recover from the stress and regaining a status of homeostasis. However, 
chronically elevated cortisol can cause damage and dysregulation and indeed high levels of 
cortisol have been associated with cardiovascular risk factors, such as the metabolic 
syndrome and its components5-7 and accelerated atherosclerosis.8,9 Accordingly, studies 
have suggested that a chronically dysregulated cortisol response is the link between stress-
related disorders, such as depression, and subsequent cardiovascular morbidity and 
mortality.10,11 However, little direct evidence exists that cortisol actually increases the risk of 
cardiovascular end-points. A few studies among patients admitted to the hospital because of 
cardiac disease have shown that high cortisol levels predict subsequent events or death,12-14 
but this could well be a reflection of acute stress or disease severity.15 Two studies reported 
a cortisol/testosterone ratio and a cortisol/DHEAS ratio to be predictive of incident ischemic 
heart disease and mortality, respectively, in middle-aged men16 and male veterans.17 In a 
general older population, cortisol was associated with increased overall mortality,18 but since 
causes of death were not available, it remains unclear whether such an association was 
driven by cardiovascular death. Thus, although the existing literature suggests that cortisol 
might increase the risk of cardiovascular mortality, no study has directly tested this 
hypothesis. Therefore, we examined whether urinary cortisol levels predict all-cause and 
cardiovascular mortality over 6 years of follow-up in a general population of older persons. 
 
Methods 
Study sample 
Participants were part of the InCHIANTI study, a prospective population-based study of 
older persons. From 1998 to 2000, the study sample was randomly selected from the 
population registry of two sites in Italy: Greve in Chianti, and Bagno a Ripoli, using a 
multistage stratified sampling method. Baseline data collection consisted of a home 
interview, a 24-hour urine collection and a medical evaluation at the study clinic. Follow-up 
visits were scheduled three and six years after the baseline visit. The study complies with 
the Declaration of Helsinki. The Italian National Institute of Research and Care on Aging 
ethical committee approved the study protocol and all respondents signed informed 
consent. A more detailed description of the study design is given elsewhere.19 
The InCHIANTI study included 1155 participants aged 65 and over, but because of 
missing data on urinary cortisol (N = 190), or incomplete (< 20 hours) urine collection (N = 
65), the present study included data from 900 participants. Excluded persons were 
significantly older (78.8 versus 74.5, p < .001), more often women (63.1% versus 54.9%, p 
= .02), and more often deceased during follow-up both from all-causes (46.3% versus 
23.0%, p < .001) as well as from cardiovascular causes (11.0% versus 5.2%, p < .001). 
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Urinary Cortisol 
The assessment of urinary cortisol over a 24-h period provides a rather stable indicator of 
the total cortisol excretion by the adrenals and measures the biologically active (unbound) 
cortisol. Before the in-clinic assessment, study participants were asked to collect all urine 
produced during a 24-h period starting after the first voided urine following awakening and 
including the first voided urine on the following day. At assessment, 10 ml aliquots of urine 
were prepared and stored at -80°C for later assaying at the Clinical Chemistry Laboratory of 
the Careggi Hospital, Italy. Urinary cortisol was measured by an immunochemiluminescence 
method and an ADVIA-Centaur immunoassay system (Bayer Diagnostics). The intra-assay 
coefficient of variation was less then 2.0% and the inter-assay coefficient of variation was 
less then 3.0%. Urinary cortisol level was defined as micrograms of cortisol excreted over  
24 h, calculated as the concentration of cortisol (μg/ml) multiplied by the total amount of 
urine volume (ml) collected. The normal reference range was 28.5-213 μg cortisol excreted 
over 24 h. Both a continuous measure as well as a tertile categorization of urinary cortisol 
was used in the present study.
 
Mortality 
Mortality data were obtained from the Mortality General Registry maintained by the Tuscany 
Region and from death certificates filed upon death at the registry office of the municipality 
of residence. Follow-up lasted from the baseline assessment until the day of death or the 
day of last contact and finished in 2006. Next to all-cause mortality, cardiovascular mortality 
was assessed based on the 9th revision of the International Classification of Diseases (ICD-
9) and included death to cerebrovascular disease (ICD codes 430-438) and ischemic heart 
disease (ICD codes 410-414). Non-cardiovascular mortality included all other causes of 
death. 
 
Covariates 
Covariates were a priori selected based on previously shown association with both cortisol 
and mortality. Sociodemographic variables included age, sex, and years of education. Health 
indicators were smoking status (non-, former, or current smoker), current alcohol intake 
(yes or no 3 or more drinks a day) and body mass index (weight in kilograms divided by 
height in meters squared). Waist circumference was measured by trained examiners at the 
largest mid-body point. Three systolic blood pressure measurements were taken using a 
standard mercury sphygmomanometer with the respondent in a supine position; the 
average of the last two readings was used in this analysis. Depressive symptoms were 
assessed using the original 20-item version of the self-report Center for Epidemiologic 
Studies-Depression Scale administered during the home interview.20 Cognitive functioning 
was assessed by means of the Mini-Mental State Examination score.21 As a global indicator 
of poor physical health, number of chronic diseases (including diabetes, cancer, liver 
disease, gastrointestinal disease, congestive heart failure, Parkinson’s disease, peripheral 
arterial disease, lung disease, hip fracture, herniated disc, arthritis, osteoporosis and 
cognitive deterioration) was calculated. Identification of cardiovascular disease at baseline 
(including angina pectoris, myocardial infarction, stroke or transient ischemic attack) was  
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Table 1. Sample characteristics 
 
Characteristic N = 900 
Sociodemographics  
Age (years), mean (SD) 74.5 (6.9) 
Women, % 54.9 
Education (years), mean (SD) 5.4 (3.3) 
Health indicators  
Smoking status  
Never, % 57.7 
Former, % 27.9 
Current, % 14.4 
Alcohol intake (≥ 3 drinks a day), % 10.4 
Body mass index, mean (SD) 27.4 (4.0) 
Waist circumference (cm), mean (SD) 92.6 (10.3) 
Systolic blood pressure (mmHg), mean (SD) 150 (19.3) 
Depressive symptoms (CES-D), mean (SD) 12.7 (8.6) 
Cognitive functioning (MMSE), median (IQR) 26 [23-28] 
Number of chronic diseases, mean (SD) 1.3 (1.0) 
Baseline cardiovascular disease, mean (SD) 13.6 
Cortisol  
Severe renal function impairment, % 2.4 
Corticosteroid use, % 1.9 
Urine volume (ml), mean (SD) 1508 (569) 
24-h Urinary cortisol (μg), mean (SD) 97.9 (48.2) 
Mortality  
Deceased, % 23.0 
Non-cardiovascular death, % 17.8 
Cardiovascular death, % 5.2 
CES-D = Center for Epidemiologic Studies Depression scale; MMSE = Mini-Mental State Exam 
 
 
based on a standardized algorithm using information on self-reported history, 
pharmacological treatments, medical exam data, and hospital discharge records.22 Further, 
some variables that might profoundly affect urinary cortisol levels were considered. Serum 
creatinine, measured through a modified Jaffe method, was used to calculate creatinine 
clearance with the Cockcroft-Gault formula. Following K/DOQI guidelines,23 a creatinine 
clearance rate of 30 ml/min or lower was considered to indicate severe renal function 
impairment. Drugs taken in the previous two weeks were identified and coded according to 
the World Health Organization Anatomical Therapeutic Chemical classification to ascertain 
use of corticosteroids (code H02).  
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Statistical analyses 
Descriptive statistics were used to present sample characteristics. Cox regression analyses 
were performed to assess whether urinary cortisol levels predict the risk of all-cause, non-
cardiovascular, and cardiovascular mortality in an age- and sex-adjusted and a fully 
adjusted (age, sex, education, smoking, alcohol intake, body mass index, waist 
circumference, systolic blood pressure, depressive symptoms, cognitive functioning, number 
of chronic diseases, baseline cardiovascular disease, renal failure, corticosteroid use and 
urine volume) model. The proportional hazards assumption was checked by including a 
time-to-event by cortisol interaction term. An additional analysis excluded persons with 
severe renal function impairment and/or corticosteroid use. Next, a baseline cardiovascular 
disease by cortisol interaction term was included in the above-mentioned model, to test 
whether associations were consistent across persons with and without pre-existing 
cardiovascular disease. SPPS 15.0 was used for all statistical analyses. A two-sided p-value 
of ≤ 0.05 was considered statistically significant. 
 
Results 
Sample characteristics are shown in Table 1. Mean age of the current sample was 74.5 (SD 
= 6.9) years, 54.9% were women and the mean 24-h urinary cortisol level was 97.9 (SD = 
48.2) μg. During an average follow-up of 5.7 (SD = 1.3) years, 207 persons deceased 
(23.0%) of whom 47 (5.2%) died from cardiovascular causes and 160 (17.8%) from other 
causes. Table 2 shows the results of both sex- and age-adjusted and fully-adjusted Cox 
regression analyses assessing the association between 24-h urinary cortisol and all-cause, 
non-cardiovascular, and cardiovascular death. The proportional hazards assumption was 
met in all analyses. Urinary cortisol was not associated with all-cause or non-cardiovascular 
mortality, but predicted cardiovascular death. After adjustment for sociodemographics, 
lifestyle, and health indicators, urinary cortisol tended to be linearly associated with 
increased risk of cardiovascular mortality (HR per SD increase = 1.27, 95% CI = 0.96-1.67). 
When examining urinary cortisol tertiles, persons in the highest tertile of urinary cortisol had 
an almost three times increased risk of dying of cardiovascular disease (HR = 2.92, 95% CI 
= 1.31-6.50). When excluding persons with severe renal function impairment and/or 
corticosteroid use (N excluded = 39), associations between urinary cortisol and 
cardiovascular mortality became somewhat stronger (e.g. highest versus lowest tertile: HR 
= 3.66, 95% CI = 1.55-8.62, p = .003). Next, a baseline cardiovascular disease by cortisol 
tertile interaction term was included in this Cox regression model, but was not significant (p 
= .66). This indicated that the association between urinary cortisol and cardiovascular 
mortality existed for both persons with and without pre-existing cardiovascular disease. 
These findings are illustrated in Figure 1. Compared to persons without baseline 
cardiovascular disease in the lowest tertile of cortisol, those in the highest tertile had a 3.6 
times increased risk of dying over 6 years when cardiovascular disease was not present at 
baseline (HR = 3.61, 95% CI = 1.36-9.62) and a 5.8 times increased risk when 
cardiovascular disease pre-existed at baseline (HR = 5.82, 95% CI =1.64-20.63).  
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Table 2. Urinary cortisol and 6-year all-cause and cardiovascular mortality 
 
Sex- & age-adjusted a Fully adjusted b
N = 900 
HR  95%CI p HR 95%CI p 
All-cause mortality (N deaths = 207)      
24-h Urinary cortisol c 1.00 0.87-1.15 .97 1.05 0.91-1.21 .49 
Tertiles of 24-h urinary cortisol       
First tertile (< 76 μg)  REF   REF  
Second tertile (76-110 μg) 0.92 0.65-1.31 .64 1.14 0.79-1.64 .49 
Third tertile (> 110 μg) 1.00 0.71-1.40 .98 1.20 0.83-1.73 .33 
Non-cardiovascular mortality (N deaths = 160)     
24-h Urinary cortisol c 0.94 0.79-1.11 .43 0.99 0.84-1.16 .86 
Tertiles of 24-h urinary cortisol       
First tertile (< 76 μg)  REF   REF  
Second tertile (77-110 μg) 0.78 0.53-1.16 .22 0.96 0.63-1.42 .83 
Third tertile (> 110 μg) 0.78 0.53-1.15 .21 0.92 0.61-1.41 .71 
Cardiovascular mortality (N deaths = 47)      
24-h Urinary cortisol c 1.23 0.95-1.59 .12 1.27 0.97-1.67 .09 
Tertiles of 24-h urinary cortisol       
First tertile (< 76 μg)  REF   REF  
Second tertile (77-110 μg) 1.69 0.78-3.69 .19 2.13 0.95-4.77 .07 
Third tertile (> 110 μg) 2.26 1.10-4.65 .03 2.93 1.31-6.50 .009 
a Based on Cox regression analyses adjusted for sex and age; b additionally adjusted for education, smoking 
status, alcohol intake, body mass index, waist circumference, systolic blood pressure, depressive symptoms, 
cognitive functioning, number of chronic diseases, baseline cardiovascular disease, renal failure, 
corticosteroid use and urine volume; c HR per SD (= 48 μg) increase. 
 
 
Discussion 
The results of this study show that basal cortisol levels in a general older population predict 
cardiovascular death, but not all-cause mortality. Persons in the highest tertile of urinary 
cortisol had a three-fold increased risk of dying of cardiovascular disease over a 6-year 
period. This finding supports the frequently hypothesized link between hyperactivity of the 
HPA-axis and cardiovascular disease. 
The HPA-axis controls a set of neuroendocrine reactions essential to life. When the 
HPA-axis is activated, corticotrophin releasing hormone (CRH) is released by the 
hypothalamus and stimulates the pituitary to release adrenocorticotrophic hormone (ACTH), 
which in turn signals to the adrenal cortex to release cortisol. Cortisol, in turn, exerts 
negative feedback on the pituitary and hypothalamus to suppress ACTH and CRH 
production, respectively.2 This implies that hyperactivity of the HPA-axis could be the result 
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Figure 1. Risk a of cardiovascular mortality across baseline cardiovascular disease and 
urinary cortisol 
CVD = cardiovascular disease. a Based on Cox regression analyses adjusted for sex, age, education, 
smoking status, alcohol intake, body mass index, waist circumference, systolic blood pressure, 
depressive symptoms, cognitive functioning, number of chronic diseases, renal failure, corticosteroid 
use and urine volume. 
 
 
of either a CRH overdrive, a strong ACTH response to CRH, a strong cortisol response to 
ACTH and/or blunted negative feedback exerted by cortisol on central glucocorticoid 
receptors.24 It has been hypothesized that hyperactivity of the HPA-axis may be a result of 
frequent or persistent stimulation.11 In particular, hyperactivity of the HPA axis has been 
found as a result of chronic stress,25 and is suggested to play a role in stress-related 
disorders such as depression.26 In addition, aging is associated with an increase in basal 
cortisol levels27,28 and an increased cortisol response to challenge.29 Hyperactivity of the 
HPA-axis in aging might in fact be the result of the ‘wear and tear’ of a lifelong exposure to 
stress.27  
Hyperactivity of the HPA-axis might exert damage to the human body in the long-run. 
High levels of cortisol have been associated with several cardiovascular risk factors, such as 
present in the metabolic syndrome and atherosclerosis.5-9 As cortisol exerts a multitude of 
effects on glucose and free fatty acids metabolism, the autonomic nervous system, the 
inflammatory system, and on sex and growth hormones,1-4 it is not surprising that 
continuous high levels of cortisol might lead to dysfunctioning of these systems which are all 
implicated in cardiovascular disease.3,10,30 For instance, by activating lipoprotein lipase and 
inhibiting lipid mobilization, cortisol promotes the accumulation of visceral fat,1 as visceral 
fat is highly sensitive to cortisol owing to a high density of glucocorticoid receptors.31 
Visceral fat, in turn, has been shown to be an important risk factor for cardiovascular 
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disease.32,33 Also, hyperactivity of the HPA-axis has been linked to the decline of immune 
functions during aging, particularly among chronically stressed older persons.34 This, again, 
may put persons at increased risk of cardiovascular disease.30  
Thus, research has demonstrated cortisol to be associated with cardiovascular risk 
factors, however, little prospective evidence exists that cortisol actually predicts the onset of 
cardiovascular end-points. One previous study in the general population among middle-aged 
men found that a cortisol/testosterone ratio was predictive of incident ischemic heart 
disease over 16.5 years of follow-up.16 No effects of either cortisol or testosterone alone 
were found. This study used a less reliable single measure of morning cortisol in blood 
which, unlike urinary or salivary cortisol, does not represent the biological active cortisol and 
could possibly be increased by an acute stress reaction due to the blood draw itself. Our 
study, within an older general population confirms that persons with high basal levels of 
cortisol are indeed at an increased risk of cardiovascular death.  
A few studies within heart patients have previously shown that cortisol predicts 
subsequent events or mortality.12-14 However, as these persons already have disease at time 
of cortisol assessment it is hard to disentangle whether cortisol is a cause or a consequence 
of disease status. The results of our study show that urinary cortisol predicted 
cardiovascular mortality in both persons with and without cardiovascular disease at baseline. 
This suggests that high cortisol levels are not merely a reflection of heart disease severity 
and might have a direct causal effect on cardiovascular death. On the other hand, it is 
possible that among those without pre-existing cardiovascular disease, those with higher 
cortisol did have worse health status. However, we adjusted for several health indicators 
and this only strengthened the association between cortisol and cardiovascular disease.  
We found that cortisol was associated with cardiovascular, but not non-cardiovascular 
mortality. This indicates that the HPA-axis might have specifically damaging effects on the 
cardiovascular system, and has less profound consequences on other vital physiological 
systems. In contrast, another recent study in an older general population by Schoorlemmer 
et al.18 did find salivary cortisol, but not serum cortisol, to be predictive of all-cause 
mortality over 7 years of follow-up. This study was not able to differentiate between causes 
of death. Therefore, it is possible that the association of cortisol was only restricted to those 
with cardiovascular deaths and not non-cardiovascular deaths, as in our study. The study by 
Schoorlemmer et al., however, did not find an association between cortisol and the onset of 
nonfatal heart disease. As heart disease was only measured by self-report, misclassification 
could have prevented the authors detecting any association between cortisol and heart 
disease. On the other hand, it is possible that when cortisol levels are increased a cardiac 
event is more likely to result in death, which is corroborated by the finding that high cortisol 
levels in heart patients seem to predict mortality.12-14 
Strengths of the present study include the use of urinary cortisol, which represents the 
biological active cortisol and can be non-stressfully measured. Furthermore, we were able to 
examine the effects of cortisol on all-cause and cardiovascular mortality in a large randomly 
selected sample of the general older population including persons with and without 
cardiovascular disease. Limitation of this study is that despite the large sample size, there 
were rather few cases of cardiovascular death. The fact that we only found a trend of 
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association of continuous urinary cortisol levels with cardiovascular death may have been a 
result of this. Nevertheless, even with this relatively small number of cases, strong clinically 
relevant significant effects of high urinary cortisol levels on cardiovascular mortality were 
found, indicating that a threshold effect, rather than a linear effect may exist.  
In conclusion, high cortisol levels in older persons predict cardiovascular death among 
both persons with and without pre-existing cardiovascular disease. The specific link with 
cardiovascular - and not all-cause - mortality suggests that hyperactivity of the HPA-axis 
might be particularly damaging to the cardiovascular system. 
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Abstract 
 
Background 
Associations between depression, and possibly anxiety, with cardiovascular disease have 
been established in the general population and among heart patients. This study examined 
whether cardiovascular disease was more prevalent among a large cohort of depressed 
and/or anxious persons. In addition, the role of specific clinical characteristics of depressive 
and anxiety disorders in the association with cardiovascular disease was explored. 
 
Methods 
Baseline data from the Netherlands Study of Depression and Anxiety were used, including 
persons with a current (i.e. past year) or remitted DSM-IV depressive or anxiety disorder (N 
= 2315) and healthy controls (N = 492). Additional clinical characteristics (subtype, 
duration, severity, and psychoactive medication) were assessed. Cardiovascular disease 
(stroke and coronary heart disease) was assessed using algorithms based on self-report and 
medication use. 
 
Results 
Persons with current anxiety disorders showed an about three-fold increased prevalence of 
coronary heart disease (OR anxiety only = 2.70, 95% CI = 1.31-5.56; OR comorbid 
anxiety/depression = 3.54, 95% CI = 1.79-6.98). No associations were found for persons 
with depressive disorders only or remitted disorders, nor for stroke. Severity of depressive 
and anxiety symptoms - but no other clinical characteristics - most strongly indicated 
increased prevalence of coronary heart disease. 
 
Limitations 
Cross-sectional design. 
 
Conclusions 
Within this large psychopathology-based cohort study, prevalence of coronary heart disease 
was especially increased among persons with anxiety disorders. Increased prevalence of 
coronary heart disease among depressed persons was largely owing to comorbid anxiety. 
Anxiety - alone as well as comorbid to depressive disorders - as risk indicator of coronary 
heart disease deserves more attention in both research and clinical practice.   
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Introduction  
In 1993 Frasure-Smith et al.1 showed that after a myocardial infarction, depressed persons 
were four-to-five times as likely to die within the next six months than their non-depressed 
counterparts. Although this initial observation turned out to overestimate the true 
relationship between depression and heart disease,2 since then, many studies have 
examined their association. Both depression and heart disease are leading disorders when 
considering disease burden. The World Health Organization projected depression and heart 
disease to become number 1 and 2, respectively, on the list of diseases with the greatest 
loss of ‘disability adjusted life years’ in 2030 in high-income countries and number 2 and 3 
worldwide.3 This suggests an enormous possible gain in public health and disease burden 
when depression, heart disease and especially their comorbidity could be prevented through 
increasing knowledge on the link between these two disabling diseases.  
Research thus far has mainly focused on two kinds of populations: heart disease 
patients and the general population. Meta-analyses have shown that among heart patients 
depression is associated with an 1.8 to 2.6 increased risk of a subsequent cardiovascular 
event or death,2,4,5 while in the general population depression increases risk of 
cardiovascular disease (CVD) about 1.6 to 1.8 times.2,6-8 Although, as suggested by 
Nicholson et al.,2 these estimates may still be inflated due to incomplete and biased 
reporting of adjustment for conventional risk factors and CVD severity. Studies on 
prevalence of CVD within a psychopathology-based population are largely lacking. From a 
psychiatrist perspective, it would be of great importance to know whether clinically 
depressed patients indeed have a higher prevalence of CVD and how much increased 
exactly this prevalence is. What’s more, it has hardly been addressed whether specific 
characteristics of depression, such as age of onset, duration, or severity of the disorder 
could further determine the exact CVD probability, or whether the association is restricted to 
specific subtypes, such as atypical or melancholic depression. This knowledge could give 
insight into underlying mechanisms that relate depression and CVD as well as into which 
patients should be most closely monitored for cardiovascular dysfunctioning.  
Besides depression, some studies have suggested anxiety to be associated with CVD as 
well.9-11 Anxiety disorders lead to comparable levels of disability as depression and heart 
disease12 and have been found to increase risk of premature all-cause and cardiovascular 
death.13,14 The association between anxiety and CVD, however, has been far less studied 
than the link between depression and heart disease. Even less studied has been the 
association between anxiety characteristics (subtype, duration, and severity) and CVD. 
Furthermore, as depression and anxiety are often found to be co-morbid, it would be of 
great importance to study the association between depression and anxiety with CVD in 
concert. This could shed light on the specificity of associations between depressive and 
anxiety disorders and CVD.  
Therefore, in the present study within a large cohort of depressed and/or anxious 
persons and healthy controls we examined the (extent of the) association between the 
presence of a psychiatric diagnosis of depressive and/or anxiety disorder with CVD. In 
addition, we assessed the specificity of these associations by directly comparing depressive 
with anxiety disorders and by examining whether specific characteristics of depressive 
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and/or anxiety disorders (subtype, duration, severity, and psychoactive medication) could be 
identified that indicate increased probability of CVD. 
 
Methods 
Sample 
The Netherlands Study of Depression and Anxiety (NESDA) is an ongoing cohort study 
designed to investigate the long-term course and consequences of depressive and anxiety 
disorders. Participants were 18 to 65 years old at baseline assessment in 2004-2007 and 
were recruited from the community (19%), general practice (54%) and secondary mental 
health care (27%). A total of 2981 persons were included, consisting of persons with a 
current or past depressive and/or anxiety disorder (N = 2329) and healthy controls (N = 
652). A detailed description of the NESDA study design and sampling procedures can be 
found elsewhere.15 The research protocol was approved by the Ethical Committee of 
participating universities and after complete description of the study all respondents 
provided written informed consent.  
As subclinical symptoms of on the one hand depressive and anxiety disorders and on 
the other hand CVD could to a certain degree resemble each other (e.g. feeling tired or pain 
on the chest) and could therefore falsely indicate or elevate an association between them, 
persons with subthreshold symptoms of depression or anxiety but no formal diagnosis of 
depressive or anxiety disorder (N = 158) and persons who self-reported CVD without 
reporting accompanying appropriate medication use (N = 16) were excluded (see below for 
more details), leaving 2807 persons for the present analyses.  
 
Psychopathology and clinical characteristics 
Presence of depressive disorder (major depressive disorder and dysthymia) and anxiety 
disorder (social phobia, generalized anxiety disorder, panic disorder and agoraphobia) was 
established using the Composite Interview Diagnostic Instrument (CIDI) according to DSM-
IV criteria.16 The CIDI is a highly reliable and valid instrument for assessing depressive and 
anxiety disorders17 and was administered by specially trained research staff. Based on CIDI, 
participants were categorized as having no, current (i.e. in past year), or a remitted 
(lifetime, but not current) depressive and/or anxiety disorder. In addition, a categorical 
variable was constructed classifying persons as having no depressive or anxiety disorder, 
remitted depressive or anxiety disorder, current depressive disorder only, current anxiety 
disorder only, or current depressive and anxiety disorder. 
Clinical characteristics examined included the subtype, duration and severity of the 
depressive or anxiety disorder. Next to CIDI diagnoses, subtypes of depressive disorder 
included first onset versus recurrent major depressive disorder (based on CIDI interview), 
presence of an atypical symptom profile, and presence of a melancholic symptom profile. 
Atypical symptom profile (mood reactivity and ≥ 2 of hyperphagia, hypersomnia, leaden 
paralysis, and interpersonal rejection sensitivity) was constructed by comparison of items of 
the 28-item self-report Inventory of Depressive Symptoms (IDS)18 with DSM-IV criteria for 
atypical depression following Novick’s algorithm.19 Similarly, melancholic symptom profile 
(lack of mood reactivity or loss of pleasure and ≥ 3 of distinct mood quality, mood worse in 
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morning, early morning awakening, psychomotor retardation or agitation, anorexia/weight 
loss, and guilt feelings) was constructed based on comparison of IDS items with DSM-IV 
criteria using the algorithm proposed by Khan.20 Additionally, for both depressive and 
anxiety disorders a distinction was made between late onset (≥ 30 years old) and early 
onset (< 30 years old) of the psychiatric disorder, as derived from the CIDI interview. Using 
the Life Chart method,21 a detailed account of the presence of depressive and anxiety 
symptoms during the past four to five years was assessed among persons with depressive 
or anxiety disorders. From this, the percent of time patients reported depressive or anxiety 
symptoms was computed as a measure of duration. Severity of depressive symptoms was 
assessed by means of the IDS; severity of anxiety symptoms by means of the 21-item Beck 
Anxiety Inventory (BAI).22  
To account for possible psychoactive medication effects, medication use was assessed 
based on drug container inspection of all drugs used in the past month and classified 
according to the World Health Organization Anatomical Therapeutic Chemical (ATC) 
classification.23 As effects of psychoactive medication are likely negligible when used 
infrequently, use of psychoactive medication was only considered present when taken on a 
regular basis (at least 50% of the time). Antidepressants included selective serotonin 
reuptake inhibitors (ATC-code N06AB), tricyclic antidepressants (N06AA) and other 
antidepressants (N06AF/N06AX). Benzodiazepines included ATC-codes N03AE, N05BA, 
N05CD and N05CF. 
 
Cardiovascular disease 
Cardiovascular disease (CVD) included stroke, angina pectoris, myocardial infarction, 
percutaneous transluminal coronary angioplasty and coronary artery bypass grafting and 
was adjudicated using standardized algorithms considering self-report and medication use 
(based on drug container inspection and ATC coding). During the interview, participants 
were asked if they ever had a stroke, a heart condition or a heart attack, and to specify the 
kind of condition. In addition, it was asked whether subjects were ever troubled by chest 
pain during physical strain and whether the pain disappeared within 10 min after standing 
still or taking a tablet under the tongue. If subjects responded positively on both questions 
this was regarded as an indication of angina pectoris (symptoms). Stroke was identified by 
self-report supported by use of either anticoagulant/antiplatelet agents (antithrombotic 
agents [ATC-code B01], acetylsalicylic acid [N02BA01; ≥ 50% use of ≤ 100 mg], or 
carbasalate calcium [N02BA15]), any medication for hypertension (antihypertensives [C02], 
diuretics [C03], beta blocking agents [C07], calcium channel blockers [C08], agents acting 
on renin-angiotensin system [C09]), or lipid modifying agents (C10). Angina pectoris and 
myocardial infarction were only considered present when self-report (or symptoms) of the 
disease was supported by use of medication for coronary heart disease (CHD; beta blocking 
agents [C07], nitrate vasodilators [C01DA], calcium channel blockers [C08], or 
anticoagulant/antiplatelet agents [B01, N02BA01 ≥ 50% use of ≤100 mg, N02BA15]). When 
self-report was not confirmed by medication use, CVD was considered to be ‘undetermined’ 
and subjects were excluded from the analyses (N = 16). When angina symptoms (N = 510) 
were not supported by medication use, persons were considered as having no CVD (N = 
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413). Percutaneous transluminal coronary angioplasty and coronary artery bypass grafting 
were based on self-report only. CVD was subdivided into stroke and CHD (angina pectoris, 
myocardial infarction, angioplasty or bypass). For sensitivity analyses, as beta blockers are 
sometimes prescribed for anxiety symptoms, a secondary measure of CHD excluded persons 
with symptoms of angina pectoris and use of a beta blocker only (N excluded = 32). 
 
Covariates  
Sociodemographic characteristics included age, sex, and years of education. As lifestyle 
characteristics can be associated with both CVD and depression/anxiety, smoking status 
(never, former, current), alcohol intake (< 1, 1-14, > 14 drinks per week), physical activity 
(measured with the International Physical Activity Questionnaire24 in MET-minutes [ratio of 
energy expenditure during activity compared to rest times the number of minutes 
performing the activity] per week) and body mass index (BMI; weight in kilograms divided 
by height in meters squared) were assessed. 
 
Statistical analyses 
Sample characteristics were compared across persons with and without CVD using 
independent t tests for continuous variables and Χ2 tests for dichotomous and categorical 
variables. Logistic regression analyses assessed the association with CVD for depressive and 
anxiety disorders separately and simultaneously, before and after adjustment for a priori 
selected covariates (sociodemographic [age, sex, years of education] and lifestyle [smoking 
status, alcohol intake, physical activity, BMI]). Next, consistency of associations with regard 
to CVD were assessed by conducting separate adjusted logistic regression analyses for 
subtypes of CVD (stroke and CHD) and subtypes of CHD (angina pectoris, myocardial 
infarction, and CHD surgery [angioplasty or bypass]). 
Specificity of associations with regard to clinical aspects of the depressive or anxiety 
disorder was assessed in a sub-sample of persons with current depressive and/or anxiety 
disorders using sociodemographic-adjusted logistic regression analyses. First, the 
association with CVD of depressive disorder versus anxiety disorder was directly compared. 
Second, associations between specific depressive disorder or anxiety disorder characteristics 
(subtype, duration, severity, and psychoactive medication use) and CVD were examined. 
 
Results 
Mean age of the present sample was 41.8 (SD = 13.0) years, 66.4% were women, 19.4% 
had a remitted and 63.1% had a current depressive or anxiety disorder, while 5.6% had 
CVD. Table 1 describes sample characteristics comparing persons with and without CVD. 
Persons with CVD were older, more often men, less educated, more often former smoker, 
less often moderate drinker, and had a higher BMI. Also, persons with CVD more often had 
a current anxiety disorder, but not depressive disorder. 
Table 2 describes the results of unadjusted and adjusted logistic regression analyses 
assessing the association of depressive and anxiety disorders with CVD. Remitted disorders 
were not statistically significantly associated with CVD, but after adjustment current 
depressive and current anxiety disorders were (OR = 1.59, 95% CI = 1.02-2.47; OR = 2.18, 
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Table 1. Sample characteristics by cardiovascular disease status 
 
Characteristic 
No CVD 
N = 2651 
CVD 
N = 156 
p a
Sociodemographic variables    
Age, years, mean (SD) 41.1 (12.9) 54.1 (7.8) <.001 
Women, % 67.7 45.5 <.001 
Years of education, mean (SD) 12.2 (3.3) 11.0 (3.2) <.001 
Lifestyle variables    
Smoking status      .001 
Never, % 28.4 18.6  
Former, % 32.3 46.2  
Current, % 39.3 35.3  
Alcohol intake      .05 
< 1 Drink a week, % 32.2 37.8  
1-14 Drinks a week, % 52.1 42.3  
> 14 Drinks a week, % 15.7 19.9  
Physical activity (in MET-minutes/week), mean (SD) 3720 (3046) 3423 (3198)    .24 
Body mass index, mean (SD) 25.4 (5.0) 28.6 (4.8) <.001 
Depression and anxiety variables    
Depressive disorder      .14 
No depressive disorder, % 30.6 23.7  
Remitted depressive disorder, % 24.4 29.5  
Current (in past year) depressive disorder, % 45.0 46.8  
Anxiety disorder      .007 
No anxiety disorder, % 37.9 26.3  
Remitted anxiety disorder, % 14.6 14.1  
Current (in past year) anxiety disorder, % 47.5 59.6  
Depressive and/or anxiety disorder      .03 
No depressive or anxiety disorder    17.8 12.2  
Remitted depressive or anxiety disorder  19.4 19.2  
Current depressive disorder only 15.2   9.0  
Current anxiety disorder only 17.7 21.8  
Current depressive and anxiety disorder 29.8 37.8  
a Based on independent t-test for continuous variables and Χ2 tests for dichotomous and categorical 
variables.  
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Table 2. Association a of depressive and anxiety disorders with cardiovascular disease 
 
  Unadjusted  Adjusted 
Psychiatric disorder status N OR 95% CI p  OR 95% CI p 
Depressive disorder        
No depressive disorder 847  REF    REF 
Remitted depressive disorder 693 1.56 1.00-2.43 .05  1.50 0.93-2.40 .10 
Current (in past year) depressive disorder 1267 1.34 0.89-2.01 .16  1.59 1.02-2.47 .04 
Anxiety disorder         
No anxiety disorder 1046  REF    REF  
Remitted anxiety disorder 408 1.40 0.82-2.38 .22  1.31 0.74-2.30 .35 
Current (in past year) anxiety disorder 1353 1.81 1.24-2.64 .002  2.18 1.45-3.28 <.001 
Depressive and/or anxiety disorder         
No depressive or anxiety disorder    492  REF    REF  
Remitted depressive or anxiety disorder  544 1.45 0.81-2.62 .21  1.27 0.68-2.37 .45 
Current depressive disorder only 418 0.86 0.43-1.74 .68  0.93 0.44-1.96 .85 
Current anxiety disorder only 504 1.80 1.01-3.20 .05  1.96 1.06-3.64 .03 
Current depressive and anxiety disorder 849 1.86 1.10-3.16 .02  2.35 1.33-4.20 .004 
a Based on logistic regression analyses unadjusted and adjusted for age, sex, years of education, smoking status, 
alcohol intake, physical activity and body mass index. 
 
 
95% CI = 1.45-3.28, respectively). When the presence or absence of a depressive or 
anxiety disorder was combined in one categorical variable, odds of CVD were increased for 
persons with a current anxiety disorder alone (OR = 1.96, 95% CI = 1.06-3.64) as well as 
for those with a combined current anxiety and depressive disorder (OR = 2.35, 95% CI = 
1.33-4.20) compared to healthy controls. Increased likelihood of CVD was not observed for 
persons with a current depressive disorder only (OR = 0.93, 95% CI = 0.44-1.96). 
Next, effects of depression/anxiety status were assessed separately for odds of having 
stroke and odds of having CHD (Table 3). Depressive and anxiety disorders were not 
associated with stroke. In contrast, persons with a current anxiety disorder were 2.5 to 3.5 
times more likely to have CHD (OR anxiety only = 2.70, 95% CI = 1.31-5.56; OR anxiety 
and depression = 3.54, 95% CI = 1.79-6.98). No significant association was found for 
persons with a depressive disorder only (OR = 1.41, 95% CI = 0.61-3.23). To gain some 
insight into the direction of the association between psychopathology and CHD, we repeated 
the current analysis among persons with an early onset (≤ 30 years) of depressive or 
anxiety disorder (N excluded = 269). Since CHD hardly occurs before the age of 30, an early 
onset suggests that psychopathology was present before CHD. Within persons with an early 
onset of depressive or anxiety disorder similar results were found (OR depression only = 
1.37, 95% CI = 0.59-3.20; OR anxiety only = 2.37, 95% CI = 1.12-5.03; OR anxiety and 
depression = 3.26, 95% CI = 1.59-6.68; data not tabulated). An additional analysis 
excluded persons (N = 32) who ‘earned’ their status of CHD only based on angina  
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Table 3. Association a of depressive and anxiety disorders with cardiovascular disease subtypes 
 
 Cardiovascular disease subtypes (N = 156) 
 
Stroke 
(N = 36) 
Coronary heart 
disease (N = 133) 
   
Psychiatric disorder status OR 95% CI p OR 95% CI p    
No depressive or anxiety disorder     REF   REF     
Remitted depressive or anxiety disorder 0.73 0.24-2.19 .57 1.65 0.79-3.43   .18    
Current depressive disorder only 0.53 0.13-2.18 .38 1.41 0.61-3.23   .42    
Current anxiety disorder only 1.02 0.34-3.11 .97 2.70 1.31-5.56   .007    
Current depressive and anxiety disorder 1.37 0.49-3.86 .55 3.54 1.79-6.98 <.001    
 Coronary heart disease subtypes (N = 138) 
 
Angina pectoris 
(N = 105) 
Myocardial 
infarction (N = 50) 
CHD surgery 
(N = 48) 
Psychiatric disorder status OR 95% CI p OR 95% CI p OR 95% CI p 
No depressive or anxiety disorder     REF   REF   REF  
Remitted depressive or anxiety disorder 2.17 0.88-5.34  .09 2.55 0.78-8.40 .12 1.44 0.49-4.24 .50 
Current depressive disorder only 2.16 0.82-5.71  .12 2.58 0.70-9.46 .15 1.60 0.50-5.10 .42 
Current anxiety disorder only 2.87 1.16-7.11  .02 3.47 1.03-11.66 .05 2.69 0.94-7.67 .06 
Current depressive and anxiety disorder 4.96 2.14-11.49 <.001 4.75 1.46-15.47 .01 2.24 0.79-6.37 .13 
CHD = coronary heart disease. a Based on logistic regression analyses adjusted for age, sex, years of education, 
smoking status, alcohol intake, physical activity and body mass index; in all analyses the specific cardiovascular disease 
or coronary heart disease subtype was compared to persons without any cardiovascular disease (N = 2651). 
 
0
1
2
3
4
5
Current 
depressive disorder
N = 418
Current 
anxiety disorder
N = 504
Current depressive 
and anxiety disorder
N = 848
OR a
 
Figure 1. OR for coronary heart disease in persons with a current depressive and/or anxiety disorder. 
a Based on logistic regression analysis adjusted for age, sex, and education. 
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Table 4. Association of depressive and anxiety disorder characteristics with coronary heart disease 
 
 
No CHD 
N = 1673 
CHD 
N = 97 
    
 
% or 
mean (SD) 
% or 
mean (SD) 
 OR 95% CI p 
Psychiatric characteristic Unadjusted  Adjusted a
Type of depressive disorder b       
First onset major depressive disorder 
(vs. recurrent) 
46.4 41.8 
 
0.95 0.56-1.61 .85 
Atypical symptoms 20.8 24.2  1.53 0.83-2.83 .17 
Melancholic symptoms 11.9 16.7  1.08 0.53-2.18 .84 
Late onset (≥ 30 years old) 35.0 61.8  1.11 0.65-1.92 .70 
Type of anxiety disorder c       
Generalized anxiety disorder 44.9 50.0  1.15 0.72-1.82 .56 
Social phobia 55.5 53.6  1.08 0.68-1.72 .74 
Panic disorder 55.1 53.6  1.13 0.71-1.80 .62 
Agoraphobia 16.0 25.0  1.21 0.70-2.10 .49 
Late onset (≥ 30 years old) 22.6 43.4  1.06 0.65-1.73 .83 
Duration d       
Percent of time with symptoms in past 4 years 52.4 (35.6) 58.8 (35.3)  1.02 0.56-1.86 .95 
Severity d       
Current depressive symptoms score (IDS) 28.5 (12.4) 32.2 (13.0)  1.32 e 1.05-1.65 .02 
Current anxiety symptoms score (BAI) 16.5 (10.8) 20.0 (9.7)  1.36 e 1.11-1.66 .003 
Psychoactive medication d       
Selective serotonin reuptake inhibitor use 25.1 21.6  0.87 0.52-1.45 .60 
Tricyclic antidepressant use 3.8 7.2  1.56 0.68-3.57 .30 
Other antidepressant use 8.8 12.4  1.26 0.65-2.41 .49 
Benzodiazepine use 10.5 22.7  1.60 0.95-2.71 .08 
CHD = coronary heart disease. a Based on logistic regression analyses adjusted for age, sex, and education; 
each line represents a single analysis; b within sub-sample of persons with a current (past year) depressive 
disorder: N = 1266; first onset vs. recurrent: persons with dysthymia only (N = 44) were excluded; c within 
sub-sample of persons with a current (past year) anxiety disorder: N = 1352; d within sub-sample of persons 
with a current (past year) depressive and/or anxiety disorder: N = 1770; e per SD increase: IDS: SD = 12.9; 
BAI: SD = 10.7. 
 
 
symptoms and use of a beta blocker - sometime used to relieve anxiety symptoms - but 
substantial associations remained (OR anxiety only = 2.06, 95% CI = 0.96-4.44; OR anxiety 
and depression = 2.89, 95% CI = 1.41-5.93; data not tabulated). When examining CHD 
subtypes (angina pectoris, myocardial infarction, and CHD surgery) associations for current 
anxiety disorder (with or without depressive disorder) were found for all (see Table 3). 
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Depressive disorders alone also showed increased odds of especially angina pectoris and 
myocardial infarction, but these were not statistically significant. Because associations of 
psychopathology were only found with CHD and not stroke, all following analyses were 
conducted with CHD as the outcome.  
Figure 1 shows that within persons with current psychopathology (N = 1770), persons 
with a current anxiety disorder had almost 80% increased odds to have CHD compared to 
persons with a current depressive disorder (OR = 1.77, 95% CI = 0.89-3.54), albeit this 
was not statistically significant. Odds of CHD for persons having an anxiety disorder in 
addition to a depressive disorder were more than twofold increased compared to having a 
depressive disorder alone (OR = 2.40, 95% CI = 1.27-4.54). 
Table 4 shows the results of separate sociodemographic-adjusted logistic regression 
analyses examining associations of depressive and anxiety disorder characteristics with CHD 
in the sub-sample of persons with current psychopathology (N = 1770). No specific subtype 
of depressive disorder was associated with CHD. For persons with a current anxiety disorder 
associations with CHD were consistent for persons with generalized anxiety disorder, social 
phobia, panic disorder and agoraphobia. Duration of depressive or anxious complaints was 
also not associated with CHD. However, the severity of depressive symptoms (OR per SD 
increase = 1.32, 95% CI = 1.05-1.65) and of anxiety symptoms (OR per SD increase= 1.36, 
95% CI = 1.11-1.66) were significantly associated with CHD. In fact, it appeared that the 
results from Figure 1 showing a somewhat higher OR in persons with comorbid depression 
and anxiety in comparison to the OR in persons with anxiety disorders alone could be 
explained by severity of symptoms. After additional adjustment for severity of depressive 
and anxiety symptoms, odds of CHD for persons with anxiety disorders were equally 
increased, irrespective of additional depressive disorder (OR anxiety only = 1.86, 95% CI = 
0.91-3.79; OR anxiety and depression = 1.95, 95% CI = 1.00-3.78). Lastly, psychoactive 
medication use did not statistically significantly increase odds of CHD, but a trend was found 
for use of benzodiazepines and higher odds of CHD (OR = 1.60, 95% CI = 0.95-2.71). 
Benzodiazepine use did not affect the before presented results (i.e. ORs of CHD as 
presented in Table 3 and Figure 1 were very similar after additional adjustment for 
benzodiazepine use).  
 
Discussion 
This study examined the association between diagnosed depressive and anxiety disorders 
and cardiovascular disease within a large cohort of depressed and/or anxious persons and 
healthy controls. The results show that, individually, both depressive and anxiety disorders 
are associated with CVD. However, the increased prevalence of CHD among depressive 
persons appeared to be mainly owing to comorbidity of anxiety disorders. No associations 
were found with stroke. Severity of depressive and anxiety symptoms - but no other clinical 
factors - identified those with the highest prevalence of CHD.  
Relatively few studies have examined the link between anxiety and CHD and most of 
these studies assessed anxiety symptoms, but not diagnosis. Although the link between 
anxiety (symptoms) and CHD has been more consistently found in initially CHD-free 
populations than among heart patients,25 a recent study26 showed that both a generalized 
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anxiety disorder, as well as severity of anxiety symptoms were associated with an increased 
risk of major adverse cardiac events in patients with stable coronary artery disease. Our 
results demonstrate that within a psychopathology-based population the prevalence of CHD 
is increased across a wide range of diagnosed anxiety disorders (social phobia, generalized 
anxiety disorder, panic disorder and agoraphobia). In fact, persons who suffered from any 
anxiety disorder in the past year were about three times as likely to have CHD. Given the 
widespread prevalence of anxiety disorders, these results suggest that the role of anxiety 
disorders in CHD is important and has been largely overlooked thus far. These findings also 
suggests that cardiac symptoms in anxiety persons might really indicate heart disease and 
underdiagnosing heart disease in anxiety patients might be a problem.  
The possible overlap in symptoms between anxiety disorders and heart disease could 
also pose a problem in examining the association between these two. We tried to handle 
this issue by only including definite cases of anxiety and by confirmation of medication use 
appropriate for CVD. Even when further excluding persons with symptoms of chest pain and 
use of a beta-blocker only - sometimes described to relieve anxiety symptoms - associations 
of anxiety disorders with CHD remained. Moreover, associations between anxiety disorders 
and CHD were found across different types of both CHD and anxiety disorders and were not 
confined to for instance angina pectoris and panic disorder, supporting the conclusion that 
the strong association observed between anxiety and CHD is real. 
Although a depressive disorder diagnosis was associated with CVD, this relationship 
appeared to be largely explained by comorbid anxiety. Previous research in the general 
population and among heart patients consistently showed an association between 
depression and CVD. Importantly, these studies often did not take into account comorbid 
anxiety, but many depressed persons have a co-morbid anxiety disorder (in our sample 
67%). Similar to our study within a psychopathology-based population, Strik et al.27 found 
that anxiety and not depressive symptoms were an independent predictor of cardiac events 
among heart patients and accounted for the relationship between depressive symptoms and 
cardiac events. Longitudinal studies should further disentangle the associations between 
depression, anxiety and CHD. 
Considering clinical characteristics, highest prevalences of CHD were found among 
those with the most severe symptoms of depression and anxiety. This might suggest that 
more severe symptoms induce an extra increased risk of CHD. Otherwise, as symptom 
scales of depression and anxiety often include a set of somatic items, it is possible that 
severity of depression or anxiety partly reflects severity of heart complaints.28 Otherwise, 
somatic health factors might be more important in depressive disorders that are associated 
with CVD. This might also (partly) explain why other studies, mostly conducted within 
somewhat older populations, which generally have more somatic conditions, do find more 
support of a relationship between depression and CVD.   
Little evidence was found of other clinical characteristics of depressive or anxiety 
disorders to be specifically related to CHD. Although we had expected longer lasting 
psychiatric disorders to be associated with higher prevalence of CVD, the results did not 
corroborate this. This finding somewhat decreases the plausibility of depressive and anxiety 
disorders directly causing CVD. Also, associations with remitted psychiatric disorders were 
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not statistically significant, perhaps partly due to decreased reliability of diagnosis 
assessment in the more far away past. On a more positive side, this might suggest that 
when persons remit from depressive or anxiety disorders, the odds of CHD decreases. 
Further, antidepressant medication use was not associated with CHD. Tricyclic 
antidepressants have been well described to have cardiovascular effects,29 but this might 
have been counterbalanced in our study by the fact that these medications are therefore 
contra-indicated in heart patients. Benzodiazepine use was somewhat more prevalent 
among persons with CHD, but whether they increase risk of CVD or whether this finding is a 
reflection of poorer health status in persons with CVD, cannot be decided from this study.  
Interestingly, our results only show an association with CHD, but not with stroke. 
Although some studies do relate psychopathology to stroke,30 this has been much less 
examined than CHD. We examined the association between depression, anxiety and stroke 
in a relatively young population where stroke was not very prevalent and we were not able 
to distinguish between ischemic or a hemorrhagic stroke. As an association of depression 
and anxiety with specifically ischemic stroke is expected, hemorrhagic strokes might have 
diluted the association.  
Our study has some important strengths. We made use of a large sample of persons 
with diagnosed psychopathology to investigate whether true psychiatric diagnoses of both 
depression and anxiety are indeed associated with a heightened prevalence of CVD. 
Furthermore, we were able to examine the effects of a large amount of clinical 
characteristics of depressive and anxiety disorders. Some limitations have to be noted as 
well. Our results are based on cross-sectional data. This makes it impossible to draw any 
conclusions about the causality of associations between depressive and anxiety disorders 
and CHD. However, a strong association between anxiety disorder and CHD existed in 
persons with an onset of psychopathology before 30 years. Since CHD hardly occurs before 
the age of 30, an early onset suggests that psychopathology was present before CHD. 
Additionally, as depression and anxiety are highly comorbid and had an early onset in most 
persons (only 269 of 2315 had late onset), it is unlikely that the finding that anxiety is more 
strongly than depression associated with CHD was biased by the cross-sectional design. 
Another limitation is that the presence of heart disease was not verified by general practice 
or hospitalization records. However, self-report was confirmed by medication use and 
previous research has shown good concordance between self-report of heart disease and 
general practitioners information, with especially little overreporting.31,32 
In conclusion, our results show that anxiety disorders are more strongly associated with 
coronary heart disease than depressive disorders and might partly account for the widely 
reported association between depression and heart disease. The highest prevalence of CHD 
is found among those with the most severe psychiatric symptoms, such as those persons 
with comorbid depression and anxiety. Anxiety as possible risk factor for cardiovascular 
disease needs to be more elaborately investigated in future research, and deserves more 
attention in clinical care as well. 
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The aim of the present thesis was to examine the association between depression and the 
metabolic syndrome, taking an epidemiological perspective. First, the cross-sectional 
association between depression and the metabolic syndrome was investigated. Next, a 
possible role of the hypothalamic-pituitary-adrenal (HPA)-axis herein was considered. 
Subsequently, the temporal direction of associations between depression and the metabolic 
syndrome was examined using longitudinal designs. Lastly, a cross-link was made to 
cardiovascular disease, which is a frequent and debilitating outcome of the metabolic 
syndrome and has recurrently been associated with depression. In the present chapter, 
findings from Chapter 2 through 9 will be integratively summarized and discussed within the 
context of current scientific evidence. In addition, some notes will be given on 
methodological issues relevant for this thesis and the possible implications for public health 
and clinical practice will be portrayed. The chapter finishes with a few suggestions for future 
research and an overall conclusion. 
 
Are depression and the metabolic syndrome associated? 
Results from each of the thesis chapters are summarized in Table 1. Cross-sectional 
examinations in the present thesis are only partly supportive of an association between 
depression and the metabolic syndrome. In Chapter 2 depressive symptoms were modestly 
associated with the metabolic syndrome in older white persons, but not in older black 
persons. In Chapter 3 a significant association was found between depressive symptoms 
and the metabolic syndrome, mainly due to high cortisol levels among the depressed. In 
Chapter 4 no significantly increased odds of metabolic syndrome was found for persons with 
major depressive disorder. Persons with subthreshold depressive symptoms even had a 
decreased odds of the metabolic syndrome. In the past few years, several other studies 
have tested the cross-sectional association between depression, almost exclusively assessed 
by means of symptoms checklists, and the metabolic syndrome.1-13 Most of these studies, 
including both smaller and larger sample size studies, and younger and older age samples, 
found an association between depressive symptoms and the metabolic syndrome.1-10 Some 
of these studies observed gender-specific effects, with associations found either only in 
women3,8 or only in men.2,10 In contrast, a small number of large studies,11-13 including 4000 
up to almost 10.000 persons, was not able to show an association between depressive 
symptoms and the metabolic syndrome. For instance, Hildrum et al.13 found no association 
between depressive symptoms and the metabolic syndrome after adjustment for physical 
activity and education in a sample of 9571 participants aged 20-89 years. This absence of 
association was consistent across sex and age groups. Important to note is that this study 
did find an association between depressive symptoms and waist circumference. In fact, the 
cross-sectional results from this thesis and of nearly all other cross-sectional studies 
revealed that waist circumference is (one of) the most important metabolic syndrome 
component in association with depressive symptoms. This stresses the importance of not 
just examining the metabolic syndrome as a whole, but to always include analyses on the 
different metabolic abnormalities. 
 
160  | CHAPTER 10 
Table 1. Associations between depression and metabolic syndrome (components) across 
thesis chapters 
 
C Study Population a Design MS AO TRI HDL BP GLU 
2 Health ABC 2917 US 
black & white  
X + b + +/ / + / 
3 InCHIANTI 867 Italians X       
  Overall  + +/ / +/ / / 
  Hyper-
cortisolemic 
 + + + + / / 
4 LASA 1212 Dutch X       
  Subthreshold  - - / - / / 
  MDD  / / / / / / 
5 Health ABC 2088 US  
black & white 
L1 NA + NA NA NA NA 
6 Health ABC 2540 US 
black & white 
L2 NA + c NA NA NA NA 
7 InCHIANTI 823 Italians L2       
  Onset  / + / / / / 
  Persistence  + +/ +/ +/ +/ / 
C = Chapter number; MS = metabolic syndrome; AO = abdominal obesity; TRI = high triglyceride 
levels; HDL = low high-density lipoprotein cholesterol levels; BP = high blood pressure; GLU = high 
fasting glucose levels; MDD = major depressive disorder; X = cross-sectional; L1 = longitudinal: 
depression -> metabolic syndrome; L2 = longitudinal: metabolic syndrome -> depression; + = positive 
association; / = no association; - = negative association; +/ = non-significant positive association; NA 
= not assessed. a All studies were conducted in the general older population; b only in white persons;    
c only in men.  
 
 
Altogether, the somewhat inconsistent findings on the cross-sectional association 
between depression and the metabolic syndrome in the present thesis are also seen in other 
research reports. A plausible explanation for these discrepancies might be that the metabolic 
syndrome is only associated with a specific subtype of depression. In Chapter 3 it was found 
that only those older depressed persons who showed signs of a hyperactive HPA-axis - i.e. 
increased urinary cortisol levels - more often had the metabolic syndrome. Conversely, in 
Chapter 4, in which depressed persons were more likely to present with hypocortisolemia, 
the odds of metabolic syndrome were not increased. These findings illustrate the 
importance of considering and searching for depression subtypes when relating depression 
to somatic health conditions. Identifying depression subtypes could also greatly improve 
treatment of both depression and somatic health consequences as it becomes more clear to 
whom specialized treatment efforts should be addressed.  
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Does depression predict metabolic syndrome onset? 
Evidence, so far, is thus only partly supportive of a cross-sectional association between 
depression and the metabolic syndrome. This does, however, not necessarily exclude the 
possibility of a longitudinal relationship. Is there evidence that depression could predict the 
onset of the metabolic syndrome? The findings of this thesis can only partly answer this 
question. In Chapter 5 it was shown that among older persons depressive symptoms were 
followed by an increase in abdominal obesity, in particular excess visceral fat (see Table 1). 
This confirmed earlier observations in a small sample size study by Weber-Hamann et al.,14 
which showed a larger accumulation of visceral fat mass over time in 29 depressed patients 
compared to 17 controls. Abdominal obesity, especially visceral fat, is often regarded as a 
principal causative factor in the metabolic syndrome.15-17 At least, it is agreed upon that 
persons with abdominal obesity are more likely to become insulin resistant and to develop 
other metabolic disturbances.18,19 Therefore, the results of this thesis certainly underline the 
possibility that depression might bring about metabolic abnormalities as seen in the 
metabolic syndrome. Only recently, a very few studies have investigated whether depressive 
symptoms predict onset of the full metabolic syndrome. Räikkönen et al.20,21 showed that 
depressive symptoms increased the risk of metabolic syndrome onset after both 7 and 15 
years of follow-up in a sample of 425 middle-aged women. Also, Goldbacher et al.22 and 
Vanhala et al.23 observed approximately two-fold increased risks of metabolic syndrome 
onset after 7 years of follow-up in middle-aged depressed women. Only Vanhala et al. also 
examined men, but did not find a risk difference of metabolic syndrome onset in men. 
Individual metabolic syndrome components were investigated by both Goldbacher et al. and 
Vanhala et al., and they found strongest associations for waist circumference and high-
density lipoprotein cholesterol, respectively. Thus, although available studies are limited, 
both this thesis and other research, support the view that depression might increase the risk 
of onset of the metabolic syndrome, most convincingly abdominal obesity and associated 
lipid abnormalities.  
 
Does depression follow metabolic syndrome? 
There are thus strong indications that depression might predict the onset of the metabolic 
syndrome. As suggested in Chapter 1, it is, however, also very plausible that depression is a 
consequence of the metabolic syndrome. What is the support of this notion from this thesis 
and other research? Findings of this thesis related to this question are also summarized in 
Table 1. The results of Chapter 6 show that in an older population, obesity and in particular 
abdominal obesity, increases the risk of new depression onset, albeit only in men. Chapter 7 
examined all metabolic syndrome components and concluded that abdominal obesity, but 
no other metabolic abnormalities, are indicative of an increased odds of the onset of 
depressive symptoms, consistent across sex. A few other recent studies have examined the 
relationship between the metabolic syndrome and depressive symptoms onset. Two large 
studies in middle-aged populations24,25 and one large study among older persons26 found 
that the metabolic syndrome increases the risk of depressive symptoms onset in both men 
and women. Risk estimates ranged from increased odds of depressive symptoms onset of 
1.4 to 2.2. Two of these studies24,25 found strongest associations for abdominal obesity and 
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lipid disturbances. Taken together, these findings suggest that depression might be a 
consequence of metabolic abnormalities, with strongest evidence for abdominal obesity and 
obesity-related factors (i.e. lipid disturbances).  
If metabolic disturbances can induce depressive symptoms, then it might be questioned 
whether they can also promote depressive symptoms after they have emerged. That is, 
does the metabolic syndrome stimulate the persistence of depressive symptoms? The 
results of Chapter 6 show that (abdominal) obesity in older men is even more strongly 
associated with the onset of persistent depressive symptoms (2-fold increased risk when 
having excessive visceral fat) than with the onset of a single depression episode (1.3-fold 
increased risk). Moreover, in Chapter 7 it was found that the metabolic syndrome, with 
contributions of all metabolic syndrome components except glucose, predicted the 
persistence of depressive symptoms. Beyond this thesis, research on the relationship 
between the metabolic syndrome and the persistence of depressive symptoms is principally 
lacking. One recent study showed that adult men with the metabolic syndrome were more 
likely to have had experienced long-term depressive symptoms, although it was not clear 
whether metabolic syndrome was more strongly associated with long-term than with short-
term depressive symptoms.10 In all, the evidence to date suggests that the metabolic 
syndrome is associated with persistent depressive symptoms or, to put it differently, 
presence of the metabolic syndrome identifies a chronic depressive subtype.   
 
Vicious cycle 
From the above, it can be concluded that the evidence of a cross-sectional association 
between depression and the metabolic syndrome is somewhat inconsistent. However, the 
support for a longitudinal association between depressive symptoms and the metabolic 
syndrome appears more consistent, although, to date, less examined. Previous reports have 
observed stronger effects for longitudinal than cross-sectional associations. For instance, 
Kendler et al.27 found only a modest lifetime association between major depression and 
coronary artery disease, but in time-dependent-models, associations between depression 
and coronary artery disease were much stronger. It might be reasoned, if there is a time-lag 
between the emergence of two conditions, that when examining the presence of both 
conditions at one moment in time, it is less likely that both conditions will be present 
compared to examining the presence of these conditions across time. Furthermore, a 
temporal association is generally considered to be stronger evidence of a causal relationship 
than a cross-sectional association. Therefore, finding stronger longitudinal than cross-
sectional associations does actually support a causative rather than an associative 
relationship, although definite conclusions on causal relationships are very hard to draw 
from observational studies. 
As was described above, support is found for both depressive symptoms predicting the 
onset of the metabolic syndrome, and the metabolic syndrome predicting the onset of 
depressive symptoms. Most compelling evidence exists for a bidirectional relationship 
between depressive symptoms with abdominal obesity and obesity-related factors 
(unhealthy lipid profile), but in particular visceral fat. This suggests a vicious cycle between 
depression and visceral fat accumulation. A schematic representation of this vicious cycle is 
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presented in Figure 1. The reciprocal relationship between depression and visceral fat 
accumulation possibly exists through related hyperactivity of the HPA-axis. Furthermore, 
once a person enters this vicious cycle, other metabolic syndrome abnormalities, provoked 
by high visceral fat, contribute to the persistence of depressive symptoms. In addition, the 
metabolic syndrome increases the risk of cardiovascular disease, which explains why 
depression and cardiovascular disease are associated. Cardiovascular disease, in turn, might 
exacerbate depressive symptoms via alternative pathways, e.g. decreased energy level, 
increased physical disability, or having to cope with disease. This notion of a vicious cycle 
between depression and metabolic disturbances makes clear that these two conditions are 
very much intertwined with large overlap in underlying pathophysiology. Therefore, it might 
be suggested that when occurring together, both depressive symptoms and metabolic 
disturbances are in truth two aspects of the same condition, which could be labeled as 
metabolic depression. 
 
 
 
HPA-axis 
hyperactivity 
Metabolic syndrome
Cardiovascular disease
Visceral fat 
accumulation Depression
 
Figure 1. Vicious cycle between depression, visceral fat accumulation, metabolic syndrome 
and cardiovascular disease. 
HPA = hypothalamic-pituitary-adrenal 
 
 
Role of the HPA-axis 
One aim of this thesis was to assess whether the HPA-axis plays a role in the relationship 
between depression and the metabolic syndrome. Activity of the HPA-axis is essential during 
stressful situations, but chronic stress might result in a hyperactive HPA-axis.28 Furthermore, 
hyperactivity of the HPA-axis has recurrently been noted in at least a subset of depressed 
persons29-32 and, in turn, high levels of cortisol have been associated with individual 
metabolic abnormalities, such as high blood pressure, insulin resistance, and obesity.33,34 
Specifically, research has suggested that cortisol promotes the accumulation of visceral fat 
by activating lipoprotein lipase and inhibiting lipid mobilization.35 Visceral fat is highly 
sensitive to cortisol owing to a high density of glucocorticoid receptors.36 Consequently, it 
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has been hypothesized that chronic stress and/or depression results in abdominal obesity 
and associated comorbidities through long-term activation of the HPA-axis.35,37 This thesis 
examined the role of the HPA-axis in Chapters 3 and 4. In Chapter 3 a profound role of 
cortisol was uncovered. The cross-sectional association between depressive symptoms and 
the metabolic syndrome largely disappeared after appropriate adjustment for urinary cortisol 
levels. This indicates a mediating role of high cortisol levels in the association between 
depression and the metabolic syndrome. Moreover, it was found that only those depressed 
persons that presented with hypercortisolemia were at increased odds of having the 
metabolic syndrome. In Chapter 4, although no association was found between depression 
and the metabolic syndrome, serum cortisol levels were associated with the metabolic 
syndrome. This again suggests that when depressed persons present with 
hypercortisolemia, the odds of metabolic syndrome are increased. The findings in this thesis 
are corroborated by two other recent studies in which cortisol levels appeared to play a 
mediating role between depression and the metabolic syndrome.38,39 
It was unexpected to find no association or even evidence of a reversed association 
between depression and the metabolic syndrome in Chapter 4. However, an explanation for 
this discrepancy might actually be found when considering cortisol levels. Previous reports 
among older persons have suggested that depressed persons are not only more likely to 
have hypercortisolemia, but might in fact also more often exhibit hypocortisolemia.40,41 
Hypocortisolemia could possibly be the result of exhaustion of the body’s responses to 
stress.42 In fact, in the Longitudinal Aging Study Amsterdam (LASA), on which the results of 
Chapter 4 are based, hypocortisolemia was more present among depressed persons than 
hypercortisolemia.40 Thus, low levels of cortisol among a large part of the depressed group 
could actually have counterbalanced, or even reversed, the association between depression 
and the metabolic syndrome. Other studies have reported protective effects of low cortisol 
on metabolic factors.42,43 Unfortunately, the number of major depression cases in LASA was 
too small to directly compare hypo- versus hypercortisolemic depressed persons in their 
likelihood of the metabolic syndrome.  
Whether hypoactivity of the HPA-axis in depression is specific to an aging population is 
not entirely clear. Usually, aging is associated with an increase in basal cortisol levels and an 
increased cortisol response to challenge.44-46 It has been suggested that hyperactivity of the 
HPA-axis in aging might be the result of the ‘wear and tear’ of a lifelong exposure to 
stress.45 However, different stress-related disorders, such as post traumatic stress disorder, 
fibromyalgia, chronic fatigue syndrome, and burn-out, have been linked to hypocortisolemia, 
possibly after prolonged periods of hyperactivity of the HPA-axis.42 Lifelong exposure to 
stress might therefore in some older persons actually lead to exhaustion of stress responses 
and associated hypocortisolemia.  
One striking result from Chapters 3 and 4 needs some additional attention. In Chapter 3 
it was concluded that hypercortisolemic depression was especially associated with the 
obesity-related components of the metabolic syndrome. Considering the role of cortisol in 
visceral fat accumulation and the important status of abdominal obesity within the metabolic 
syndrome, this result was definitely expected. However, in Chapter 4, although serum 
cortisol levels were associated with the metabolic syndrome and most of its components, no 
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association with waist circumference was found. If anything, serum cortisol levels showed a 
negative association with waist circumference. This inconsistency may, however, be 
explained by the measure of cortisol used. Urinary cortisol levels over a 24-h period provide 
a rather stable indicator of the total cortisol excretion by the adrenals and measure the 
biologically active (unbound) cortisol non-invasively.47 In contrast, morning cortisol levels in 
blood do not represent the biological active cortisol and could possibly be increased by an 
acute stress reaction due to the blood draw itself. In Chapter 4 this was partly accounted for 
by calculating a cortisol free index, however a single measure of cortisol at one time-point 
may be less reliable than a 24-h index. What is even more important, research has 
suggested that in obese persons, cortisol secretion might be increased, but this might be 
coupled with an increased metabolic clearance of cortisol.48,49 Therefore, when measured in 
serum or plasma, cortisol levels may be found to be decreased, while in urine they are 
increased, reflecting HPA-axis hyperactivity.  
To summarize, this thesis illustrates that cortisol likely plays an important role in the 
link between depression and the metabolic syndrome, such that only hypercortisolemic 
depressed persons show an increased prevalence of the metabolic syndrome. As the designs 
of the studies used were cross-sectional it is difficult to draw conclusions on the direction of 
mediation by cortisol in the depression-metabolic syndrome relationship. Considering that 
depression could be caused by, or in itself could be regarded as, a chronic stressor and that 
the accumulation of visceral fat could be due to actions of cortisol, this seems to suggest a 
pathway from depression to metabolic syndrome. However, HPA-axis hyperactivity has been 
noted before the onset of depression50 and is also present in obese persons who are not 
depressed,51 implying a possible reverse direction. The role of cortisol within the vicious 
cycle of depression, visceral fat accumulation, and metabolic syndrome is depicted in Figure 
1. 
 
Other potential underlying pathways 
The HPA-axis plays an important role in the association between depression and the 
metabolic syndrome, but other possible pathways are likely to contribute as well. These will 
shortly be addressed below. 
 
Psychological and behavioral pathways 
Psychological factors that may underlie an association between depression and the 
metabolic syndrome include a poor self-image or perceived stigma in those persons who are 
obese.52 Also, persons with the metabolic syndrome might feel depressed about having to 
cope with their condition. Furthermore, depressed persons might have poorer health habits, 
e.g. they exercise less or have more fat intake, thereby increasing their metabolic risk. 
These explanations probably do not significantly contribute to the link between depression 
and the metabolic syndrome. In this thesis it was clearly found that associations with 
depression were specific to abdominal obesity, more strongly and independent of overall 
obesity. Comparable associations with overall obesity would be expected if psychological or 
behavioral mechanisms were at hand. Furthermore, in all analyses adjustments for lifestyle 
variables (smoking behavior, alcohol intake, physical activity) were made, which hardly 
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changed any of the findings. No information was available on diet, so it is possible that 
depressed persons had a poorer dietary pattern. However, again, a poor diet in itself would 
likely lead to an increase in both overall and abdominal obesity.53 In combination with a 
hyperactive HPA-axis, however, it is possible that excess caloric intake is preponderantly 
stored into visceral fat depots.54 
 
Somatic pathways 
Cardiovascular disease and diabetes 
Abundant evidence supports an association between depression with cardiovascular 
disease55-61 and diabetes.62-65 In this thesis it is postulated that depression might increase 
the risks of these two major outcomes by promoting the occurrence of the metabolic 
syndrome. Although the metabolic syndrome is often thought of as a precursor of diabetes 
or cardiovascular disease, the definition of metabolic syndrome does in itself not explicitly 
exclude the presence of these two diseases.66 Therefore, it is possible, when a relationship 
between depression and the metabolic syndrome is found, that this is in fact due to an 
increased presence of diabetes or cardiovascular disease among persons with the metabolic 
syndrome. However, in this thesis we either adjusted for cardiovascular disease or diabetes, 
performed additional analyses excluding persons with prevalent diseases, and/or tested for 
interaction effects for the presence or absence of cardiovascular disease or diabetes. These 
analyses consistently confirmed that associations between depression and metabolic 
syndrome exist independent of cardiovascular disease or diabetes. 
 
General health status 
Next to cardiovascular disease and diabetes, a poor general health status should be 
considered a confounder when linking depression with obesity or the metabolic syndrome. 
Poor general health is usually linked with both depression and the presence of multiple 
somatic conditions.67 Especially in old age, the importance of somatic health aspects 
increases. Because in older persons physical complaints and somatic conditions are very 
prevalent, the presence of these conditions should be considered since they can affect 
results when relating mental to physical health. Depression that first emerges in late-life is 
more often accompanied by somatic problems, possibly representing a different concept 
than early-life onset depression. In addition, somatic conditions might alter lifestyle 
behaviors (e.g. quit smoking or decrease physical activity), which then indirectly confound 
an association between depression and the metabolic syndrome. In this thesis adjustments 
for both general health status and lifestyle behaviors were consistently made, which little 
affected results.  
 
Biological pathways 
Inflammation 
Inflammation is characterized by a chronic mildly elevated activity of the immune system 
which is illustrated by higher levels of, for example, C-reactive protein (CRP) and interleukin 
(IL)-6. With aging, inflammation levels generally increase steadily over time, thereby 
reaching levels that are closer to critical levels at which health impacts could occur. IL-6 has 
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been termed the ‘cytokine for gerontologists’.68 Although it has been linked with poor health 
in younger samples as well, its role in aging populations is eminent and striking. High levels 
of IL-6 have been linked to a large range of unfavorable health outcomes in older 
populations, varying from overall mortality, onset of cardiovascular disease, lung disease, 
cancer, frailty and physical decline.69-76 Consequently, inflammation is considered to be a 
very general biological risk factor that could be an interlinking mechanism between different 
disease processes.  
Inflammation is also critically involved in the metabolic syndrome. Inflammatory 
markers have been linked to obesity, lower high-density lipoprotein cholesterol levels, and 
higher triglycerides and fasting glucose concentrations.77,78 Moreover, several studies have 
notably confirmed an association between CRP, IL-6, tumor necrosis factor-alpha, and 
fibrinogen with the metabolic syndrome.79,80 It has even been postulated that inflammatory 
markers should be included in metabolic syndrome definitions.80,81 One explanation for this 
strong association between inflammation and the metabolic syndrome is the release of 
cytokines by (visceral) fat depots.79,82 Next to its association with the metabolic syndrome, 
chronic low-grade inflammation has been suggested to play a role in depression as well.83 
Depressed persons are found to have higher levels of CRP, IL-1 and IL-6, which could be a 
two-way association. One direction might be via the HPA-axis. Although the HPA-axis in 
normal situations should temper inflammatory reactions, prolonged hyperactivity of the 
HPA-axis could result in blunted anti-inflammatory responses to glucocorticoids resulting in 
increased inflammation.84 A recent study indeed found that depressive symptoms predicted 
6-year increases in IL-6.85 A reverse association is also plausible as administration of pro-
inflammatory cytokines (for instance in cancer or hepatitis C treatment) has consistently 
been shown to induce depression in about a third of patients.86 One recent study was able 
to show that an association between depressive symptoms and the metabolic syndrome was 
partly mediated by inflammation, although an independent association of depressive 
symptoms with the metabolic syndrome remained.87  
 
Sex steroid hormones 
One other biological pathway could be through sex steroid hormones, as low levels of 
testosterone and dehydroepiandrosterone sulfate (DHEA-S) have been associated with 
major depression.88 Alternatively, low levels of sex steroid hormones have been linked to 
various metabolic abnormalities.89,90 Specifically, sex steroid hormones exert opposite effects 
compared to cortisol. Sex steroid hormones inhibit lipoprotein lipase synthesis and 
stimulates lipid mobilization, thereby reducing visceral fat depots.35 When levels of sex 
steroid hormones are low, the visceral fat reducing effect is diminished, resulting in a larger 
accumulation of visceral fat, especially in the presence of high cortisol levels. The role of sex 
steroid hormones might be in particular important in older persons as with aging, and 
especially after menopause, levels of sex steroid hormones, such as testosterone, estradiol 
and DHEA-S, decrease.91,92 It needs to be shown whether sex steroid hormones indeed play 
a mediating role in the relationship between depression and the metabolic syndrome. 
 
 
168  | CHAPTER 10 
Vascular depression 
The vascular depression hypothesis93 states that vascular damage in the brain might 
predispose, precipitate, or perpetuate depression in the elderly. More specifically, this 
hypothesis suggests that small vessel damage in frontal and subcortical regions of the brain, 
which play key roles in mood regulation, might increase the risk of depression. Indeed, 
magnetic resonance imaging of older depressed patients has revealed structural 
abnormalities in frontal-subcortical brain regions.94 This vascular damage may be caused by 
continuing and profound influence of vascular risk factors, possibly including or resulting 
from metabolic abnormalities, inflammation or hypercortisolemia.  
 
Hypercortisolemic, metabolic and vascular depression 
Throughout this thesis different names for depressive subtypes were introduced, including 
hypercortisolemic depression, metabolic depression and vascular depression. What is the 
relationship between these concepts and how do they identify different subtypes? To start 
with, these three conditions definitely overlap. As was shown in this thesis, hyperactivity of 
the HPA-axis is plausibly involved in the association between depression and the metabolic 
syndrome. In fact, depressed persons with hypercortisolemia were at increased risk of 
having metabolic syndrome (Chapter 3). However, there is still a significant proportion of 
hypercortisolemic depressed persons that does not have the metabolic syndrome and 
depressed persons with the metabolic syndrome do not always show hypercortisolemia. 
Similarly, some persons with metabolic depression might have vascular brain lesions 
resulting in vascular depression, but as shown in Chapter 7, it is very likely that a metabolic 
depression exists apart from profound vascular damage. In turn, vascular depression does 
not have to be the result of metabolic disturbances. Thus, although the concepts of 
hypercortisolemic, metabolic, and vascular depression overlap, they certainly are not the 
same. Hypercortisolemic depression might increase the risk of metabolic depression, which 
increases the risk of vascular depression, but this is not a definite road to go and other 
factors promote the occurrence of metabolic and vascular depression. The benefit of 
identifying these different subtypes is that, besides from stimulating research into the 
pathophysiology of depression, it gives hints for both prevention and treatment of 
depression and its consequences. Treating hypercortisolemia in depressed persons might in 
theory both resolve depression and prevent metabolic disturbances. Managing metabolic 
disturbances in depressed persons might possibly improve depression prognosis and prevent 
further vascular damage throughout the body as well as the brain. 
 
Metabolic syndrome: is it truly a syndrome? 
Up until here, this thesis has treated the metabolic syndrome as if it is truly an existing 
syndrome, which can be related to other health aspects. However, in scientific literature 
some debate still exists whether it really is a unique condition. Arguments against the 
existence of the metabolic syndrome include the seemingly absence of one underlying 
causative factor, a lack of consensus on components to be included, and the limited 
evidence of increased predictive value of the metabolic syndrome beyond the risks from 
individual components.19 These arguments indeed question the current metabolic syndrome 
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definition, but do not maintain that the concept of a metabolic condition should be 
disregarded. Most scientists do belief that several metabolic factors tend to cluster and 
occur together more often than by change alone. The doubts that are being raised should in 
fact stimulate more research into this metabolic concept, to eventually come to a definition 
that describes an etiological coherent condition and/or identifies persons at specific high-risk 
of developing diabetes or cardiovascular disease. Up until now the use of a metabolic 
syndrome definition in research has resulted in an impressive expansion of insight into 
pathophysiological processes underlying the occurrence of diabetes and cardiovascular 
disease as well as of associated diseases, such as depression. The main benefit of the 
metabolic syndrome concept for research purposes is that cardiovascular risk factors are not 
investigated in isolation, but multiple factors are being considered at once and their relative 
effects can be compared.  
 
Cardiovascular disease 
This thesis focuses on the relationship between depression and the metabolic syndrome. 
However, as was shown in Chapter 1, Figure 1, cardiovascular disease forms an important 
component of the research model investigated in this thesis. Several relationships with 
cardiovascular disease form the basis of this thesis and are assumed in this model. These 
are: associations of cardiovascular disease with 1) depression; 2) HPA-axis hyperactivity; 
and 3) the metabolic syndrome. A relationship between the metabolic syndrome and 
cardiovascular disease is not only very likely to exist - as all components of the metabolic 
syndrome represent individual cardiovascular risk factors - but has also been proven to exist 
by a multitude of studies.95-101 The other two presumed relationships deserve somewhat 
more attention. First, although many studies have shown that depression predicts 
cardiovascular events and mortality in the general population, is a prognostic indicator of 
poor cardiovascular outcome in heart patients, and shows an increased onset after 
cardiovascular events, convincing evidence from the psychiatric patients’ perspective was 
still lacking. In this thesis, in Chapter 9, it was confirmed in a psychopathology-based 
sample that depression is associated with an increased likelihood of cardiovascular disease, 
although in fact this might be largely owing to comorbid anxiety. Although from this cross-
sectional study the temporal direction between depression and cardiovascular disease 
remains unclear, strong associations were found among those with a psychiatric disorder 
onset before the age of 30, most likely before cardiovascular disease had occurred. These 
results give additional support to a hypothesized pathway from depression to metabolic 
syndrome to cardiovascular disease.  
This leaves one other presumed association in the hypothesized model: does a 
hyperactive HPA-axis eventually result in cardiovascular end-points? Many studies have 
assumed that high cortisol levels give rise to cardiovascular disease, and have therefore 
suggested that cortisol might mediate an association between depression and cardiovascular 
disease.37,102 Several studies have shown that cortisol is associated with multiple 
cardiovascular risk factors, such as high blood pressure, obesity, high glucose and 
cholesterol levels, the metabolic syndrome and atherosclerosis.33,34,38,39,103,104 However, 
direct evidence for a relationship between cortisol and the onset of cardiovascular end-
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points was very sparse. One study reported a cortisol/testosterone ratio to be predictive of 
incident ischemic heart disease in middle-aged men.105 In a general older population, a 
morning plasma cortisol level was not associated with self-reported non-fatal cardiovascular 
disease.106 The results of this thesis (Chapter 8) confirm the long speculated relationship 
between urinary cortisol levels and cardiovascular mortality in an older general population. 
Even more, it was shown that high urinary cortisol levels were exclusively related to 
cardiovascular mortality and not to other causes of mortality, demonstrating a specific 
damaging effect of a hyperactive HPA-axis to the cardiovascular system.  
 
Anxiety and other psychosocial factors 
This thesis has its primary focus on depression and depressive symptoms. However, some 
attention is given to anxiety and other psychosocial risk factors. Their role will be shortly 
discussed here. In Chapter 2, next to depressive symptoms, the cross-sectional association 
between anxiety symptoms, recent life events and inadequate emotional support with the 
metabolic syndrome was assessed. These factors all appeared to be associated with the 
metabolic syndrome, although anxiety symptoms only in men. What’s more, a cumulative 
index of psychosocial risk factors was most strongly associated with the metabolic 
syndrome. When examining the relative importance of the different psychosocial risk 
factors, most consistent results were found for recent life events and inadequate emotional 
support. Possibly, direct stressors through activation of the HPA-axis exert stronger effects 
on metabolic processes. Nevertheless, depressive symptoms are unrecognizably associated 
with the metabolic syndrome as is portrayed in this thesis. 
Examination of anxiety disorders in relation to cardiovascular disease in an adult 
population was included in Chapter 9. It not only appeared that anxiety disorders were 
strongly associated with the presence of coronary heart disease, but also it was shown that 
this association was stronger than for depression. In fact, the association between 
depression and cardiovascular disease was mainly owing to depressions’ comorbidity with 
anxiety disorders. Although not frequently examined, a stronger association with 
cardiovascular disease for anxiety than for depressive disorders is reported by others.107 In 
contrast, some studies describe an association between depression, but not anxiety, with 
the metabolic syndrome.6,7 Pathophysiological pathways linking depression versus anxiety 
with cardiovascular disease might partly differ. Together these results at least suggest that 
anxiety disorders are important to consider when relating depression and other mental 
health aspects to cardiovascular risk factors or disease. 
 
Depressive symptoms versus diagnosis 
Most of the chapters included in this thesis made use of the Center for Epidemiologic 
Studies-Depression (CES-D) scale108 to assess depressive symptoms. Although this scale can 
detect the presence of clinically relevant depressive symptoms109 it does not equal a 
depressive disorder diagnosis. The most important differences is that to fulfill criteria for a 
major depressive disorder diagnosis, key symptoms (depressed mood and/or lack of 
interest) must be experienced. In contrast, the CES-D, as most other depressive symptoms 
checklists, regards all symptoms as equal and makes a count of the number of depressive 
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symptoms present, without requirement of the presence of key symptoms. Depressive 
symptom checklists in general contain a considerable number of somatic symptoms, e.g. 
fatigue, sleep problems and appetite or weight changes. Persons with many somatic health 
problems, which are especially common in older persons, could theoretically score high on 
this depressive symptoms questionnaire simply because of their somatic symptoms. This is 
important to realize when relating depressive symptoms to somatic health aspects. By 
adjusting analyses for physical factors, both lifestyle factors and disease and health-related 
factors, the possible influence of depression misclassification due to somatic symptoms was 
tried to kept to a minimum in this thesis. Besides, despite the theoretic possibility of 
misclassification, the CES-D has been proven to be a valid and reliable instrument and has 
shown very good sensitivity and specificity when identifying major depressive disorder in 
older persons.109 
 
Methodological considerations 
Several methodological considerations have already been made throughout the current 
chapter. These include the possibility of information bias (e.g. assessing depression by 
means of symptoms checklists, defining the metabolic syndrome, measuring cortisol), 
properly taking into account possible confounding factors (e.g. lifestyle behaviors, general 
health aspects) and the restricted ability of drawing definite causal inferences from 
observational research. In this section additional comments on possible selection bias 
(selective survival) and generalizability will be made.  
Nearly all the results in this thesis are based on older populations. By definition, when 
recruiting a sample of older persons, those who have already died are not included in the 
cohort. Also, during follow-up the less healthy are more likely to withdraw, to get lost or to 
die. It is essential to take into account the possibility of selective survival for a 
comprehensive interpretation of causality between mental and somatic health. It is certainly 
possible that examined risk factors are not predictive of diminished health, solely because 
those who were both exposed and affected by the risk factor of interest are no longer alive. 
For example, depression and life-events have found to be less predictive of mortality in the 
oldest (85 years and up) compared to the young old (70 to 84 years),110,111 which could be 
partly explained by selective survival. These findings illustrate that selective survival tends to 
decrease the strength of investigated associations, but suggest that when associations are 
found (as in this thesis) in reality the relationship might be even stronger. 
Furthermore, as mentioned before, in an older population somatic health problems are 
much more prevalent and depression that first emerges in late-life might be much more 
entangled with somatic conditions than depression that emerges earlier in life. On the other 
hand, competing (i.e. stronger) risk factors for health outcomes in old age, such as other 
somatic conditions, could override the effects of mental health factors. These considerations 
implicate that results of the present thesis cannot automatically be generalized to younger 
populations. However, as described in the first sections of this chapter, others have 
confirmed associations between depression and the metabolic syndrome in middle-aged and 
even younger study samples.  
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Public health & clinical implications 
The prevalence of obesity is increasing alarmingly world-wide112 and with it the prevalence 
of metabolic syndrome. Also, depression holds a top position among the list of diseases with 
high disease burden across the world, which will continue to rise over the next years.113 
Depression, obesity and metabolic syndrome are clearly not only of major public health 
interest, but also have profound impact on well-being and daily functioning of the individual, 
especially when occurring together and in older persons.114-116 This thesis shows that a 
vicious cycle might exist between depressive symptoms and abdominal obesity, and in a 
later stage metabolic syndrome. Evidently, trying to prevent that persons enter this vicious 
cycle could greatly benefit public health as well as clinical care. It is important to realize that 
even if the intimate association between depression and metabolic syndrome is only present 
in older persons, pathophysiological processes leading to the rise of, for instance, metabolic 
depression are probably already occurring at younger ages. One possible way to prevent the 
occurrence of both metabolic syndrome and depression or to promote the reduction of 
depressive symptoms and metabolic abnormalities, might be to stimulate physical activity. 
Although physical activity does not appear to be an important confounder in the relationship 
between depression and the metabolic syndrome, this does not imply a lack of impact of 
physical activity on both conditions. In fact, multiple (randomized) controlled trials have 
shown that physical activity can decrease visceral fat depots and other metabolic 
abnormalities.117,118 Furthermore, meta-analyzed evidence suggests that exercise can 
improve depressive symptoms to some degree.119 Promoting physical activity can both be 
done within a public health and a clinical setting. Next to physical activity, promoting a 
general healthy life style (e.g. healthy diet) might be beneficial.  
The above mentioned implications apply to public health as well as clinical care. From a 
clinical care perspective additional implications of the results of this thesis can be made. The 
results suggest that a clinician, regardless a psychiatrist, a general practitioner or a 
geriatrist, should be aware that depression and metabolic disturbances tend to co-occur, 
conceivably promote each other and possibly hinder treatment. The results of the present 
thesis show that 30-35% of depressed older persons have the metabolic syndrome; even 
higher prevalences are found in the hypercortisolemic depressed (42%). This implicates that 
a significant proportion of depressed persons might benefit from assessment of the 
presence of metabolic abnormalities as treating these secondary conditions could improve 
general health status of these patients and possibly prevent subsequent disease (i.e. 
diabetes and cardiovascular disease). Whether treatment of metabolic disturbances could 
improve depression prognosis and whether treatment of depressive symptoms could 
improve the metabolic profile needs to be examined.   
 
Future research 
The present thesis provides evidence for the concept of a metabolic depression, which 
represents a chronic depressive subtype associated with metabolic disturbances. Future 
research should confirm the existence of such a condition in men and women in both older 
and younger populations using prospective designs. In addition, the temporal associations 
between depression, HPA-axis hyperactivity, and the metabolic syndrome need to be further 
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explored to help improve prevention and treatment of depression as well as metabolic 
syndrome. Next to these more or less ‘confirmatory’ investigations, more innovative 
research is needed as well. Other pathophysiological mechanisms apart from the HPA-axis 
may underlie or might be involved in the relationship between depression and metabolic 
syndrome, such as chronic low-grade inflammation. Research has only just begun to unravel 
the role of inflammation as mediating factor between depression and metabolic or 
cardiovascular risks. What’s even more unexplored is the role of possible genetic influences 
that might explain some of the found associations between depression, visceral fat 
accumulation and the metabolic syndrome. Possibly, genetic factors are (partly) responsible 
for the vicious cycle as presented in this thesis. When known, treatment could be targeted 
at the biological systems that are regulated by these genetic factors. Another aspect that 
needs to be more elaborately explored is the role of anxiety disorders. In general, research 
on the link between mental and somatic health aspects has focused on depression, leaving 
anxiety relatively untouched. The results of Chapter 9, however, suggest that anxiety 
disorders are very important to consider as well. Lastly, there is a pressing need for 
intervention studies examining whether treatment of either depression or metabolic 
abnormalities could relieve or prevent symptoms of the other condition. Ultimately, an 
integrated intervention program for persons with metabolic depression, addressing both 
depression and metabolic syndrome should be tested for its capability of treating both 
conditions at once. 
 
In conclusion 
Depression and abdominal obesity appear to have a two-directional relationship. When both 
conditions are present, additional metabolic abnormalities might promote a chronic 
character of the depressive symptoms. These results are suggestive of a vicious cycle and 
are indicative of the existence of a specific condition, which might be labeled as metabolic 
depression. Although the notion of a vicious cycle and a chronic depressive subtype 
suggests a poor prognosis, the implications of this thesis are positive as well. As depression 
and metabolic disturbances are in principal treatable conditions, this gives hope for a better 
prognosis of metabolic depression. Knowing that depression and metabolic syndrome often 
do not occur in isolation has direct implications for prevention and treatment of both 
conditions. 
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Depression is a common mental disorder which causes high burden for both the community 
and the individual. According to the World Health Organization depression ranks high in the 
top ten of diseases with the highest disease burden due to a marked loss in quality of life. 
Also high in this top ten is cardiovascular disease. Depressed persons have approximately a 
two-fold increased risk of having or developing cardiovascular disease. Further, after a 
cardiovascular event the risk of onset of depression is increased, resulting in poorer 
cardiovascular outcome. Mechanisms underlying this comorbidity between depression and 
cardiovascular disease are still largely unknown. The metabolic syndrome, a constellation of 
cardiovascular risk factors including (abdominal) obesity, hypertension, dyslipidemia and 
hyperglycemia, has been suggested to be one possible pathway linking depression and 
cardiovascular disease. Evidence exists that metabolic disturbances might occur more 
frequently in depressed persons. Disturbed functioning of one of the most important stress 
systems of the human body, the hypothalamic-pituitary-adrenal (HPA)-axis, might underlie 
the association between depression and metabolic syndrome. Evidence for these hypotheses 
is largely confined to cross-sectional research and to investigation of individual as opposed 
to the combination of metabolic disturbances. Therefore, the general aim of this thesis is to 
examine whether depressive disorders or symptoms are associated with, predict or follow 
metabolic disturbances, such as present in metabolic syndrome. In addition, a possible 
mediating role of the HPA-axis in the relationship between depression on the one hand and 
metabolic syndrome and cardiovascular disease on the other hand is examined. Knowledge 
to be gained by this thesis could increase our understanding of pathophysiological processes 
linking depression and cardiovascular disease, which might be very useful for prevention 
and treatment of both conditions. To study these research questions data from several large 
prospective cohort studies are used. Focus is given to older populations as both depressive 
symptoms and cardiovascular conditions are highly prevalent among the aged. After the 
theoretical background and research model is presented in Chapter 1, Chapters 2 through 
9 report on research outcomes. 
 
First, the cross-sectional association between depression and metabolic syndrome is 
investigated. Chapter 2 reports on data from the Health, Aging and Body Composition 
(ABC) study and examines the cross-sectional relationship between several psychosocial risk 
factors (depressive and anxiety symptoms, negative life events, and inadequate emotional 
support) and metabolic syndrome in a community-based sample of black and white older 
persons (N = 2917). All examined psychosocial risk factors were (modestly) associated with 
metabolic syndrome, although depressive symptoms only in white persons and anxiety 
symptoms only in men. A combined psychosocial risk index showed the strongest 
association with metabolic syndrome, which was not confined to a specific component of the 
metabolic syndrome. Chapter 3 presents results from the InCHIANTI study among 867 
persons aged 65 years and older. Also in this study, depressive symptoms and metabolic 
syndrome were associated. Findings from the Longitudinal Aging Study Amsterdam (LASA), 
including 1212 participants aged 65 years and older, are described in Chapter 4. However, 
results of this study did not show significantly increased odds of metabolic syndrome in 
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persons with major depressive disorder. Persons with subthreshold depressive symptoms 
even had a decreased odds of metabolic syndrome.  
 
Next, a possible role of the HPA-axis in the association between depression and the 
metabolic syndrome is examined. Cortisol levels, from urine or blood, provide an index of 
HPA-axis activity. In Chapter 3, based on the InCHIANTI study, a profound role of cortisol 
is uncovered. The reported cross-sectional association between depressive symptoms and 
metabolic syndrome largely disappeared after appropriate adjustment for urinary cortisol 
levels. This indicates a mediating role of high cortisol levels in the association between 
depression and metabolic syndrome. Moreover, it was found that only those depressed 
persons that presented with hypercortisolemia were at increased odds of having metabolic 
syndrome. In particular, high levels of cortisol were associated with a large waist 
circumference, high triglyceride levels and low high-density lipoprotein cholesterol levels in 
depressed persons. Although no positive association was found between depression and 
metabolic syndrome in LASA (Chapter 4), results from this study did show that serum 
cortisol levels are associated with metabolic syndrome. This again suggests that when 
depressed persons present with hypercortisolemia, odds of metabolic syndrome are 
increased.  
 
Subsequently, the temporal direction of associations between depression and metabolic 
syndrome is examined using longitudinal designs. Special focus is given to (abdominal) 
obesity as this is a central component in metabolic syndrome. Chapter 5 examines whether 
depressive symptoms predict an increase in abdominal obesity using 5-year follow-up data 
from 2088 participants of the Health ABC study. This study showed that having depressive 
symptoms was followed by an increase in abdominal obesity, specifically visceral fat. This 
increase was independent of overall obesity, suggesting that there may be specific 
pathophysiological mechanisms that link depression with visceral fat accumulation. In 
Chapter 6 the reverse direction is investigated in the Health ABC study, namely whether 
(abdominal) obesity increases the risk of onset of significant depressive symptoms in 2547 
persons without depression at baseline. Both overall and abdominal obesity predicted onset 
of depressive symptoms over 5 years of follow-up in men, but not in women. When 
examined simultaneously, only the effect of visceral fat, but not overall obesity, was an 
independent predictor of depressive symptoms onset. Stronger associations were found for 
the onset of depressive symptoms that persisted. Chapter 7 examines whether metabolic 
syndrome and its components are associated with both the onset and the chronicity of 
depressive symptoms using data from 823 participants of the InCHIANTI study. Higher 
waist circumference, but no other metabolic syndrome component, increased odds of 
depressive symptoms onset after 3 or 6 years in initially non-depressed persons. Among 
depressed persons, metabolic syndrome was associated with an almost 3-fold increased 
odds of persistence of depressive symptoms. Findings suggest that a vicious cycle between 
depression and visceral fat accumulation might eventually result in a chronic depressive 
subtype, characterized by metabolic disturbances (‘metabolic depression’). 
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Lastly, to make the research model complete, presumed associations between both HPA-
axis hyperactivity and depression with cardiovascular disease are tested. HPA-axis activity 
has been linked to several cardiovascular risk factors, but it’s effect on clinical cardiovascular 
endpoints has hardly been examined. Chapter 8 again uses data from the InCHIANTI study 
to examine whether urinary cortisol levels predict all-cause and cardiovascular mortality over 
6 years of follow-up among 900 participants. Persons having urinary cortisol levels in the 
top tertile had an almost 3-fold increased risk of dying of cardiovascular disease within 6 
years. Risk of all-cause mortality was not increased. These findings confirm that high 
cortisol levels might be particularly damaging to the cardiovascular system. Chapter 9 
investigates whether the frequently reported association between depression and 
cardiovascular disease extents to a psychopathology-based sample, as evidence for this 
association almost exclusively comes from studies among heart patients or the general 
population. In addition, anxiety disorders are taken into account as they are often comorbid 
to depression. Data are from 2807 persons with current or remitted depressive or anxiety 
disorders and healthy controls of the Netherlands Study of Depression and Anxiety. Results 
show that persons with a current anxiety disorder were approximately three-fold more likely 
to have coronary heart disease. Increased prevalence of coronary heart disease among 
depressed persons was largely owing to comorbid anxiety. 
 
The thesis ends with a general discussion (Chapter 10) of the findings of Chapters 2 
through 9. Taken together, this thesis suggests that in older persons the association 
between depression and metabolic syndrome might be restricted to a specific subgroup of 
depressive patients, those that present with hyperactivity of the HPA-axis. In a longitudinal 
perspective, depressive symptoms and abdominal obesity appear to have a two-directional 
relationship. When both conditions are present, additional metabolic disturbances might 
promote a chronic character of the depressive symptoms. These results are suggestive of a 
vicious cycle and are indicative of the existence of a specific condition, which might be 
labeled as metabolic depression. Awareness of and appropriate monitoring of comorbid 
metabolic disturbances in depressed patients might improve their somatic health status and  
could possibly prevent subsequent cardiovascular disease. Whether treatment of metabolic 
disturbances could improve depression prognosis needs to be examined. 
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Depressie is een veelvoorkomende psychische stoornis die een hoge ziektelast veroorzaakt 
voor zowel de samenleving als het individu. De Wereldgezondheidsorganisatie (WHO) heeft 
aangetoond dat depressie hoog in de top tien staat van ziektes met een hoge ziektelast. Dit 
komt vooral door de grote mate van verlies van kwaliteit van leven die gepaard gaat met 
depressie. Niet alleen depressie staat hoog in deze zogenaamde ‘ziektelasten-lijst’. Ook hart- 
en vaatziekten veroorzaken in de wereld veel ziektelast door een combinatie van vroegtijdig 
overlijden en verlies van kwaliteit van leven. Mensen met een depressie hebben ongeveer 
tweemaal zoveel kans om een hartziekte te hebben of te ontwikkelen dan mensen die niet 
aan een depressie lijden. Bovendien heeft onderzoek uitgewezen dat depressie vaak 
ontstaat nadat iemand bijvoorbeeld een hartaanval heeft gehad. De depressie heeft weer 
een negatieve invloed op het herstel en verloop van een aanwezige hartziekte. Het is nog 
steeds voor een groot deel onbekend welke mechanismen ten grondslag liggen aan deze 
samenhang tussen depressie en hart- en vaatziekten. Mogelijk is het metabool syndroom 
één route die de link tussen depressie en hart- en vaatziekten kan verklaren. Het metabool 
syndroom bestaat uit een verzameling van risicofactoren voor hart- en vaatziekten zoals 
overgewicht (rondom de buik), hoge bloeddruk, verstoorde cholesterolwaardes, en 
verhoogde bloedsuikerspiegels. Er zijn aanwijzingen dat deze metabole verstoringen vaker 
voorkomen bij mensen met een depressie. Disfunctioneren van één van de meest 
belangrijke stress-systemen van het lichaam, de zogenaamde hypothalamus-hypofyse-
bijnier (HPA)-as, zou een rol kunnen spelen in de relatie tussen depressie en het metabool 
syndroom. Bewijzen voor deze hypothesen komen voornamelijk voort uit dwarsdoorsnede 
onderzoek. In dit type onderzoek worden alle factoren, dus zowel depressie als metabole 
verstoringen, gemeten op hetzelfde moment waardoor men geen conclusies kan trekken 
betreffende oorzaak en gevolg. Ook is het zo dat eerdere onderzoeken de relatie tussen 
depressie en individuele metabole verstoringen vaak in afzondering van elkaar onderzocht  
hebben, terwijl ze juist vaak samen voorkomen zoals in het metabool syndroom. Met dit in 
het achterhoofd is het algemene doel van dit proefschrift te onderzoeken of depressieve 
symptomen vaak samen voorkomen met het metabool syndroom, of depressieve 
symptomen het ontstaan van metabole verstoringen voorspellen en, of depressieve klachten 
het gevolg zijn van metabole ontregelingen. Bovendien onderzoekt dit proefschrift of een 
verstoord functioneren van de HPA-as een rol speelt in de relatie tussen depressie aan de 
ene kant en het metabool syndroom en hart- en vaatziekten aan de andere kant. Kennis die 
met het onderzoek uit dit proefschrift verkregen wordt, vergroot ons begrip van de 
onderliggende biologische processen die depressie en hart- en vaatziekten met elkaar 
verbinden. Deze kennis zou gebruikt kunnen worden om preventie en behandeling van 
beide ziektes te verbeteren. Om deze vragen te kunnen beantwoorden worden gegevens 
gebruikt van enkele grote observationele studies. De nadruk ligt in dit proefschrift op 
ouderen, omdat depressieve symptomen en hart- en vaatziekten veel voorkomend zijn bij 
oudere mensen. Nadat een theoretische achtergrond geschetst wordt en het 
onderzoeksmodel gepresenteerd wordt in Hoofdstuk 1, zullen Hoofdstuk 2 tot en met 9 de 
onderzoeksresultaten rapporteren.  
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Als eerste wordt het verband tussen depressie en het metabool syndroom onderzocht met 
behulp van dwarsdoorsnede - oftewel cross-sectionele - gegevens. Hoofdstuk 2 geeft 
verslag van gegevens van de Health, Aging and Body Composition (ABC) studie, een studie 
onder de algemene oudere Amerikaanse bevolking. In dit hoofdstuk wordt onderzocht of het 
metabool syndroom vaker vóórkomt bij mensen met psychosociale klachten (depressieve en 
angst symptomen, negatieve levensgebeurtenissen, en gebrek aan emotionele steun). In 
totaal doen 2917 blanke en zwarte mensen mee aan deze studie. Voor alle psychosociale 
factoren blijkt dat wanneer mensen hier last van hebben, ze ook vaker het metabool 
syndroom hebben. Wel wordt gevonden dat depressieve symptomen alleen een verband 
tonen met het metabool syndroom bij blanke mensen en angstsymptomen alleen bij 
mannen. Wanneer mensen tegelijkertijd meerdere psychosociale klachten hebben, is de 
samenhang met het metabool syndroom sterker. Hoofdstuk 3 presenteert resultaten van 
de InCHIANTI studie onder 867 Italianen van 65 jaar en ouder. Ook in deze studie blijken 
mensen met depressieve symptomen vaker het metabool syndroom te hebben. Bevindingen 
van de Longitudinal Aging Study Amsterdam (LASA), onder 1212 deelnemers van 65 jaar en 
ouder, worden beschreven in Hoofdstuk 4. In tegenstelling tot de twee voorafgaande 
hoofdstukken, tonen de resultaten van deze studie niet aan dat mensen met een 
depressieve stoornis meer kans op het metabool syndroom hebben. Personen die last 
hebben van depressieve klachten zonder dat ze aan de criteria van een depressieve stoornis 
voldoen, hebben zelfs minder kans om het metabool syndroom te hebben.  
 
Vervolgens is onderzocht of de HPA-as een rol speelt in de samenhang tussen depressie en 
het metabool syndroom. Cortisol spiegels, uit bijvoorbeeld urine of bloed, zijn een maat voor 
de activiteit van de HPA-as. In Hoofdstuk 3, gebaseerd op de InCHIANTI studie, blijkt dat 
de rol van cortisol erg belangrijk is. Het hierboven beschreven verband tussen depressieve 
symptomen en het metabool syndroom verdwijnt grotendeels nadat rekening wordt 
gehouden met cortisol spiegels in de urine. Deze resultaten duiden erop dat hoge cortisol 
spiegels een intermediaire rol spelen in de relatie tussen depressie en het metabool 
syndroom. Bovendien wordt gevonden dat alleen depressieve mensen met verhoogde 
cortisol spiegels een verhoogd risico op het metabool syndroom hebben. Bij depressieve 
personen blijken hoge cortisol spiegels vooral samen te hangen met een grote tailleomvang, 
hoge triglyceriden niveaus (hangen samen met het slechte cholesterol) en lage waardes van 
het high-density lipoprotein (HDL) cholesterol (het goede cholesterol). Hoewel in de LASA 
studie (Hoofdstuk 4) geen positieve relatie gevonden werd tussen depressie en het 
metabool syndroom, blijkt uit deze studie wel dat hoge cortisol spiegels samenhangen met 
het metabool syndroom. Dus ook uit deze studie kan men concluderen dat wanneer 
depressieve personen hoge cortisol waardes hebben, zij meer kans hebben op het metabool 
syndroom.  
 
In een volgende stap wordt de temporele relatie tussen depressie en het metabool 
syndroom onderzocht, gebruikmakend van studies met meerdere meetmomenten over de 
jaren heen. Hierbij wordt speciale aandacht gegeven aan overgewicht (rondom de buik) 
omdat dit een centraal onderdeel is van het metabool syndroom. Uit onderzoek blijkt dat het 
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hebben van veel buikvet (met name het vet tussen de organen) grotere gezondheidsrisico’s 
met zich meebrengt dan vet op andere plekken in het lichaam. Hoofdstuk 5 onderzoekt of 
depressieve symptomen samenhangen met een toename in buikvet over 5 jaar. Gegevens 
van 2088 deelnemers aan het Health ABC onderzoek worden hiervoor gebruikt. Deze studie 
toont aan dat depressieve symptomen inderdaad gevolgd worden door een toename in 
buikvet, met name het vet tussen de organen. Deze toename in buikvet wordt niet 
veroorzaakt door een toename in algeheel overgewicht. Dit ondersteunt de gedachte dat de 
relatie tussen depressie en in het bijzonder buikvet deels verklaard kan worden door 
biologische mechanismen. Immers, wanneer psychologische of gedragsmatige 
mechanismen een belangrijke rol zouden spelen, zou ook een verband met algeheel 
overgewicht te verwachten zijn. In Hoofdstuk 6 wordt, ook in de Health ABC studie, de 
tegenovergestelde richting onderzocht, namelijk of overgewicht (rondom de buik) het risico 
op het ontstaan van depressieve klachten verhoogd. Hiervoor worden 2547 personen 
onderzocht die op de beginmeting geen depressieve klachten hebben. Zowel algeheel 
overgewicht als overgewicht rondom de buik voorspellen het ontstaan van depressieve 
symptomen over 5 jaar bij mannen, maar niet bij vrouwen. Wanneer de effecten van 
algeheel overgewicht en buikvet tegelijkertijd bekeken worden, blijkt dat alleen het hebben 
van veel buikvet samenhangt met het ontstaan van depressieve klachten. Het verband 
tussen algeheel overgewicht en depressie lijkt dus te wijten aan het feit dat deze mensen 
ook veel buikvet hebben. Daarnaast blijkt dat buikvet vooral samenhangt met het ontstaan 
van depressieve symptomen die lang aanhouden. In Hoofdstuk 7 wordt de vraag gesteld 
of het metabool syndroom samenhangt met het ontstaan en/of het blijven bestaan van 
depressieve symptomen. Gegevens van 823 deelnemers aan de InCHIANTI studie zijn 
hiervoor beschikbaar. Eerst wordt de groep mensen onderzocht die aanvankelijk vrij is van 
depressieve klachten. Uit de resultaten blijkt dat mensen met een grote tailleomvang meer 
kans hebben om depressieve symptomen te ontwikkelen. Voor geen enkel ander onderdeel 
van het metabool syndroom wordt deze relatie gevonden. Binnen de groep mensen mét 
depressieve klachten bij aanvang van de studie, blijkt het metabool syndroom gepaard te 
gaan met het blijven bestaan van de klachten. Dit geldt voor alle onderdelen van het 
metabool syndroom. De kans op een chronisch beloop van de depressieve klachten is drie 
maal groter wanneer een depressief persoon ook het metabool syndroom heeft. De 
bovenstaande bevindingen suggereren dat er een vicieuze cyclus bestaat tussen depressie 
en het opeenhopen van buikvet en de daarmee gepaard gaande metabole verstoringen. 
Deze vicieuze cyclus zou verantwoordelijk kunnen zijn voor het ontstaan van een chronisch 
subtype van depressie, welke gekarakteriseerd wordt door metabole verstoringen (een 
‘metabole depressie’).  
 
Tenslotte, om het onderzoeksmodel compleet te maken, worden in dit proefschrift enkele 
vooronderstelde verbanden met hart- en vaatziekten getest, te weten de relatie tussen HPA-
as activiteit en hart- en vaatziekten en de relatie tussen depressie en hart- en vaatziekten. 
Onderzoek heeft aangetoond dat verschillende risicofactoren voor hart- en vaatziekten 
gepaard gaan met verhoogde activiteit van de HPA-as. Of hoge cortisol spiegels ook 
daadwerkelijk van invloed zijn op het optreden van ernstige hartproblemen is echter 
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nauwelijks onderzocht. In Hoofdstuk 8 worden nogmaals de gegevens van 900 InCHIANTI 
deelnemers gebruikt. Ditmaal om te onderzoeken of cortisol waardes in urine een 
voorspellende waarde hebben ten aanzien van de totale sterfte en van sterfte door hart- en 
vaatziekten in het bijzonder, over een periode van 6 jaar. Uit de resultaten blijkt dat 
personen met hoge cortisol waardes in de urine een bijna 3 maal zo groot risico lopen om 
binnen 6 jaar aan een hart- en vaataandoening te overlijden. Het risico op overlijden in het 
algemeen is niet verhoogd. Deze bevindingen tonen aan dat hoge cortisol spiegels mogelijk 
specifiek schadelijk zijn voor het cardiovasculaire systeem. Hoofdstuk 9 onderzoekt of het 
herhaaldelijk gevonden verband tussen depressie en hart- en vaatziekten ook zichtbaar is in 
een groep mensen met psychische klachten. Eerder onderzoek heeft zich bijna alleen maar 
gericht op de algemene bevolking en patiënten met hartklachten. Daarnaast wordt 
onderzocht wat de rol is van angststoornissen, die vaak gepaard gaan met een depressie. 
Voor deze vragen zijn gegevens beschikbaar van 2807 personen met een huidige depressie 
of angststoornis, een depressie of angststoornis in het verleden, en gezonde controle-
personen die allen meedoen aan de Nederlandse Studie naar Depressie en Angst. 
Resultaten tonen aan dat personen met een huidige angststoornis bijna 3 maal zo vaak een 
aandoening aan de kransslagaders hebben in vergelijking met mentaal gezonde personen. 
Het meer vóórkomen van hartziekten onder depressieven lijkt voornamelijk te worden 
verklaard door het gegeven dat deze mensen daarnaast dikwijls een angststoornis hebben. 
 
Dit proefschrift eindigt met een algemene discussie (Hoofdstuk 10) van de bevindingen in 
Hoofdstuk 2 tot en met 9. Samenvattend suggereert dit proefschrift dat het verband tussen 
depressie en het metabool syndroom in ouderen zich beperkt tot een subgroep van 
depressieve patiënten, namelijk diegenen met een verhoogde activiteit van de HPA-as. Over 
de tijd gezien, blijken depressieve symptomen en buikvet een twee-richtingen relatie te 
hebben. Wanneer beide aandoeningen aanwezig zijn, zorgen bijkomende metabole 
verstoringen er mogelijk voor dat de depressie meer chronisch verloopt. Deze resultaten 
ondersteunen het idee van een vicieuze cyclus en wijzen op het bestaan van een aparte 
aandoening die een metabole depressie genoemd zou kunnen worden. Alert zijn op 
metabole verstoringen bij depressieve patiënten zou hun lichamelijke gezondheidsstatus 
positief kunnen beïnvloeden en mogelijk zelfs hartaandoeningen kunnen voorkomen. Het 
moet nog onderzocht worden of behandeling van metabole verstoringen ook een gunstig 
effect heeft op het verbeteren van depressieve klachten. 
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Het dankwoord. Het smeuïge stukje inside information dat als één van de eerste stukken 
gelezen wordt in je proefschrift (of ben alleen ik dat?) Wie gaat er bedankt worden? En wie 
niet? Hoe groot zijn de loftuitingen naar collega’s, promotoren en partner? Natuurlijk ben ik 
ook een aantal mensen dank verschuldigd voor hun directe of indirecte steun of bijdrage 
aan mijn proefschrift. Dus hier komen ze! 
 
Uiteraard begin ik met mijn promotoren te bedanken.  
Beste Brenda, ik heb veel van jou geleerd. Hoe zeggen ze dat ook al weer: “goed voorbeeld, 
doet goed volgen”? Dankjewel voor je vele én snelle input op alle stukken die ik je in de 
afgelopen jaren heb voorgelegd. Voor het overzicht dat jij steeds behield en voor het feit 
dat ik altijd wel even bij je aan kon kloppen, hoe druk je het ook hebt. Ik hoop dat we ook 
na mijn promotie nog een tijd fijn samen zullen werken. 
Beste Aartjan, iets meer op een afstandje was jij goed in staat advies te geven over wat 
bijvoorbeeld een artikel nog nodig had. “Wat is nu precies de klinische relevantie van wat je 
onderzocht hebt?“, “Je moet de lezer bij de hand nemen en hen elk stapje uitleggen”.  
Wanneer je zelf met je neus diep in de data zit is het fijn iemand te hebben die je daaruit 
trekt en vraagt wat je nou eigenlijk aan het doen bent! Dank daarvoor! 
 
In addition I would like to thank all my co-authors for their valuable input into the papers 
that are the result of my PhD project. In particular, I would like to thank the key persons 
who allowed me to make use of their extensive datasets from large scaled cohort studies, 
Stephen Kritchevsky (Health ABC), Luigi Ferrucci (InCHIANTI study) and Dorly Deeg (LASA). 
Thanks for the fruitful collaborations! Dank voor de samenwerking! Dear Steve, I also 
appreciate I was welcome to visit the Sticht Center on Aging, in Winston-Salem, North 
Carolina. For several months I had the chance to work in a different setting and country. I 
really got inspired by gerontological research during that period! Dear Denise, although we 
never made it to co-authors, I’d like to thank you for you looking after me and being a very 
pleasant colleague during my time in W-S. Ook wil ik de stagiaires, Lisette, Gerard, Manon 
en Ingrid niet vergeten die in meer of mindere mate hebben bijgedragen aan de inhoud van 
dit proefschrift. Verder wil ik hier graag de leden van mijn beoordelingcommissie bedanken 
omdat zij bereid zijn mij op 23 april grondig aan de tand te voelen. 
 
Dan, niet te vergeten: mijn directe collega’s. De mensen waarmee je dagelijks je 
bezigheden als AIO deelt en die je promotietraject van dichtbij meemaken. Beste Sophie, 
dankjewel voor al die keren dat je tijd voor me maakte als ik bij je aanklopte om je een 
probleem voor te leggen of een vraag had over cortisol, of gewoon om even een praatje te 
maken. Ik vind het heel leuk dat je mijn paranimf wilt zijn! Ook mijn andere mede-AIO’s, 
Carmilla, Didi, Inger, Jenneke en Adrie wil ik bedanken voor hun hulp, luisterend oor en 
vooral gezelligheid. Beste Carmilla, ik hoop dat we nog een tijdje collega’s blijven en in de 
toekomst meer gaan samenwerken. Beste Didi, in het begin van mijn AIO-schap hebben we 
eventjes een kamer gedeeld. Dat was een leuke tijd, jammer dat je onderzoekstijd nu heel 
spaarzaam is. Beste Inger, je hebt als één van de eersten het NESDA-nest verlaten, maar 
we houden contact! Beste Jenneke, hopelijk blijven we je nog wel met regelmaat zien als je 
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zo meteen in opleiding bent. Beste Adrie, het was gezellig samen in Chicago, hopelijk volgen 
er nog meer gezamenlijke congressen! Beste allemaal, ook al is onze intervisie nooit echt 
van de grond gekomen, de avondjes dat we bij elkaar gegeten hebben, waren erg gezellig! 
Net zoals de (iets te weinig) gezamenlijke buiten-de-deur-lunches en borrels! Hopelijk 
kunnen we deze losvaste traditie voortzetten nu iedereen langzaamaan zijn eigen richting 
opgaat. Ook alle andere collega’s bij NESDA/psychiatrie, in het bijzonder Femke, Marissa, 
Carla, Suzie, Tim en Reen: bedankt voor de fijne werkomgeving. Lynn en Josine, dankjewel 
voor het plezier dat ik heb in het begeleiden van jullie!  
 
Natuurlijk zijn er ook een aantal mensen buiten werk die ik wil bedanken. Lieve Dagmar, we 
zijn al 12½ jaar goede vriendinnen. Ook al zien we elkaar de laatste jaren wat minder dan 
tijdens onze studententijd, ik waardeer onze vriendschap enorm en hoop dat we nog lang 
vriendinnen zullen blijven. Ik ben heel blij dat jij tijdens mijn promotie naast me staat als 
paranimf! Lieve Femke, wij kennen elkaar zelfs nog langer! Onze ‘afspraakjes’ zijn altijd heel 
gezellig en dat moeten we zeker blijven volhouden. Dankjewel dat je een lieve vriendin voor 
me bent. Lieve mam en pap, bedankt voor jullie goede zorgen en voor het creëren van een 
fijn thuis. Jullie zijn echte doorzetters, wat er ook gebeurt. Dankjewel voor het bijbrengen 
van zo’n goede eigenschap! Lieve Alain en Maurice, het is fijn om twee grote broers als jullie 
te hebben. Lieve Chantal, mijn allerliefste grote zus, jij hebt me geïnspireerd voor de 
wetenschap (en zoveel meer). Jij hebt jouw promotie helaas nooit af kunnen maken, maar 
ik hoop dat je nu trots op me zou zijn geweest. Ik mis je. Tot slot, lieve Richard, waar moet 
ik beginnen? Dankjewel dat je er voor mij bent! 
 
x Nicole 
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Nicole Vogelzangs werd op 14 oktober 1978 geboren in het Noord-Limburgse dorpje Lomm, 
gemeente Arcen en Velden. Zij behaalde haar gymnasium diploma in 1997 aan het Thomas 
College in Venlo. Hierna volgde ze de opleiding Biologische Psychologie met een specialisatie 
in Neuropsychologie aan de Universiteit van Maastricht. Tijdens haar studie verbleef zij zes 
maanden in Montreal, Canada. Hier deed ze een onderzoeksstage aan the Department of 
Psychiatry, McGill University naar de effecten van zuurstof op de aanmaak van serotonine. 
In 2005 begon zij als promovenda bij GGZ inGeest, afdeling Psychiatrie en EMGO+ van het 
VU medisch centrum, Amsterdam. Zij onderzocht de relatie tussen depressie en het 
metabool syndroom met dit proefschrift als eindresultaat. Als onderdeel van haar 
promotieonderzoek dat grotendeels gebaseerd is op Amerikaanse data, bezocht zij in 2006 
voor vier maanden het Sticht Center on Aging, aan het Wake Forest University Baptist 
Medical Center in Winston-Salem, North Carolina in de Verenigde Staten. Daarnaast volgde 
ze de postinitiële opleiding epidemiologie verzorgd door EMGO+ in Amsterdam en behaalde 
deze master in 2007. Vanaf juli 2008 hebben haar onderzoeksactiviteiten zich uitgebreid  
buiten haar promotieonderzoek. In januari 2010 begon Nicole aan een 2-jarig fellowship 
beschikbaar gesteld door EMGO+ om, voortbordurend op haar proefschrift, de rol van 
ontstekingsfactoren in depressie en angst en in hun relatie met somatische aandoeningen te 
onderzoeken. Nicole woont in Maarssen samen met haar partner Richard Gubbels en kat 
Pippa. 
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Nicole Vogelzangs was born on October 14, 1978 in Lomm a little village in the North of 
Limburg, the Netherlands. She graduated from high school (gymnasium) in 1997 at the 
Thomas College in Venlo. After this she studied Biological Psychology with a specialization in 
Neuropsychology at the Maastricht University. During her study she spent six months in 
Montreal, Canada. Here she did a scientific internship at the Department of Psychiatry, 
McGill University on the effects of oxygen on serotonin synthesis. In 2005 she started as 
PhD student at GGZ inGeest, department of Psychiatry and EMGO+ at the VU University 
Medical Center, Amsterdam. She investigated the association between depression and 
metabolic syndrome, which resulted in this thesis. As part of her PhD project, largely based 
on American data, she visited the Sticht Center on Aging at the Wake Forest University 
Baptist Medical Center in Winston-Salem, North Carolina in de United States in 2006 for four 
months. In addition, she obtained a masters degree in epidemiology in 2007. Since July 
2008 her research activities have elaborated beyond her PhD project. In January 2010 
Nicole started a 2-year fellowship funded by EMGO+ to follow up on her PhD research, 
examining the role of inflammatory markers in depression and anxiety and in their 
relationship with somatic diseases. Nicole lives in Maarssen together with her partner 
Richard Gubbels and Pippa the cat. 
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